<SEC-DOCUMENT>0001640334-20-002095.txt : 20200813
<SEC-HEADER>0001640334-20-002095.hdr.sgml : 20200813
<ACCEPTANCE-DATETIME>20200813171647
ACCESSION NUMBER:		0001640334-20-002095
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200813
DATE AS OF CHANGE:		20200813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		201100259

	BUSINESS ADDRESS:	
		STREET 1:		5910 PACIFIC CENTER BLVD, SUITE 320
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(949) 480-9051

	MAIL ADDRESS:	
		STREET 1:		5910 PACIFIC CENTER BLVD, SUITE 320
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>embi_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html><head><title>embi_10q.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><table style="font-size:1px;width:100%" cellpadding="1"> <tr> <td style="border-bottom:5px solid;padding:1px;"></td></tr> <tr> <td style="border-bottom:2px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;padding-right:1px;padding:1px;"></td></tr></table> <p style="margin:0px">&nbsp; </p><p style="MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM 10-Q</font></strong></p><p style="MARGIN: 0px; text-align:justify;">(Mark One)</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">&#9746;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:left;">For the quarterly period ended <strong><u>June 30, 2020</u></strong></p></td></tr></table> <p style="MARGIN: 0px; text-align:left;">&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>or</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px;margin:0px"> <td></td> <td> <p style="MARGIN: 0px; text-align:left;">For the transition period from ___________ to ___________</p></td></tr></table> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;">Commission File Number: <strong><u>000-55136</u></strong></p><p style="MARGIN: 0px; text-align:left;">&nbsp; &nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:50%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">Emerald Bioscience, Inc.</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Nevada</strong></p></td> <td style="width:10%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>45-0692882</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(State or other jurisdiction</p><p style="MARGIN: 0px; text-align:center;">of incorporation or organization)</p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(I.R.S. Employer</p><p style="MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><u>5910 Pacific Center Blvd, San Diego, CA 92121</u></strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(Address of principal executive offices) (Zip Code)</p></td></tr></table> <p style="margin:0px">&nbsp;&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><u>(949) 480-9051</u></strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p></td></tr></table> <p style="MARGIN: 0px; text-align:left;">&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>_____________________________________________</strong></p><p style="MARGIN: 0px; text-align:center;">(Former name, former address and former fiscal year, if changed since last report)</p><p style="MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Title of each class</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Name of each exchange </p><p style="MARGIN: 0px; text-align:center;">on which registered</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">None</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">None</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">None</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(g) of the Act:</p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Title of each class</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Name of each exchange </p><p style="MARGIN: 0px; text-align:center;">on which registered</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Common Stock, par value $0.001</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">EMBI</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">OTCQB</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; No</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744; No</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td> <td style="width:20%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Accelerated filer</p></td> <td style="width:20%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Non-accelerated filer</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9746;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Smaller reporting company</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9746;</p></td></tr> <tr style="height:15px"> <td colspan="2"></td> <td> <p style="MARGIN: 0px; text-align:justify;">Emerging growth company</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&#9744; Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746; No</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">As of August&nbsp;12, 2020, there were&nbsp;239,541,081&nbsp;shares of the issuer&#8217;s $0.001 par value common stock issued and outstanding.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp; </p><table style="font-size:1px;width:100%" cellpadding="1"> <tr> <td style="border-bottom:2px solid;padding:1px;"></td></tr> <tr> <td style="border-bottom:5px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;padding-right:1px;padding:1px;"></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="margin:0px">&nbsp;&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong><a name="toc">TABLE OF CONTENTS</a></strong></p><p style="MARGIN: 0px; text-align:left;"><strong>&nbsp; </strong></p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="5"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#p1">PART I-FINANCIAL INFORMATION</a></strong></p></td></tr> <tr style="height:15px"> <td style="width:9%;"></td> <td></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it1">Item 1.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it1">Financial Statements:</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">4</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#bs">Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">4</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#sc">Condensed Consolidated Statements of Comprehensive (Loss) Income for the Three and Six Months Ended June 30, 2020 and 2019 (Unaudited)</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">5</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#cf">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019 (Unaudited)</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">6</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#sd">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three and Six Months Ended June 30, 2020 and 2019 (Unaudited) </a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">7</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#no">Notes to the Unaudited Condensed Consolidated Financial Statements </a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">8</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it2">Item 2.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">23</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it3">Item 3.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it3">Quantitative and Qualitative Disclosures about Market Risk</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">30</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it4">Item 4.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#it4">Controls and Procedures</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">30</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="5"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#p2">PART II - OTHER INFORMATION</a></strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt1">Item 1.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt1">Legal Proceedings</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">31</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt1a">Item 1A.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt1a">Risk Factors</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">31</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt2">Item 2.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt2">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">31</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt3">Item 3.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt3">Defaults Upon Senior Securities</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">31</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt4">Item 4.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt4">Mine Safety Disclosures</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">31</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt5">Item 5.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt5">Other Information</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">31</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt6">Item 6.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#itt6">Exhibits</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">32</p></td> <td></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:center;"><strong>FORWARD-LOOKING STATEMENTS</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">Statements in this Quarterly Report on Form 10-Q that are not descriptions of historical facts are forward-looking statements that are based on management&#8217;s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, you can identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section titled &#8220;Risk Factors&#8221; including, without limitation, risks relating to:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the early stage of our product candidates presently under development;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to retain or hire key scientific or management personnel;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our dependence on the University of Mississippi, third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to develop successful sales and marketing capabilities in the future as needed;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">competition in our industry;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the duration and impact of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic; and</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">regulatory developments in the United States and foreign countries.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, such as the COVID-19 outbreak and associated business disruptions including delayed clinical trials and laboratory resources, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;"><strong><a name="p1">PART I - FINANCIAL INFORMATION</a></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;"><a name="it1"><strong><u>Item 1. </u></strong><strong><u>Financial Statements</u></strong></a><strong> </strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong><a name="bs">EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(Note 2)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>ASSETS</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current assets</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,524</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,829,977</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Restricted cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Prepaid expenses </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">114,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,695</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Other current assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,643</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,550</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total current assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,955</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,994,760</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Property and equipment, net </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,252</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,983</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">227,207</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>LIABILITIES AND STOCKHOLDERS</strong><strong>&#8217;</strong><strong> (DEFICIT) EQUITY</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current liabilities </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Accounts payable </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,096,283</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,809</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Accounts payable to related party </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">77,290</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Accrued interest due to related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,726</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">PPP loan current</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51,653</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Other current liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">426,884</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,406</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Derivative liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">465,287</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,603</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total current liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,155,123</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">970,818</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Noncurrent liabilities </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">PPP loan non-current</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,047</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Convertible multi-draw credit agreement - related party, net of discount </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">651,461</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">387,070</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Derivative liabilities, non-current </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,321,631</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,448,685</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Commitments and contingencies </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Stockholders</strong><strong>&#8217;</strong><strong> (deficit) equity</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019 </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Common stock, $0.001 par value; 500,000,000 shares authorized; 183,207,747 and 182,895,247 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">183,208</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,895</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Additional paid-in-capital </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,657,546</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,538,445</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:justify;">Accumulated deficit </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(35,935,178</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,173,282</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total stockholders&#8217; (deficit) equity</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,094,424</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">548,058</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 30px; text-align:justify;">Total liabilities and stockholders&#8217; (deficit) equity</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">227,207</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="13" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements. </p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:center;"><strong><a name="sc">EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p><p style="MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS</strong><strong>) INCOME</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p><p style="MARGIN: 0px; text-align:left;">&nbsp; &nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Three Months Ended</strong> </p><p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong> </p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Six Months Ended</strong> </p><p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Operating expenses</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Research and development</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">428,529</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,041</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,228,141</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,009,026</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">General and administrative</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">792,129</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,082,846</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,203,725</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,276,928</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Total operating expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,220,658</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,770,887</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,431,866</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,285,954</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Operating loss</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,220,658</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,770,887</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,431,866</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,285,954</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Other expense (income)</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Change in fair value of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,353</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,971,742</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,550</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,151,124</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Interest expense </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">171,625</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">293,965</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">337,980</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,028</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Total other expense (income), net</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">197,978</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(17,677,777</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">328,430</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,418,452</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>(Loss) income before income taxes</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,418,636</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,906,890</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,760,296</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,132,498</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Provision for income taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net (loss) income and comprehensive (loss) income </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,420,236</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,905,290</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(3,761,896</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,130,898</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>(Loss) earnings per common share:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.12</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.02</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.08</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.02</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Weighted average shares of common stock outstanding used to compute earnings per share:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">183,052,175</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,923,037</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">182,654,571</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,826,677</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">183,052,175</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">189,094,958</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">182,654,571</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">172,058,053</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="margin:0px">&nbsp;&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements.</p><p style="MARGIN: 0px; text-align:left;">&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:center;"><strong><a name="cf">EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong> </p><p style="MARGIN: 0px; text-align:center;"><strong>CONDENSED</strong> <strong>CONSOLIDATED STATEMENTS OF CASH FLOWS</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Six Months Ended</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from operating activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Net (loss) income </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,761,896</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,130,898</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Adjustments to reconcile net (loss) income to net cash used in operating activities:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Depreciation</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92,851</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">344,577</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Change in fair value of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,550</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,151,124</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Amortization of debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264,391</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">244,751</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Changes in assets and liabilities:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45px">Prepaid expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,445</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(169,079</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45px">Other current assets</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,907</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45px">Accounts payable</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,474</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,862</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45px">Accounts payable to related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,290</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45px">Accrued interest related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,726</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45px">Other current liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,478</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">182,494</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 60px">Net cash used in operating activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,294,153</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,036,246</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from financing activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Proceeds from PPP loan</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,700</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Proceeds from multi-draw credit agreement &#8211; related party, net of $0 and $9,301 issuance costs for the June 30, 2020 and June 30, 2019 periods, respectively</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,990,699</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Net cash provided by financing activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">566,700</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,990,699</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net (decrease) increase in cash and restricted cash</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,727,453</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">954,453</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash and restricted cash</strong>,<strong> beginning of period</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,857,885</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash and restricted cash, end of period</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">107,062</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,812,338</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Supplemental disclosures of cash-flow information:</em></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Reconciliation of cash and restricted cash:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,524</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,807,826</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Restricted cash</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,512</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 30px">Total cash and restricted cash shown in the consolidated statements of cash flows</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">107,062</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,812,338</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cash paid during the period for:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Interest</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,277</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Income taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Supplemental disclosures of non-cash financing activities:</em></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Reclassification of warrant liabilities to equity from exercise of warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,563</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,375</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,414</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Beneficial conversion feature on convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="9" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements. </p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; &nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="21" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a name="sd">EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p></td></tr> <tr style="height:15px"> <td colspan="21" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS</strong><strong>&#8217;</strong><strong> EQUITY</strong><strong> (</strong><strong>DEFICIT</strong><strong>)</strong></p></td></tr> <tr style="height:15px"> <td colspan="21" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Additional</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Paid-In</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Stockholders&#8217;</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Amounts</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, January 1, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>133,907,747</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>133,908</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>17,528,947</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(33,225,107</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(15,562,252</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,493</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,493</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants issued in connection with convertible multi-draw credit agreement, related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss for the three months ended March 31, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,774,392</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,774,392</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, March 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>133,907,747</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>133,908</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>20,001,400</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(47,999,499</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(27,864,191</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">173,084</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">173,084</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,188</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,375</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net income for the three months ended June 30, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,905,290</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,905,290</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, June 30, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>134,095,247</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>134,095</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>20,318,672</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(32,094,209</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(11,641,442</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></table> <p style="margin:0px">&nbsp; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="6" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Additional</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Paid-In</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Stockholders</strong><strong>&#8217;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Equity</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Amounts</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>(Deficit)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, January 1, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,895,247</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,895</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>32,538,445</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(32,173,282</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>548,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,142</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,142</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Series B warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">312,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">313</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,563</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Net loss for the three months ended March 31, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,341,660</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,341,660</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, March 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>183,207,747</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>183,208</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>32,628,837</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(34,514,942</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(1,702,897</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,709</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,709</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Net loss for the three months ended June 30, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,420,236</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,420,236</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, June 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>183,207,747</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>183,208</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>32,657,546</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(35,935,178</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(3,094,424</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></table>&nbsp; <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:center;"><strong><a name="no">EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO THE CONDENSED</strong> <strong>CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>1. Nature of Operations and Business Activities</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Nature of Operations</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="margin:0px">Emerald Bioscience, Inc. (the &#8220;Company&#8221;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#8220;Merger&#8221;) pursuant to which Nemus, a California corporation (&#8220;Nemus Sub&#8221;), became the Company&#8217;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub to form a Nevada company.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald Health Sciences&#8221;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &#8220;Emerald Financing&#8221;). As part of the transaction, the Company&#8217;s Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#8217;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company (Note 8).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On February 11, 2019, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and majority stockholder unanimously approved an amendment to the Company&#8217;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&#8217;s name to Emerald Bioscience, Inc. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#8220;EMBI Australia&#8221;), in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#8217;s product candidates.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#8217;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 7 - Related Party Matters for additional information. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">The Company is a biopharmaceutical company located in San Diego, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#8220;UM&#8221;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">As of June 30, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Liquidity and Going Concern</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company has incurred operating losses and negative cash flows from operations since inception and as of June 30, 2020, had an accumulated deficit of $35,935,178, a stockholders&#8217; deficit of $3,094,424 and a working capital deficit of $1,929,168. The Company anticipates operating losses and negative cash flows from operations into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of June 30, 2020, the Company had unrestricted cash in the amount of $102,524 as compared to $1,829,977 as of December 31, 2019. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company&#8217;s expected cash requirements, without obtaining additional funding management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company&#8217;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#8220;Credit Agreement&#8221;) with Emerald Health Sciences (See Note 4). </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &#8220;Amended Credit Agreement&#8221;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the three months ended June 30, 2020 the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. The advances bear interest at 7% per annum and mature on October 5, 2022. The Company intends to use the proceeds from the advances for general corporate and working capital purposes. Emerald Health Sciences has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and that no warrants will be issued with the advances.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#8220;PPP Loan&#8221;) from City National Bank (the &#8220;PPP Loan Lender&#8221;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (&#8220;SBA&#8221;) (Note 4). </p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On July 31, 2020, the Company entered into the August 2020 Financing (Note 8), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction are $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company intends to use the net proceeds of the Offering for general corporate purposes, including working capital.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#8217;s compensation and 100% of the Board of Director and committee fees indefinitely. In August 2020, subsequent to closing the August 2020 Financing, the Board of Directors determined that the Company has been sufficiently financed and authorized the Company to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&#8217;s ability to raise additional capital and obtain the necessary funds. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of NB1111 from the second half of 2020, to the 2021 timeframe. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>2. Summary of Significant Accounting Policies</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Basis of Presentation</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&#8217;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&#8217;s audited financial statements as of December 31, 2019, which are included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&#8217;s business and the risks inherent therein.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#8217;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Risks and Uncertainties</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company&#8217;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#8217;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#8217;s ability to attract new funding. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurements</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#8220;exit price&#8221;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:6%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 1:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 2:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 3:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">The carrying values of the Company&#8217;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&#8217;s relatively short term the carrying value approximates fair value.&nbsp; As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was&nbsp;$387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#8217;s Condensed Consolidated Balance Sheets. As of June 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Convertible Instruments</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, <em>Debt with Conversion and Other Options</em> (&#8220;ASC 470-20&#8221;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company also follows ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#8217; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Warrants Issued in Connection with Financings</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive (Loss) Income .</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Debt Issuance Costs and Interest</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Research and Development Expenses and Licensed Technology</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#8217;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Stock-Based Compensation Expense </em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#8217;s actual stock volatility adjusted for periods in which significant financial variability was identified.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividends - The dividend yield assumption is based on the Company&#8217;s history and expectation of paying no dividends in the foreseeable future.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>(Loss) Earnings Per Common Share </em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net (loss) earnings per common share. Basic (loss) earnings per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted (loss) earnings per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss (earnings) per share of common stock for the periods presented because including them would have been anti-dilutive:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Three Months </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Ended June 30, </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Six Months </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Ended June 30, </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock options </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,186,786</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,411,846</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,186,786</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,814,505</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unvested restricted stock</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">209,055</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">237,798</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Common shares underlying convertible debt</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,125,364</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,125,364</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,722,222</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,304,750</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,844,002</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,304,750</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,353,145</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Recent Accounting Pronouncements</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU 2020-06, <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</em>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes </em>(Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#8217;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>3. Warrants and Derivative Liabilities</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Warrants</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s warrants. These judgments and estimates include assumptions regarding the Company&#8217;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">Warrants vested and outstanding as of June 30, 2020 are summarized as follows:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Vested and</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Source</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>(Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Pre 2015 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">6-10</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,660,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2015 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">1.15-5.00</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">5-10</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">256,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Common Stock Warrants to Series B Stockholders</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">718,750</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Common Stock Warrants to Service Providers</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.15</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Series C Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Series D Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Common Stock Warrants to Service Provider</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.41</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2018 Emerald Financing Warrants </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Multi-Draw Credit Agreement Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2019 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.35</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,000,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total warrants vested and outstanding as of June 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>22,304,750</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Emerald Multi-Draw Credit Agreement Warrants </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the six months ended June 30, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants were equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions: </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">91.6-92.1</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">2.23-2.51</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">0.33-0.69</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Derivative Liabilities</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The following tables summarize the activity of derivative liabilities for the periods indicated: </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2020</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2019,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong> </p><p style="MARGIN: 0px; text-align:center;"><strong>Fair value of </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>of Derivatives</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>to Equity </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2020,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Financing - warrant liability <sup>(2)</sup> </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,024</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">76,708</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">352,732</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability <sup>(3)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134,579</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,539</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,563</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">112,555</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>501,400</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(9,550</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(26,563</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>465,287</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>410,603</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>465,287</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; &nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2019</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2018,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>of Derivatives</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>to Equity</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2019,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219,453</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">516,058</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(219,134</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">516,377</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Financing - warrant liability (2)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,251,413</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,887,929</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,363,484</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability (3)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">487,500</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(44,061</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(144,375</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">299,064</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>15,958,366</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>516,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(5,151,124</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(144,375</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>11,178,925</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(516,377</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,738,913</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>10,662,548</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em> </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#8217;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes model for each payment period. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. For the three and six months ended June 30, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Emerald Financing Warrant Liability (2)</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity</em><em>&#8217;</em><em>s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s. </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>June 30, </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82.2</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.5</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.17</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.62</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.63</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.16</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Series B Warrant Liability (3)</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a &#8220;down-round&#8221; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">104.9</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.2</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.16</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.60</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.14</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.64</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.16</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the six months ended June 30, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#8217;s common stock on the exercise dates.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>4. Debt </strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Multi-Draw Credit Agreement- Related Party</em></p><p style="MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p><p style="MARGIN: 0px; text-align:justify;">The Company&#8217;s Debt with Emerald Health Sciences consists of the following:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Conversion</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value of convertible debt&#8212;related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,358,687</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,622,344</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt issuance costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,352</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Carrying value of total convertible debt - related party</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>651,461</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value of non-convertible debt&#8212;related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">n/a</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px"><strong>&nbsp;</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,101,461</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 7). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, dated October 5, 2018. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Amended Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&#8217; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of June 30, 2020, the unused portion of the credit facility is $13,550,000. The drawdowns are subject to approval by the Company&#8217;s Board, which is controlled by the directors of Emerald Health Sciences. As such, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place, however, there is no guarantee of continued funding.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#8217;s stockholders (See Note 3).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#8217;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&#8217;s Condensed Consolidated Balance Sheets.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the six months ended June 30, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income for the six months ended June 30, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the three months ended June 30, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. The Lender has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and gave notice to the Company that no warrants will be issued in connection with the advances.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. As of June 30, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 2.27 years. The fair value of the shares underlying the convertible advances under the Amended Credit agreement was $790,691 at June 30, 2020. As of June 30, 2020, the if-converted value did not exceed the principal balance.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>PPP Loan</em></p><p style="MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p><p style="MARGIN: 0px; text-align:justify;">On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing seven months from the date of funding. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and seven-month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Interest Expense</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company&#8217;s interest expense consists of the following:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended<br>June 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Related party interest expense &#8211; stated rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,726</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">106,167</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,371</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">165,277</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">PPP loan interest expense &#8211; stated rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">218</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Non-cash interest expense:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Amortization of debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">133,310</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,313</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,657</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">238,293</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 15px">Amortization of transaction costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">371</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,485</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">734</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,458</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>171,625</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>293,965</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>337,980</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>410,028</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>5. Stock-Based Compensation </strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Stock Incentive Plan</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On October 31, 2014, after the closing of the Merger, the Board approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of June 30, 2020, the Company had 13,159,631 shares available for future grant under the 2014 Plan.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Stock Options </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">There was no option activity under the Company&#8217;s 2014 Plan during the three and six months ended June 30, 2020.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the three and six months ended June 30, 2020, 643,501 restricted stock awards (&#8220;RSAs&#8221;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. At June 30, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Awards Granted Outside the 2014 Plan</em></strong> </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Options</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During the three and six months ended June 30, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&#8217;s former CFO. At June 30, 2020 there are 869,144 options vested and outstanding with a weighted average exercise price of $0.25 and a weighted average remaining life of 0.13 years. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The following is a summary of RSA activity outside of the Company&#8217;s 2014 Plan during the six months ended June 30, 2020: </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Average</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Grant </strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Date Fair</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, December 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>450,000</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.19</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Released</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, June 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Stock-Based Compensation Expense</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company recognizes compensation expense using the straight-line method over the requisite service period. For the three months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of $28,709 and $173,084, respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income. For the six months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of $92,851 and $344,577, respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income .The total amount of unrecognized compensation cost was $164,798 as of June 30, 2020. This amount will be recognized over a weighted average period of 2.18 years.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>6. Significant Contracts - University of Mississippi</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>UM 5050 Pro-Drug and UM 8930 Analog Agreements</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, related to an analog formulation of cannabidiol (&#8220;CBD&#8221;). On May 24, 2019, the ocular delivery licenses were replaced by &#8220;all fields of use&#8221; licenses for both UM 5050 and UM 8930 (collectively, the &#8220;License Agreements&#8221;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">i)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">ii)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">iii)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#8217;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#8217;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#8217;s dissolution or cessation of operations, the Company&#8217;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#8217;s control, or the Company&#8217;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#8217; written notice to UM.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">As of June 30, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>UM 5070 License Agreement</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#8220;UM 5070&#8221;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;). </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#8217;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#8217;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#8217;s control. The Company may terminate the license agreement upon 60 days&#8217; written notice to UM.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">As of June 30, 2020, none of the milestones under this license agreement have been met.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>7. Related Party Matters</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Emerald Health Sciences</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&#8217;s Chief Executive Officer and Emerald Health Sciences&#8217; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of June 30, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three and six months ended June 30, 2020. Under this agreement, for the three and six months ended June 30, 2019, the Company incurred expenses of $150,000 and $300,000, respectively.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; &nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#8217;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon&#8217;s consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. Under this agreement, for the three and six months ended June 30, 2020, the Company incurred fees of $36,387 and $66,387, respectively. As of June 30, 2020, the Company has accrued $70,258 in expense related to the Independent Contractor Services Agreement.&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">As of the date of this filing Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. Jim Heppell is also a board member of Emerald Health Sciences, Inc. Additionally, the Company shares the same office location as Emerald Health Pharmaceuticals.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>8. Subsequent Events</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>August 2020 Financing</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On July 31, 2020, the Company entered into a Securities Purchase Agreement with institutional investors with H.C. Wainwright &amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The common units and pre-funded units were sold a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The exercise price and number of shares of Common Stock underlying the Warrants are subject to adjustment upon the issuance by the Company of stock dividends, stock splits, and similar proportionately applied changes affecting the Company&#8217;s outstanding Common Stock. Holders of the Warrants will be entitled to participate in any dividends or other distribution of the Company&#8217;s assets declared or made to holders of the Company&#8217;s Common Stock. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In connection with the registered public offering, the Company incurred issuance costs of $825,698, for net proceeds of $6,113,969. Additionally, the Company has issued 8,166,667 common stock warrants to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years. The offering closed on August 4, 2020. The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em><strong>Management and Board Deferral Agreements</strong></em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Upon the closing of the August 2020 financing, the Company&#8217;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees including the retention bonus to management and the Board in the aggregate amount of $293,078.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Exercise Price Adjustment to Emerald Financing Warrants</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">Upon entering into the August 2020 Financing, the Company entered into an agreement with a holder of the Emerald Financing Warrants to permanently set the exercise price of such holder&#8217;s remaining Emerald Financing warrants to $0.10 and waive such holder&#8217;s rights to anti-dilution protection upon subsequent issuances or sales of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>Stock Option Grants</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In August 2020, 22,750,000 stock options with an exercise price of $0.045 were granted to certain directors, officers, employees and consultants of the Company under the 2014 Plan. The stock options will vest 10% on the grant date and 90% in equal semi-annual installments over the vesting schedules as set forth by the Company&#8217;s Board of Directors.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On August 7, 2020, the Board approved an Amendment No. 2 to the 2014 Plan. The amendment removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year.&nbsp;In connection with the option grants the Company will register an additional 18,486,435 common shares as required under the 2014 Plan.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em><strong>Separation of Chief Executive Officer, Chief Medical Officer and Member of the Board</strong></em><em> &nbsp;</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On August 7, 2020, the effective date, Company entered into a Separation and Release Agreement (the &#8220;Separation Agreement&#8221;) with Dr. Brian Murphy, Chief Executive Officer. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Pursuant to the Separation Agreement, Dr. Murphy has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Dr. Murphy compensation and benefits as follows: (i) a gross payment of $195,000 in consideration for the restrictive covenants contained in the Separation Agreement, to be paid over six months; and&nbsp;(ii) a continuation of health insurance benefits for a period of six months following the Separation Date. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em><strong>Appointment of Chief Executive Officer</strong></em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On August 7, 2020, Punit Dhillon resigned his position as the Chair of the Audit Committee and member of the Compensation, Nomination and Corporate Governance Committees and was appointed as the Chief Executive Officer of the Company. Mr. Dhillon remains as the Chairman of the Board and Chairman of the Finance and Business Development Committee.&nbsp;Mr. Dhillon will be eligible to receive a minimum of 6 months&#8217; severance if he is terminated by the Company without cause and will receive 12-months&#8217; severance if he is employed by the Company for at least 12 months commencing on August 10, 2020, or a 24 months&#8217; severance if he is employed by the Company for at least 24 months commencing on August 10, 2020.</p><p style="margin:0px">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><a name="it2"><strong><u>Item 2. Management</u></strong><strong><u>&#8217;</u></strong><strong><u>s Discussion and Analysis of Financial Condition and Results of Operations.</u></strong></a></p><p style="MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p><p style="MARGIN: 0px; text-align:justify;"><em>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements for the three and six months ended June 30, 2020 and 2019 (unaudited) and the year ended December 31, 2019 together with the notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under </em><em>&#8220;</em><em>Risk Factors</em><em>&#8221;</em><em> and elsewhere in this Quarterly Report on Form 10-Q.</em></p><p style="MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p><p style="MARGIN: 0px; text-align:justify;"><em>Unless otherwise provided in this Quarterly Report, references to </em><em>&#8220;</em><em>we,</em><em>&#8221;</em><em> </em><em>&#8220;</em><em>us,</em><em>&#8221;</em><em> </em><em>&#8220;</em><em>our,</em><em>&#8221;</em><em> </em><em>&#8220;</em><em>the Company,</em><em>&#8221;</em><em> and </em><em>&#8220;</em><em>Emerald Bioscience</em><em>&#8221;</em><em> in this discussion and analysis refer to Emerald Bioscience, Inc., a Nevada corporation formerly known as Nemus Bioscience, Inc. and Load Guard Logistics, Inc., together with its wholly-owned subsidiaries, Nemus, a California corporation, and EMBI Australia Pty Ltd., an Australian proprietary limited company.</em></p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">We are a biopharmaceutical company targeting the discovery, development, and commercialization of cannabinoid-based therapeutics, through a number of license agreements with the University of Mississippi (&#8220;UM&#8221;). UM holds the only contract to cultivate cannabis for research purposes on behalf of the Federal Government of the United States and has held that federal license since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, processing and manufacture of cannabis extracts as well as the chemistry and physiology of cannabinoid molecules. We strive to serve as UM&#8217;s partner for the development and commercialization of cannabinoid-based therapeutics, and the realization of this partnership will depend on the successful development of these compounds through the regulatory requirements of drug approval agencies, like the Food and Drug Administration (the &#8220;FDA&#8221;) in the United States and the European Medicines Agency in the European Union.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Effective March 25, 2019, we changed our name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In August 2019, we formed a new subsidiary in Australia, EMBI Australia Pty Ltd, in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for our product candidates.</p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Recent Events and Significant Contracts. </strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Expansion of UM 5050 and UM 8930 Licenses from Ocular Delivery Only to All Fields of Use </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On May 24, 2019, we executed two restated and amended license agreements with UM which expanded our use of UM 5050, a pro-drug of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, an analog of cannabidiol (&#8220;CBD&#8221;), from ocular delivery only to all fields of use. Pursuant to these license agreements, we have exclusive, perpetual, worldwide licenses related to UM 5050 and UM 8930. Additionally, with the prior written consent of UM, we have the right to sublicense the licensed intellectual property.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The all fields use for tetrahydrocannabinol-valine-hemisuccinate (&#8220;THCVHS&#8221;), the proprietary prodrug of THC, is expected to allow us to explore related uses for the active moiety of the prodrug, namely THC. Independent in vitro and in vivo studies have demonstrated the potential use of THC in a variety of potential indications based on the ability of the cannabinoid to act as an anti-inflammatory, anti-fibrotic, and/or inhibitor of neovascularization. The Company has generated data related to these effects using an ex vivo human tissue model of the eye. The prodrug technology employed in THCVHS is designed to enhance the bioavailability and pharmacokinetic predictability of the active part of the molecule, once introduced into the body through routes of administration currently being considered by the development team. Given the positive data accumulated to date in studies of the eye, we could explore additional central nervous system applications for THCVHS. We expect to develop strategic collaborations to identify and advance these applications.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The all fields use of cannabidiol-valine-hemisuccinate (&#8220;CBDVHS&#8221;), the analog of CBD, is expected to permit us to expand research and development into organ systems outside of the current ocular space. Potential disease targets over time could involve the central nervous system, the gastrointestinal tract, the endocrine/metabolic system, reproductive system diseases, or as yet unrecognized opportunities. This bioengineered version of CBD is expected to enlarge the disease target pool by virtue of new routes of administration into the body, thereby enhancing bioavailability. The determination by the DEA that CBDVHS is not a controlled substance permits us to enlarge the potential pool of clinical test sites and a more diverse patient pool in the study of disease. We expect to develop strategic collaborations to identify and advance these applications.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>NB1111</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">NB1111, our lead ocular compound, is a prodrug of THC. We have delayed our first-in-human studies of NB1111, from the second-half of 2020, to the 2021 timeframe. The first-in-human studies are expected to be conducted in both normal controls and patients with glaucoma or ocular hypertension in Australia (the &#8220;Clinical Trial&#8221;). The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of COVID-19 there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">During 2019 and the six months ended June 30, 2020, we achieved various milestones related to the research and development of NB1111, including the following:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">UM completed experiments showing that NB1111 was statistically superior in lowering intraocular pressure (&#8220;IOP&#8221;) compared to the prostaglandin-based therapy, latanoprost, the current standard-of-care for treating glaucoma. Significance was reached across multiple timepoints during a seven-day course of dosing using a validated rabbit normotensive ocular model and NB1111 exerted pharmacologic activity consistent with twice-daily dosing.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Glauconix Biosciences Inc. (&#8220;Glauconix&#8221;) completed their pilot study to research the mechanism of action and IOP-lowering ability of THC when administered into an ex vivo model of a 3D-human trabecular meshwork using both healthy and glaucomatous-derived tissues. The Glauconix study validated the mechanism of action of NB1111 in lowering IOP, a defining disease process of hypertensive glaucoma. Additionally, biomarkers associated with inflammation and fibrosis in both normal and tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states; and data revealed that biomarkers associated with neovascularization, a disease process of new blood vessel formation that can damage the retina in a variety of ocular diseases, was also inhibited by THC, prompting further study for the utility of this drug in diseases of the retina. These data were consistent with <em>in vivo</em> rabbit IOP response data that was conducted in parallel to the Glauconix study as were internal Glauconix validation testing using cannabinoid receptor stimulator molecules that acted as proxy receptor agonists for THC, the active moiety of NB1111.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In August 2019, EMBI Australia Pty Ltd entered into a start-up agreement with Novotech (Australia) Pty Limited (&#8220;Novotech&#8221;). The start-up agreement is being entered into in connection with the launch of the Clinical Trial. We expect to pay approximately $45,000 in professional fees and pass through costs in connection with the services provided for in the start-up agreement. Additionally, on September 26, 2019, EMBI Australia Pty Ltd and Novotech executed a Master Services Agreement and anticipate entering into project agreements covering all anticipated services to be provided by Novotech to us in connection with the Clinical Trial.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In August 2019, EMBI Australia entered into a master service agreement and initial statement of work with Agilex Biolabs Pty Ltd (&#8220;Agilex&#8221;), pursuant to which Agilex would assist with the assay set up for the anticipated Clinical Trial.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In August 2019, we executed an agreement with Bioscience Laboratories, Inc. to complete Draize testing in advance of the anticipated Clinical Trial.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">AMRI worked toward closing the synthesis validation pathway to manufacture cGMP API of THCVHS with validation of drug product purity. In turn, on April 30, 2019, we entered into an additional agreement with AMRI related to non-GMP synthesis of a demonstration batch of our pro-drug of THC. In August 2019, our manufacturing agreement with AMRI for THCVHS that was executed in July 2018 was replaced by the agreement with Noramco discussed below.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp; &nbsp; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">On August 7, 2019, we entered into a first amendment to our agreement with Noramco to manufacture THCVHS (the &#8220;Noramco Agreement,&#8221; as amended from time to time). CBDVHS was being manufactured pursuant to the Noramco Agreement prior to the amendment. We paid $257,800 upfront to add the manufacture of THCVHS to the Noramco Agreement and additional payments will be made upon Noramco&#8217;s shipping of the GMP active pharmaceutical ingredient to us. All other material terms of the Noramco Agreement remain the same.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In January 2019, we engaged RRD International, LLC (&#8220;RRD&#8221;) to provide strategic ophthalmic 505(b)(2) regulatory planning, prepare a Pre- IND meeting briefing book, and schedule and represent us at the Pre-IND meeting with the FDA. In May 2019, we executed a change order to extend our work with RRD as we continue to progress toward our Pre-IND meeting. In August 2019, we executed an additional work order with RRD to assist us in preparing an investigator&#8217;s brochure to support the Clinical Trial.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In January 2019, we executed an agreement with Pharmaceuticals International, Inc. (&#8220;PII&#8221;) to conduct studies to determine options for producing a sterile dosage form which can be dosed in humans in a clinical study. PII will conduct appropriate formulation studies to determine storage and processing options. Pursuant to the terms of the agreement, we paid $72,500 to initiate the project. After the initial evaluation we have agreed to pay additional fees and expenses upon completion of certain milestones.</td></tr></table> <p style="margin:0px">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;"><em>NB2222 </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">NB2222 is the ocular formulation of our proprietary CBD analog (CBDVHS). We have embarked on studies with UM exploring the utility of our drug candidate NB2222 as an eye drop nanoemulsion for the potential treatment and management of several eye diseases, including but not limited to, uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In July 2019, we engaged Glauconix to conduct research as to whether CBD or CBDVHS is associated with an increase in IOP and, if so, what the potential mechanism of action would be by exposing the 3D-human trabecular meshwork tissue constructs to these molecules. In December 2019, we announced that data generated by Glauconix Biosciences, Inc. showed significant anti-inflammatory and anti-fibrotic activity in ocular tissue with CBDVHS when compared to CBD, indicating therapeutic potential as a neuroprotectant, especially in diseases of the retina. Additionally, CBD was associated with biomarkers related to the elevation of IOP while CBDVHS was not associated with elevating IOP at anti-fibrotic concentrations. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In the second quarter of 2019, UM also completed pre-clinical experiments showing that NB2222 exhibited an ability to penetrate multiple chambers of the eye and reach the optic nerve. These findings support the therapeutic potential to provide ocular neuroprotection of retinal ganglion cells, an important goal in treating diseases that lead to vision loss. The data were published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics in a paper titled, &#8220;Analog Derivatization of Cannabidiol for Improved Ocular Permeation&#8221; (2019&#894; volume 35 (5): 1-10).</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In February 2019, we entered into the Noramco Agreement to provide manufacturing and product development services for our analog formulation of CBD. We paid $146,386 upfront and additional payments will be made upon Noramco&#8217;s shipping of the active pharmaceutical ingredient to us. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>NB3111 </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">NB3111 is a proprietary cannabinoid cocktail currently undergoing testing as an anti-infective agent against multiple strains of antibiotic resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;). These studies look to examine the utility of cannabinoid-based therapies against a variety of MRSA strains and other gram-positive bacterial infections and viral species.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><em>Other Development Programs </em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">We plan to continue to work with UM to explore other potential indications and associated routes of administration based on the expanded UM5050 and UM 8930 licenses. Our decision to advance a potential therapeutic candidate will be influenced by a number of criteria, including but not limited to, pre-clinical data, synthesis and formulation capability as well as prevailing market conditions.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In July 2019, we engaged StemoniX to evaluate CBD and CBDVHS (and possibly additional CBD-derivatives) in a human in vitro neural model with an application to epilepsy. The series of experiments are designed to provide insight into how these cannabinoids stabilize neuronal cells. In November and December 2019, we also executed additional pre-clinical research agreements with StemoniX related to CBDVHS. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In December 2019, we announced data generated by StemoniX, that CBDVHS was both pharmacologically and therapeutically distinct from CBD when studied in an in vitro human neural tissue model mimicking chemically-induced seizure-like hyperactivity. Additionally, CBDVHS was observed to gain potency in anti-seizure-like activity over the seven-day observation period whereas the suppressive effect afforded by CBD dissipated by day three. In assessing safety parameters of CBDVHS, the molecule was not found to be toxic to the neurologic cells tested in multiple assays, both in acute and longer-term exposure. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. We consider certain accounting policies related to fair value measurements, convertible instruments, warrants issued in connection with financings, stock-based compensation expense, and earnings per share to be critical accounting policies that require the use of significant judgments and estimates relating to matters that are inherently uncertain and may result in materially different results under different assumptions and conditions.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Management assessed the critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019 and determined that there were no changes to our critical accounting policies and estimates during the three and six months ended June 30, 2020.</p><p style="MARGIN: 0px; text-align:justify;"><em><strong>&nbsp;</strong></em></p><p style="MARGIN: 0px; text-align:justify;"><em><strong>Recently Issued and Adopted Accounting Pronouncements </strong></em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">See Note 2 to the accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for information on recently issued accounting pronouncements and recently adopted accounting pronouncements. While we expect certain recently adopted accounting pronouncements to impact our estimates in future periods, the impact upon adoption was not significant to our current estimates and operations. </p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Results of Operations </strong></p><p style="MARGIN: 0px; text-align:justify;"><em><strong>&nbsp;</strong></em></p><p style="MARGIN: 0px; text-align:justify;"><em><strong>For the three months ended June 30, 2020 and 2019 </strong></em></p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Revenues.</strong> To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Operating expenses. </strong>For the three months ended June 30, 2020, our total operating expenses were $1,220,658 as compared to $1,770,887 for the three months ended June 30, 2019. The decrease in operating expenses was due to the items noted below:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><u>Research and development.</u> Research and development expenses for the three months ended June 30, 2020 were $428,529, which consisted of expenses including salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, the annual license maintenance fee paid to UM, and fees related to contract manufacturing paid to Noramco. Research and development expenses for the three months ended June 30, 2019 were $688,041, which consisted of the upfront payments for the all fields of use licenses for UM 5050 and UM 8930, contract research and development fees paid to UM, regulatory consulting fees paid to RRD, and fees related contract manufacturing paid to AMRI and Noramco. The decrease in research and development expenses was primarily due to a decrease contract manufacturing activity, regulatory consulting fees and license fees during the three months ended June 30, 2020.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><u>General and administrative.</u> General and administrative expenses for the three months ended June 30, 2020 were $792,129, which primarily consisted of salaries, general legal, insurance, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. By comparison, general and administrative expenses for the three months ended June 30, 2019 were $1,082,846, which primarily consisted of salaries, stock compensation expense, general legal, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. General and administrative expenses decreased period over period primarily due to decreases in travel costs, consulting and legal legal fees and stock compensation expenses which were offset by an increase in salaries due to increased severance from the separation of our former CFO. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Other expense (income).</strong> For the three months ended June 30, 2020, we had other expense of $197,978 related primarily to interest expense of $171,625 and an increase in the fair value of our derivative liabilities of $26,353. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">For the three months ended June 30, 2019, the Company had other income of $17,677,777 related primarily to the decrease in fair value of our derivative liabilities by $17,971,742 which was driven by the decrease in our stock price.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The decrease in interest expense period over period was related to a lower principal balance on the Credit Agreement from the paydown of the facility in December 2019. </p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Net (loss) income and comprehensive (loss) income.</strong> For the three months ended June 30, 2020, we had a net loss of $1,420,236 as compared to net income of $15,905,290 for the three months ended June 30, 2019. The change was primarily attributable to an increase in other expense which was partially offset by a decrease in our operating expenses. We expect to incur net losses for the foreseeable future.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><em>For the six months ended June 30, 2020 and 2019</em></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Operating expenses. </strong>For the six months ended June 30, 2020, our total operating expenses were $3,431,866 as compared to $3,285,954 for the six months ended June 30, 2019. The increase in operating expenses was due to the items noted below:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><u>Research and development.</u> Research and development expenses for the six months ended June 30, 2020 were $1,228,141, which consisted of salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees paid to UM, fees related to contract manufacturing paid to Noramco, fees related to contract formulation work paid to PII, a $200,000 license fee incurred under the UM 8930 Analog Agreement for the receipt for the first United States Patent and Trademark Office notice of allowance and the annual license maintenance fee for UM 5070.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Research and development expenses for the six months ended June 30, 2019 were $1,009,026, which consisted of the upfront payments for the all fields of use licenses for UM 5050 and UM 8930, the annual license maintenance fee for UM 5070, contract research and development fees paid to UM and Glauconix, regulatory consulting fees paid to RRD, and fees related contract manufacturing paid to AMRI, Noramco and ElSohly Laboratories.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">For the six months ended June 30, 2020, research and development expenses increased by $219,115, as compared to the six months ended June 30, 2019. The increase is primarily due to an increase in license fees and salaries.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><u>General and administrative.</u> General and administrative expenses for the six months ended June 30, 2020 were $2,203,725, which primarily consisted of salaries, insurance, general legal and patent related fees, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. By comparison, general and administrative expenses for the six months ended June 30, 2019 were $2,276,928, which primarily consisted of salaries, stock compensation expense, general legal and patent related fees, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. General and administrative expenses remained relatively constant period over period.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Other expense (income).</strong> For the six months ended June 30, 2020, the Company had other expense of $328,430 related primarily to interest expense under the Credit Agreement (as defined below). For the six months ended June 30, 2019, the Company had other income of $4,418,452 related primarily to the decrease in fair value of our derivative liabilities which was driven by the decrease in our stock price. In addition, we initiated drawdowns under the Credit Agreement which required us to bifurcate compound embedded derivatives and record an additional charge for the fair value of such instruments in excess of proceeds. The decrease of $4,746,882 in other income period over period was attributable to the change in fair value of derivative liabilities from fluctuations in the Company&#8217;s stock price during the period and the quantity of outstanding instruments underlying the derivative balance. In December 2019, 40,800,000 of the Emerald Financing Warrants were exercised which caused a decrease in the overall balance of the derivative liability. The proceeds from the exercise of the Emerald Financing Warrants were used to pay down a portion of the Credit Agreement which also decreased interest expense recognized for the six months ended June 30, 2020 as compared to the six months ended June 30, 2019.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Net (loss) income and comprehensive (loss) income.</strong> For the six months ended June 30, 2020, we had a net loss of $3,761,896 as compared to net income of $1,130,898 for the six months ended June 30, 2019. The change to a net loss from net income was primarily attributable to the increase in other expense and was offset by an increase in operating expenses. We expect to incur net losses for the foreseeable future.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources </strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">We have incurred operating losses and negative cash flows from operations since our inception and as of June 30, 2020, had an accumulated deficit of $35,935,178, a stockholders&#8217; deficit of $3,094,424 and a working capital deficit of $1,929,168. We anticipate that we will continue to incur net losses into the foreseeable future in order to advance and develop several potential drug candidates into preclinical and clinical development activities and support our corporate infrastructure, which includes the costs associated with being a public company. We had cash of $102,524 as of June 30, 2020, as compared to $1,829,977 as of December 31, 2019. The decrease was primarily attributable to a decrease in financing activities during the quarter to date period. Without additional funding, management believes that we will not have enough funds to meet our obligations beyond one year after the date the Condensed Consolidated Financial Statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">On October 5, 2018, we secured a Credit Agreement with Emerald Health Sciences (the &#8220;Credit Agreement&#8221;), providing us with a credit facility of up to $20,000,000. Under the Credit Agreement, we may draw a remaining amount of up to $14,000,000 in advances from Emerald Health Sciences from time to time, each in a principal amount of at least $250,000. The advances are subject to approval by our Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. As of March 31, 2020, we have effected three drawdowns under the Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $6,000,000 in advances, and have issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock at an exercise price of $0.50 per share. On December 20, 2019, we entered into a Warrant Exercise Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences has exercised 40,800,000 of such warrants and paid the aggregate exercise price of approximately $4,080,000 for the related warrant shares in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement. Upon consummation of the transactions under the Warrant Exercise Agreement, the total outstanding principal amount excluding discounts under the Credit Agreement was $2,014,500.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On April 22, 2020, we entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#8220;PPP Loan&#8221;) from City National Bank. The PPP Loan was obtained pursuant to the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act administered by the U.S. Small Business Administration. We used the proceeds of the PPP loan for payment of payrolls and rent for our office space. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On April 29, 2020, we entered into an Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, as reported in the current report on the Form 8-K filed with the SEC on April 29, 2020. The Amended Credit Agreement provides for a credit facility to us in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment and advances of at least $150,000 for each of May, June and July 2020. During the three months ended June 30, 2020, we received the fourth and fifth advances of $150,000 and $300,000 pursuant to the Amended Credit Agreement. The advances bear interest at 7% per annum and mature on October 5, 2022. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">On July 28, 2020, we filed a registration statement on Form S-1/A, which has been declared effective as of July 31, 2020, and on July 31, 2020, we filed a related registration statement on a Form S-1MEF that became effective under Rule 462(b). On July 31, 2020, we sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant, which securities were registered under the foregoing registration statements under a securities purchase agreement, as reported in our current report on the Form 8-K filed with the SEC on August 5, 2020. The net proceeds from the transaction were $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. We intend to use the net proceeds of the Offering for general corporate purposes, including working capital.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">During March 2020, we approved a plan to defer up to 50% of the members of senior management&#8217;s compensation and 100% of the Board of Director and committee fees indefinitely. In August 2020, subsequent to closing the August 2020 Financing, our Board of Directors determined that we have been sufficiently financed and authorized us to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance. </p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions could impact our ability to raise additional capital and obtain the necessary funds.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Notably, we rely on third-party manufacturers to produce our product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent COVID-19 pandemic, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we have shifted the expected start of our first-in-human studies of the lead drug candidate, NB1111, from the second half of 2020, to the 2021 timeframe.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">The ultimate impact on us and overall delay in our drug product research and development is unknown, but our operations and financial condition will suffer in the event of business interruptions, delayed clinical trials, production or a lack of laboratory resources due to the pandemic. As of the date of this filing, we are aware of the impact on our business as a result of COVID-19 but uncertain as to the extent of this impact on our condensed consolidated financial statements. There is uncertainty as to the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.</p><p style="MARGIN: 0px; text-align:justify;"><em>&nbsp;</em></p><p style="MARGIN: 0px; text-align:justify;"><em>Going Concern</em></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Our independent registered public accounting firm has issued a report on our audited financial statements for the fiscal year ended December 31, 2019 that included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Off-Balance Sheet Arrangements</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="it3">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Not applicable.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="it4">Item 4. Controls and Procedures.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>&nbsp;</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>Evaluation of disclosure controls and procedures.</strong> We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">We conducted an evaluation, under the supervision and with the participation of our principal executive and financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2020. Based upon their evaluation and subject to the foregoing, the principal executive and financial officers have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong>Changes in internal controls.</strong> Management determined there were no changes in our internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; </p><p style="MARGIN: 0px; text-align:justify;"><strong><a name="p2">PART II - OTHER INFORMATION</a></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt1">Item 1. Legal Proceedings</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">There have been no other material developments with respect to previously reported legal proceedings discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt1a">Item 1A. Risk Factors.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Investing in our common stock involves a high degree of risk. Our Annual Report on Form 10-K for the year ended December 31, 2019 includes a detailed discussion of our risk factors under the heading &#8220;Part I, Item 1A-Risk Factors.&#8221; There are no changes from the risk factors previously disclosed in our Annual Report on Form 10-K. You should carefully consider the risk factors discussed in our Annual Report on Form 10-K, as well as the other information in this report before deciding whether to invest in shares of our common stock. The occurrence of any of the risks discussed in the Annual Report on Form 10-K could harm our business, financial condition, results of operations or growth prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">None.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt3">Item 3. Defaults Upon Senior Securities.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">None.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt4">Item 4. Mine Safety Disclosures.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Not applicable.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt5">Item 5. Other Information.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">None.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="itt6">Item 6. Exhibits.</a></u></strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:9%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex101.htm">10.1</a></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex101.htm">Amended and Restated Multi-Draw Credit Agreement, dated April 29, 2020, by and between Emerald Bioscience, Inc. and Emerald Health Sciences, Inc. <sup>(1)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex102.htm">10.2</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420000959/embi_ex102.htm">Separation and Release Agreement, dated April 29, 2020, between Emerald Bioscience, Inc. and Doug Cesario <sup>(1)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex101.htm">10.3</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex101.htm">Form of Securities Purchase Agreement, dated as of July 31, 2020, between the Company and certain purchasers set forth in the signature page thereto <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex41.htm">10.4</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex41.htm">Form of Common Warrant <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex42.htm">10.5 </a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex42.htm">Form of Pre-Funded Warrant <sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex311.htm">31.1*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex312.htm">31.2*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex321.htm">32.1*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex321.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex322.htm">32.2*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex322.htm">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">________</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;vertical-align:top;"> <p style="margin:0px">(1) </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Included as exhibit to our Current Report on Form 8-K filed on April 29, 2020.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Included as exhibit to our Current Report on Form 8-K filed on August 5, 2020.</p></td></tr></table> <p style="margin:0px">&nbsp;</p><p style="margin:0px">(*) Filed herewith.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#toc">Table of Contents</a></em></td></tr></table> <p style="margin:0px">&nbsp;&nbsp; &nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Emerald Bioscience, Inc.,</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>a Nevada corporation</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:3%;"></td> <td style="width:35%;"></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">August 13, 2020</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Chief Executive Officer, Chairman of the Board, and Director</p><p style="margin:0px">(Principal Executive Officer)</p></td> <td></td></tr></table> <p style="margin:0px">&nbsp; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">August 13, 2020</p></td> <td style="width:3%;"> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Elena Traistaru</em></p></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td></td> <td></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><em>Elena Traistaru</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Chief Financial Officer</p><p style="MARGIN: 0px; text-align:justify;">(Principal Financial and Accounting Officer)</p></td> <td></td></tr></table>&nbsp;&nbsp;&nbsp;&nbsp; <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr></table> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>embi_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head><title>embi_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>Certification of Principal Executive Officer,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</strong></p><p style="MARGIN: 0px; text-align:left;">&nbsp;&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">I, Punit Dhillon, certify that:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp; &nbsp; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of Emerald Bioscience, Inc. for the quarter ended June 30, 2020;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; &nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Punit Dhillon </em></p><p style="MARGIN: 0px; text-align:justify;">Chief Executive Officer, Chairman of the Board, and Director</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;Date: August 13, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="margin:0px">&nbsp;&nbsp;&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>embi_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head><title>embi_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>Certification of Principal Financial Officer,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</strong></p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">I, <em>Elena Traistaru</em>, certify that:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of Emerald Bioscience, Inc. for the quarter ended June 30, 2020;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; &nbsp; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Elena Traistaru</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Elena Traistaru</em></p><p style="MARGIN: 0px; text-align:justify;">Chief Financial Officer</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">Date: August 13, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>embi_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head><title>embi_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="margin:0px">In connection with the Quarterly Report of Emerald Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Punit Dhillon, Chief Executive Officer, Chairman of the Board, and Director of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp; </p><p style="MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Punit Dhillon</em></p><p style="margin:0px">Chief Executive Officer, Chairman of the Board, and Director</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">August 13, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="margin:0px">&nbsp;&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>embi_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head><title>embi_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:center;"><strong>Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350,</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</strong></p><p style="MARGIN: 0px; text-align:center;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">In connection with the Quarterly Report of Emerald Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Elena Traistaru, Chief Financial Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><p style="MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="MARGIN: 0px; text-align:justify;">&nbsp;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Elena Traistaru</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Elena Traistaru</em></p><p style="MARGIN: 0px; text-align:justify;">Chief Financial Officer</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">August 13, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="margin:0px">&nbsp;&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>embi-20200630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
 <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:embi="http://www.emeraldbio.life/20200630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">













































































































































































































































































































































































































































































































































































































































































































































































































  <link:schemaRef xlink:href="embi-20200630.xsd" xlink:type="simple"></link:schemaRef>
  <context id="C_20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="C_20200812">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-08-12</instant>
    </period>
  </context>
  <context id="C_20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-08-04</instant>
    </period>
  </context>
  <context id="C_20200801to20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiManagementDeferralAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:ManagementDeferralAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="C_20200801to20200812_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:StockOptions2014PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-12</endDate>
    </period>
  </context>
  <context id="C_20200801to20200807_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSeparationAndReleaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-07</endDate>
    </period>
  </context>
  <context id="C_20200801to20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-04</endDate>
    </period>
  </context>
  <context id="C_20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200701to20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsToSeriesBStockholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:AmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-29</instant>
    </period>
  </context>
  <context id="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">embi:PaycheckProtectionProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-24</instant>
    </period>
  </context>
  <context id="C_20200422_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramPromissoryNoteMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">embi:PaycheckProtectionProgramPromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-22</instant>
    </period>
  </context>
  <context id="C_20200401to20200630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:AmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-04-29</endDate>
    </period>
  </context>
  <context id="C_20200401to20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">embi:PaycheckProtectionProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-04-24</endDate>
    </period>
  </context>
  <context id="C_20200331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200301to20200330_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-03-01</startDate>
      <endDate>2020-03-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsToSeriesBStockholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiFifthAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:FifthAmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiFourthAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:FourthAmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20191231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-12-01</startDate>
      <endDate>2019-12-19</endDate>
    </period>
  </context>
  <context id="C_20190630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190401to20190630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="C_20181231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="Context_Custom_31_Oct_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-31</startDate>
      <endDate>2018-11-01</endDate>
    </period>
  </context>
  <context id="C_20181030to20181101_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-30</startDate>
      <endDate>2018-11-01</endDate>
    </period>
  </context>
  <context id="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-10-05</instant>
    </period>
  </context>
  <context id="C_20181001to20181005_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProDrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProDrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProDrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:OptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="C_20180201to20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-16</endDate>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-28</instant>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5070LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-01-01</startDate>
      <endDate>2017-01-10</endDate>
    </period>
  </context>
  <context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2014-10-31</instant>
    </period>
  </context>
  <context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <unit id="Percent">


        <measure>embi:Percent</measure>
  </unit>
  <unit id="USD">


        <measure>iso4217:USD</measure>
  </unit>
  <unit id="USD_per_Share">


        <divide>



              <unitNumerator>


                    <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>


                    <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">


        <measure>pure</measure>
  </unit>
  <unit id="shares">


        <measure>shares</measure>
  </unit>
  <us-gaap:CommitmentsAndContingencies contextRef="C_20200630" id="Fxbrl_20200810103520953" unitRef="USD" xsi:nil="true"></us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommitmentsAndContingencies contextRef="C_20191231" id="Fxbrl_20200810103525691" unitRef="USD" xsi:nil="true"></us-gaap:CommitmentsAndContingencies>
  <dei:EntityCentralIndexKey contextRef="C_20200101to20200630" id="Fdei_EntityCentralIndexKey_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">0001516551</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="C_20200101to20200630" id="Fdei_CurrentFiscalYearEndDate_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory contextRef="C_20200101to20200630" id="Fdei_EntityFilerCategory_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:AmendmentFlag contextRef="C_20200101to20200630" id="Fdei_AmendmentFlag_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">false</dei:AmendmentFlag>
  <dei:DocumentFiscalYearFocus contextRef="C_20200101to20200630" id="Fdei_DocumentFiscalYearFocus_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="C_20200101to20200630" id="Fdei_DocumentFiscalPeriodFocus_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:EntitySmallBusiness contextRef="C_20200101to20200630" id="Fdei_EntitySmallBusiness_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany contextRef="C_20200101to20200630" id="Fdei_EntityEmergingGrowthCompany_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityShellCompany contextRef="C_20200101to20200630">false</dei:EntityShellCompany>
  <dei:EntityInteractiveDataCurrent contextRef="C_20200101to20200630">Yes</dei:EntityInteractiveDataCurrent>
  <dei:DocumentType contextRef="C_20200101to20200630" id="F22_10Q">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="C_20200101to20200630" id="F43_June302019">2020-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="C_20200101to20200630" id="F73_EmeraldBio">Emerald Bioscience, Inc.</dei:EntityRegistrantName>
  <dei:EntityCommonStockSharesOutstanding contextRef="C_20200812" decimals="INF" id="F229_134095247" unitRef="shares">239541081</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102241956_684" unitRef="USD">102524</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102241956_690" unitRef="USD">1829977</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102300029_700" unitRef="USD">4538</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102300029_707" unitRef="USD">4538</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102312875_717" unitRef="USD">114250</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102312875_724" unitRef="USD">152695</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102336157_734" unitRef="USD">4643</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102336157_741" unitRef="USD">7550</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102350254_751" unitRef="USD">225955</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102350254_758" unitRef="USD">1994760</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102521737_xbrl_20200810102404699_787" unitRef="USD">1252</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102521737_xbrl_20200810102404699_794" unitRef="USD">1983</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102420323_803" unitRef="USD">227207</us-gaap:Assets>
  <us-gaap:Assets contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102420323_809" unitRef="USD">1996743</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102546003_877" unitRef="USD">1096283</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102546003_883" unitRef="USD">129809</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102608610_xbrl_20200506161608137" unitRef="USD">77290</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102608610_xbrl_20200506161655573" unitRef="USD">10000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102757250_xbrl_20200506161732559" unitRef="USD">37726</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ShortTermBorrowings contextRef="C_20200630" decimals="0" id="Fxbrl_20200810113313032" unitRef="USD">51653</us-gaap:ShortTermBorrowings>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102839545_893" unitRef="USD">426884</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102839545_900" unitRef="USD">420406</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102851226_910" unitRef="USD">465287</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102851226_917" unitRef="USD">410603</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20181231" decimals="0" id="Fxbrl_20200810100806908_xbrl_20200506171810074" unitRef="USD">15738913</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20190630" decimals="0" id="Fxbrl_20200810100806908_xbrl_20200506164454119" unitRef="USD">10662548</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102904997_927" unitRef="USD">2155123</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102904997_934" unitRef="USD">970818</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebt contextRef="C_20200630" decimals="0" id="Fxbrl_20200810113344516" unitRef="USD">65047</us-gaap:LongTermDebt>
  <embi:MultidrawCreditAgreementRelatedPartyNoncurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810124124323" unitRef="USD">450000</embi:MultidrawCreditAgreementRelatedPartyNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810102946919_983" unitRef="USD">651461</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810102946919_990" unitRef="USD">387070</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122227587" unitRef="USD">450000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122241594" unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103045290_1000" unitRef="USD">90797</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810100656232_xbrl_20200506163009940" unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20181231" decimals="0" id="Fxbrl_20200810100806901_xbrl_20200506171802173" unitRef="USD">219453</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20190630" decimals="0" id="Fxbrl_20200810100806901_xbrl_20200506164443121" unitRef="USD">516377</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103107444_1017" unitRef="USD">3321631</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103107444_1024" unitRef="USD">1448685</us-gaap:Liabilities>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20200630" decimals="3" id="Fxbrl_202008101037121040" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20191231" decimals="3" id="Fxbrl_20200810103712104" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20200630" decimals="INF" id="Fxbrl_202008101037278060" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_20200810103727806" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="C_20191231" decimals="INF" id="Fxbrl_202008101037406062" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="C_20200630" decimals="INF" id="Fxbrl_202008101037406060" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="C_20191231" decimals="INF" id="Fxbrl_202008101037406061" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="C_20200630" decimals="INF" id="Fxbrl_20200810103740606" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103300612_xbrl_20200506172303668" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103300612_xbrl_20200506172309386" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20191231" decimals="4" id="Fxbrl_202008101110323900" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20200630" decimals="4" id="Fxbrl_20200810111032390" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_202008101111125140" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20200630" decimals="INF" id="Fxbrl_20200810111112514" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20200630" decimals="INF" id="Fxbrl_202008101111364960" unitRef="shares">183207747</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20191231" decimals="INF" id="Fxbrl_202008101111589490" unitRef="shares">182895247</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="C_20200630" decimals="INF" id="Fxbrl_20200810111136496" unitRef="shares">183207747</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="C_20191231" decimals="INF" id="Fxbrl_20200810111158949" unitRef="shares">182895247</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103504787_1165" unitRef="USD">183208</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103504787_1172" unitRef="USD">182895</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103455963_1182" unitRef="USD">32657546</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103455963_1189" unitRef="USD">32538445</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103445139_1199_32094209" unitRef="USD">-35935178</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103445139_1205_33225107" unitRef="USD">-32173282</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103422851_1214_11641442" unitRef="USD">-3094424</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103422851_1220_15562252" unitRef="USD">548058</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200506165353333" unitRef="USD">133908</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506165515074" unitRef="USD">17528947</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200506165618603" unitRef="USD">-33225107</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231" decimals="0" id="Fxbrl_20200506165621107" unitRef="USD">-15562252</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200506165410009" unitRef="USD">133908</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506165523045" unitRef="USD">20001400</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200506165627194" unitRef="USD">-47999499</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331" decimals="0" id="Fxbrl_20200506165629682" unitRef="USD">-27864191</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200506165432809" unitRef="USD">134095</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506165549538" unitRef="USD">20318672</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200506165557307" unitRef="USD">-32094209</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630" decimals="0" id="Fxbrl_20200506165601003" unitRef="USD">-11641442</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200810103800952_37" unitRef="USD">182895</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200810103800952_311" unitRef="USD">32538445</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200810103800952_315" unitRef="USD">-32173282</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200810103800952_117" unitRef="USD">183208</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200810103800952_1111" unitRef="USD">32628837</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200810103800952_1115" unitRef="USD">-34514942</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331" decimals="0" id="Fxbrl_20200810103800952_1119" unitRef="USD">-1702897</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200810103800952_177" unitRef="USD">183208</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200810103800952_1711" unitRef="USD">32657546</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200810103800952_1715" unitRef="USD">-35935178</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20200630" decimals="0" id="Fxbrl_20200810103409377_1228" unitRef="USD">227207</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20191231" decimals="0" id="Fxbrl_20200810103409377_1234" unitRef="USD">1996743</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20200401to20200630" decimals="0" id="F1401" unitRef="USD">428529</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20191105123842957" unitRef="USD">688041</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121037785" unitRef="USD">1228141</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121040912" unitRef="USD">1009026</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20200401to20200630" decimals="0" id="F1429" unitRef="USD">792129</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190401to20190630" decimals="0" id="F1436" unitRef="USD">1082846</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121047050" unitRef="USD">2203725</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121053051" unitRef="USD">2276928</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="C_20200401to20200630" decimals="0" id="F1460" unitRef="USD">1220658</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20190401to20190630" decimals="0" id="F1467" unitRef="USD">1770887</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121102298" unitRef="USD">3431866</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121104593" unitRef="USD">3285954</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="C_20200401to20200630" decimals="0" id="F1527_1770887" unitRef="USD">-1220658</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20190401to20190630" decimals="0" id="F1533_1080190" unitRef="USD">-1770887</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121111311" unitRef="USD">-3431866</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121114903" unitRef="USD">-3285954</us-gaap:OperatingIncomeLoss>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200507011618917" unitRef="USD">26353</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20190401to20190630" decimals="0" id="F1631" unitRef="USD">-17971742</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121122115" unitRef="USD">-9550</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121126479" unitRef="USD">-5151124</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200506182043686" unitRef="USD">-0</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810164805361" unitRef="USD">-0</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810164821396" unitRef="USD">-0</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121149352" unitRef="USD">-322644</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20190101to20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124501953" unitRef="USD">-322644</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <us-gaap:InterestExpense contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20191106122017147" unitRef="USD">171625</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200506174736395" unitRef="USD">293965</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121157844" unitRef="USD">337980</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121200682" unitRef="USD">410028</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810121222455" unitRef="USD">-197978</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810121228027" unitRef="USD">17677777</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121230928" unitRef="USD">-328430</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121233575" unitRef="USD">4418452</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810121301251" unitRef="USD">-1418636</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810121309211" unitRef="USD">15906890</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121306666" unitRef="USD">-3760296</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121312017" unitRef="USD">1132498</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810121329729" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810121334753" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121337577" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121340009" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810121355816" unitRef="USD">-1420236</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810121400690" unitRef="USD">15905290</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121403337" unitRef="USD">-3761896</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121405828" unitRef="USD">1130898</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200506170436345" unitRef="USD">-14774392</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20200506170425081" unitRef="USD">-14774392</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200506170419481" unitRef="USD">15905290</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200810103800952_915" unitRef="USD">-2341660</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20200331" decimals="0" id="Fxbrl_20200810103800952_919" unitRef="USD">-2341660</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200810103800952_1515" unitRef="USD">-1420236</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic contextRef="C_20200401to20200630" decimals="2" id="Fxbrl_20191106093642166" unitRef="USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20190401to20190630" decimals="2" id="F2104_002" unitRef="USD_per_Share">0.12</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20200101to20200630" decimals="2" id="Fxbrl_20200810121551067" unitRef="USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20190101to20190630" decimals="2" id="Fxbrl_20200810121607921" unitRef="USD_per_Share">0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20200401to20200630" decimals="2" id="Fxbrl_20191106093656253" unitRef="USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20190401to20190630" decimals="2" id="F2129_002" unitRef="USD_per_Share">0.08</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20200101to20200630" decimals="2" id="Fxbrl_20200810121620887" unitRef="USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20190101to20190630" decimals="2" id="Fxbrl_20200810121623769" unitRef="USD_per_Share">0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20200401to20200630" decimals="0" id="F2220" unitRef="shares">183052175</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20190401to20190630" decimals="0" id="F2227" unitRef="shares">132923037</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121632541" unitRef="shares">182654571</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121634848" unitRef="shares">132826677</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20200401to20200630" decimals="0" id="F2251" unitRef="shares">183052175</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20190401to20190630" decimals="0" id="F2258" unitRef="shares">189094958</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810121639842" unitRef="shares">182654571</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810121642137" unitRef="shares">172058053</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:Depreciation contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320253_2391_731" unitRef="USD">731</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320253_2397_813" unitRef="USD">731</us-gaap:Depreciation>
  <us-gaap:ShareBasedCompensation contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320261_2407_344577" unitRef="USD">92851</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320261_2413_330212" unitRef="USD">344577</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200506101843686" unitRef="USD">28709</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200506101859674" unitRef="USD">173084</us-gaap:ShareBasedCompensation>
  <embi:FairValueAdjustmentOfDerivativeLiabilities contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320270_2423_5151124" unitRef="USD">9550</embi:FairValueAdjustmentOfDerivativeLiabilities>
  <embi:FairValueAdjustmentOfDerivativeLiabilities contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320270_2430_602749" unitRef="USD">5151124</embi:FairValueAdjustmentOfDerivativeLiabilities>
  <embi:FairValueOfDerivativeLiabilityExcessOfProceeds contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320278_2446_7174634" unitRef="USD">322644</embi:FairValueOfDerivativeLiabilityExcessOfProceeds>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320286_2472_244751" unitRef="USD">264391</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320286_2478_34608" unitRef="USD">244751</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320292_2500_169079" unitRef="USD">-38445</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320292_xbrl_20200506152346086" unitRef="USD">169079</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320299_xbrl_20191105122516336" unitRef="USD">-2907</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320303_2533_57862" unitRef="USD">966474</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320303_2539_89001" unitRef="USD">57862</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320311_xbrl_20200506152636329" unitRef="USD">67290</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
  <embi:IncreaseDecreaseAccruedInterestDueToRelatedParty contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320315_xbrl_20200506153733401" unitRef="USD">37726</embi:IncreaseDecreaseAccruedInterestDueToRelatedParty>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320320_xbrl_20200506153154509" unitRef="USD">6478</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320320_2571_79487" unitRef="USD">182494</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320328_2581_3036246" unitRef="USD">-2294153</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320328_2588_2112575" unitRef="USD">-3036246</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ProceedsFromNotesPayable contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320335_xbrl_20200810111849059" unitRef="USD">116700</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810144211125" unitRef="USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810144235638" unitRef="USD">9301</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20200801to20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20200810122459157" unitRef="USD">825698</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320341_xbrl_20200506153958644" unitRef="USD">450000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114630567" unitRef="USD">3990699</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320345_2736_3731799" unitRef="USD">566700</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114636966" unitRef="USD">3990699</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320351_xbrl_20191106103644979" unitRef="USD">-1727453</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320351_2763_1614839" unitRef="USD">954453</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20191231" decimals="0" id="Fxbrl_20200810114320358_2786_1857885" unitRef="USD">1834515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20181231" decimals="0" id="Fxbrl_20200810114320358_2793_264383" unitRef="USD">1857885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20200630" decimals="0" id="Fxbrl_20200810114320366_2815_2812338" unitRef="USD">107062</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20190630" decimals="0" id="Fxbrl_20200810114320366_2822_1879222" unitRef="USD">2812338</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <embi:CashAndCashEquivalents contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320373_2868_2807826" unitRef="USD">102524</embi:CashAndCashEquivalents>
  <embi:CashAndCashEquivalents contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320373_2875_1874720" unitRef="USD">2807826</embi:CashAndCashEquivalents>
  <embi:SupplementalRestrictedCash contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320380_2885_4512" unitRef="USD">4538</embi:SupplementalRestrictedCash>
  <embi:SupplementalRestrictedCash contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320380_2891_4502" unitRef="USD">4512</embi:SupplementalRestrictedCash>
  <embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320388_2902_2812338" unitRef="USD">107062</embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated>
  <embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320388_2909_1879222" unitRef="USD">2812338</embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated>
  <us-gaap:InterestPaidNet contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114650162" unitRef="USD">165277</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaidNet contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114320400_xbrl_20200810111917159" unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeTaxesPaidNet contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114320400_xbrl_20200810111930722" unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
  <embi:ExerciseOfWarrants contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810114826634" unitRef="USD">26563</embi:ExerciseOfWarrants>
  <embi:ExerciseOfWarrants contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114832227" unitRef="USD">144375</embi:ExerciseOfWarrants>
  <embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114844457" unitRef="USD">716110</embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114854575" unitRef="USD">193414</embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810114904419" unitRef="USD">1584850</embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement>
  <us-gaap:SharesIssued contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200506164828091" unitRef="shares">133907747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200506164824730" unitRef="shares">133907747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200506164817894" unitRef="shares">134095247</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200810103800952_33" unitRef="shares">182895247</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200810103800952_113" unitRef="shares">183207747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200810103800952_173" unitRef="shares">183207747</us-gaap:SharesIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506165959491" unitRef="USD">171493</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20200506170006214" unitRef="USD">171493</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506170011322" unitRef="USD">173084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200506170022986" unitRef="USD">173084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200810103800952_511" unitRef="USD">64142</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20200331" decimals="0" id="Fxbrl_20200810103800952_519" unitRef="USD">64142</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200810103800952_1311" unitRef="USD">28709</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810103800952_1319" unitRef="USD">28709</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506170118626" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20200506170329670" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="F11185_716110" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506170121363" unitRef="USD">1584850</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20200506170335027" unitRef="USD">1584850</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200506170257914" unitRef="shares">187500</embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200810103800952_73" unitRef="shares">312500</embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200506170232553" unitRef="USD">187</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200506170131090" unitRef="USD">144188</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200506170220673" unitRef="USD">144375</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200810103800952_77" unitRef="USD">313</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200810103800952_711" unitRef="USD">26250</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20200331" decimals="0" id="Fxbrl_20200810103800952_719" unitRef="USD">26563</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200810095149487">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1. Nature of Operations and Business Activities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Emerald Bioscience, Inc. (the &amp;#x201c;Company&amp;#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &amp;#x201c;Merger&amp;#x201d;) pursuant to which Nemus, a California corporation (&amp;#x201c;Nemus Sub&amp;#x201d;), became the Company&amp;#x2019;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Sub to form a Nevada company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&amp;#x201c;Emerald Health Sciences&amp;#x201d;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &amp;#x201c;Emerald Financing&amp;#x201d;). As part of the transaction, the Company&amp;#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&amp;#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&amp;#x2019;s Board.&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company (Note 8).&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On February 11, 2019, the Company&amp;#x2019;s Board of Directors (the &amp;#x201c;Board&amp;#x201d;) and majority stockholder unanimously approved an amendment to the Company&amp;#x2019;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&amp;#x2019;s name to Emerald Bioscience, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&amp;#x201c;EMBI Australia&amp;#x201d;), in order to qualify for the Australian government&amp;#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&amp;#x2019;s product candidates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&amp;#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 7 - Related Party Matters for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company is a biopharmaceutical company located in &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;San Diego&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&amp;#x201c;UM&amp;#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As of June 30, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;The Company has incurred operating losses and negative cash flows from operations since inception and as of June 30, 2020, had an accumulated deficit of $35,935,178, a stockholders&amp;#x2019; deficit of $3,094,424 and a working capital deficit of $1,929,168. The Company anticipates operating losses and negative cash flows from operations into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of June 30, 2020, the Company had unrestricted cash in the amount of $102,524 as compared to $1,829,977 as of December 31, 2019.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company&amp;#x2019;s expected cash requirements, without obtaining additional funding management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&amp;#x2019;s ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;The Company&amp;#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &amp;#x201c;Credit Agreement&amp;#x201d;) with Emerald Health Sciences (See Note 4).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &amp;#x201c;Amended Credit Agreement&amp;#x201d;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;During the three months ended June 30, 2020 the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. The advances bear interest at 7% per annum and mature on October 5, 2022. The Company intends to use the proceeds from the advances for general corporate and working capital purposes. Emerald Health Sciences has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and that no warrants will be issued with the advances.&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &amp;#x201c;PPP Loan&amp;#x201d;) from City National Bank (the &amp;#x201c;PPP Loan Lender&amp;#x201d;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &amp;#x201c;PPP&amp;#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;CARES Act&amp;#x201d;) administered by the U.S. Small Business Administration (&amp;#x201c;SBA&amp;#x201d;) (Note 4).&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On July 31, 2020, the Company entered into the August 2020 Financing (Note 8), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction are $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively, The term of the common stock warrants is five years&amp;#160;and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company intends to use the net proceeds of the Offering for general corporate purposes, including working capital.&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&amp;#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely. In August 2020, subsequent to closing the August 2020 Financing, the Board of Directors determined that the Company has been sufficiently financed and authorized the Company to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;In December 2019, a novel strain of coronavirus (&amp;#x201c;COVID-19&amp;#x201d;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&amp;#x2019;s ability to raise additional capital and obtain the necessary funds.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of NB1111 from the second half of 2020, to the 2021 timeframe.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <embi:WorkingCapitalDeficit contextRef="C_20200630" decimals="0" id="Fxbrl_20200810094314651" unitRef="USD">-1929168</embi:WorkingCapitalDeficit>
  <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095630243" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095645793" unitRef="USD">6000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123144141" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <embi:DrawDownsLoansInAggregatePrincipalAmount contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506151642434" unitRef="USD">6000000</embi:DrawDownsLoansInAggregatePrincipalAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506151736556" unitRef="shares">7500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="INF" id="Fxbrl_202008101103169120" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="INF" id="Fxbrl_20200810110316912" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200506190627034" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20200812032419956" unitRef="shares">8166667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506151826801" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember" decimals="2" id="Fxbrl_20200810104122121" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember" decimals="3" id="Fxbrl_20200810104519992" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember" decimals="2" id="Fxbrl_20191101141039417" unitRef="USD_per_Share">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="Fxbrl_20200810094341631" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20200810094347448" unitRef="USD_per_Share">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember" decimals="2" id="Fxbrl_20191101124813770" unitRef="USD_per_Share">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="Fxbrl_20191101140403604" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="2" id="F11042" unitRef="USD_per_Share">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="2" id="F11065" unitRef="USD_per_Share">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="F11088" unitRef="USD_per_Share">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="2" id="Fxbrl_20200810164306721" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20200810162508561" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="2" id="Fxbrl_20200810153549838" unitRef="USD_per_Share">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="2" id="Fxbrl_202008101104137530" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="2" id="Fxbrl_20200810110413753" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="2" id="Fxbrl_20200506141753275" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" decimals="2" id="Fxbrl_20200506141808360" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="2" id="Fxbrl_20200506190439870" unitRef="USD_per_Share">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506123330853" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200808141746389" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200808142230843" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="3" id="Fxbrl_20200812032544790" unitRef="USD_per_Share">0.075</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsMember" decimals="2" id="Fxbrl_20200810123439642" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiFourthAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095910754" unitRef="USD">150000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiFifthAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095917886" unitRef="USD">300000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200810095947187" unitRef="pure">0.07</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506123203233" unitRef="pure">0.07</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:DebtInstrumentMaturityDate contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" id="Fxbrl_20200810100020231">2022-10-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" id="Fxbrl_20200506123222642">2022-10-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="C_20200401to20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" id="Fxbrl_20200808131031271">2022-04-24</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20200422_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramPromissoryNoteMember" decimals="0" id="Fxbrl_20200810100110446" unitRef="USD">116700</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124256772" unitRef="USD">4000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="0" id="Fxbrl_20200810114850188" unitRef="USD">116700</us-gaap:DebtInstrumentFaceAmount>
  <embi:NumberOfCommonStockUnitsSold contextRef="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="INF" id="Fxbrl_20200810104024041" unitRef="shares">56333334</embi:NumberOfCommonStockUnitsSold>
  <embi:NumberOfPreFundedUnitsSold contextRef="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="INF" id="Fxbrl_20200810104534485" unitRef="shares">60333334</embi:NumberOfPreFundedUnitsSold>
  <embi:TermOfWarrants contextRef="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" id="Fxbrl_20200810124503977">P5Y</embi:TermOfWarrants>
  <embi:SeniorManagementCompensationPlanDescription contextRef="C_20200101to20200630" id="Fxbrl_20200810102442780">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&amp;#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely.</embi:SeniorManagementCompensationPlanDescription>
  <embi:SeniorManagementCompensationPlanDescription contextRef="C_20200701to20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" id="Fxbrl_20200810102520573">In August 2020, subsequent to closing the August 2020 Financing, the Board of Directors determined that the Company has been sufficiently financed and authorized the Company to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance.</embi:SeniorManagementCompensationPlanDescription>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20200101to20200630" id="Fb4c22e21-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 1.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2. Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&amp;#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&amp;#x201c;GAAP&amp;#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&amp;#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&amp;#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&amp;#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&amp;#x2019;s business and the risks inherent therein.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Use of Estimates&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Risks and Uncertainties&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Fair Value Measurements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:6%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&amp;#x2019;s relatively short term the carrying value approximates fair value.&amp;#160; As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was&amp;#160;$387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Condensed Consolidated Balance Sheets. As of June 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Convertible Instruments&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Warrants Issued in Connection with Financings&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive (Loss) Income .&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Debt Issuance Costs and Interest&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Research and Development Expenses and Licensed Technology&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Stock-Based Compensation Expense &lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividends - The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;(Loss) Earnings Per Common Share&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies FASB ASC No. 260, Earnings per Share in calculating its basic and diluted net (loss) earnings per common share. Basic (loss) earnings per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted (loss) earnings per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss (earnings) per share of common stock for the periods presented because including them would have been anti-dilutive:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Three Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Ended June 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Six Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Ended June 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;4,186,786&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,411,846&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;4,186,786&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,814,505&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;209,055&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;237,798&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Common shares underlying convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5,125,364&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5,125,364&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;11,722,222&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;18,844,002&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;20,353,145&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Recent Accounting Pronouncements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&amp;#x2014;&lt;em&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#x2014;Contracts in Entity&amp;#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&amp;#x2019;s Own Equity.&lt;/em&gt; This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, the FASB issued ASU No. 2019-12 &lt;em&gt;Income Taxes&lt;/em&gt; (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150006585">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&amp;#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&amp;#x201c;GAAP&amp;#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&amp;#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&amp;#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&amp;#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&amp;#x2019;s business and the risks inherent therein.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="C_20200101to20200630" id="Fxbrl_20200506150017150">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Use of Estimates&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <embi:RisksAndUncertaintiesPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150024586">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Risks and Uncertainties&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</embi:RisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150035376">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Fair Value Measurements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:6%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&amp;#x2019;s relatively short term the carrying value approximates fair value.&amp;#160; As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was&amp;#160;$387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Condensed Consolidated Balance Sheets. As of June 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:AdvancesFairValueDisclosure contextRef="C_20191231" decimals="0" id="Fxbrl_20200812030942396" unitRef="USD">1877938</us-gaap:AdvancesFairValueDisclosure>
  <us-gaap:DerivativesPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150047256">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Convertible Instruments&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <embi:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150058752">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Warrants Issued in Connection with Financings&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive (Loss) Income .&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</embi:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150104464">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Debt Issuance Costs and Interest&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20200101to20200630" id="Fxbrl_20200506150111336">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Research and Development Expenses and Licensed Technology&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150116241">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Stock-Based Compensation Expense &lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividends - The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150126682">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;(Loss) Earnings Per Common Share&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company applies FASB ASC No. 260, Earnings per Share in calculating its basic and diluted net (loss) earnings per common share. Basic (loss) earnings per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted (loss) earnings per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss (earnings) per share of common stock for the periods presented because including them would have been anti-dilutive:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Three Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Ended June 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Six Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Ended June 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;4,186,786&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,411,846&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;4,186,786&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,814,505&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;209,055&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;237,798&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Common shares underlying convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5,125,364&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5,125,364&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;11,722,222&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;18,844,002&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;20,353,145&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506135137877">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Three Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Ended June 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Six Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Ended June 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;4,186,786&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,411,846&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;4,186,786&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;2,814,505&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;209,055&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;237,798&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Common shares underlying convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5,125,364&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5,125,364&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;11,722,222&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;18,844,002&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;20,353,145&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200401to20200630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20200506134914728" unitRef="shares">4186786</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190401to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20200506134936546" unitRef="shares">2411846</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20200810094443744" unitRef="shares">4186786</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20200810094450672" unitRef="shares">2814505</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200401to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200506134855200" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190401to20190630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200506134830454" unitRef="shares">209055</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200810094458264" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200810094504841" unitRef="shares">237798</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200401to20200630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20200506134958924" unitRef="shares">5125364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190401to20190630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20200506135018782" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20200810094511143" unitRef="shares">5125364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20200810094517815" unitRef="shares">11722222</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20200506135049646" unitRef="shares">22304750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20200506135107374" unitRef="shares">18844002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20200810094528576" unitRef="shares">22304750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190630_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20200810094534870" unitRef="shares">20353145</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506150320510">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Recent Accounting Pronouncements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&amp;#x2014;&lt;em&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#x2014;Contracts in Entity&amp;#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&amp;#x2019;s Own Equity.&lt;/em&gt; This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, the FASB issued ASU No. 2019-12 &lt;em&gt;Income Taxes&lt;/em&gt; (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <embi:WarrantsAndDerivativeLiabilitiesTextBlock contextRef="C_20200101to20200630" id="Fb4c22e22-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3. Warrants and Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&amp;#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Warrants vested and outstanding as of June 30, 2020 are summarized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Vested and&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td style="BORDER-BOTTOM:1px solid" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Pre 2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;1.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;6&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,660,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;1.15&amp;#x2014;5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;5&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;256,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Common Stock Warrants to Series B Stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;718,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2016 Common Stock Warrants to Service Providers&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;1.15&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;40,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.40&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.25&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;480,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2017 Common Stock Warrants to Service Provider&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.41&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2018 Emerald Financing Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span id="xbrl_20191107101846769"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;7,500,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2019 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;0.35&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;8,000,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Total warrants vested and outstanding as of June 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;22,304,750&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the six months ended June 30, 2019, the Company issued&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants were equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;At&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Issuance&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;91.6&amp;#x2014;92.1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;2.23&amp;#x2014;2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5.0&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;0.33&amp;#x2014;0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following tables summarize the activity of derivative liabilities for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six Months Ended June 30, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair value of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;to Equity &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Financing - warrant liability &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;76,708&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;352,732&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Series B - warrant liability &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,539&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(26,563&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;112,555&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(9,550&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(26,563&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;465,287&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;465,287&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-align:left"&gt;&amp;#160; &amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six Months Ended June 30, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;516,058&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(219,134&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;516,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Financing - warrant liability (2)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(4,887,929&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,363,484&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Series B - warrant liability (3)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(44,061&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(144,375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;299,064&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(5,151,124&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(144,375&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;11,178,925&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(516,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;10,662,548&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160; &amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&amp;#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes model for each payment period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. For the three and six months ended June 30, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;Emerald Financing Warrant Liability (2)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, &lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt;, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, &lt;em&gt;Derivatives and Hedging/Contracts in Entity&lt;/em&gt;&lt;em&gt;&amp;#x2019;&lt;/em&gt;&lt;em&gt;s Own Equity&lt;/em&gt;, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, &lt;em&gt;Fair Value Measurement&lt;/em&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;82.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;Series B Warrant Liability (3)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a &amp;#x201c;down-round&amp;#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the six months ended June 30, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&amp;#x2019;s common stock on the exercise dates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</embi:WarrantsAndDerivativeLiabilitiesTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_20200101to20200630" id="Fb4ddf380-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Vested and&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td style="BORDER-BOTTOM:1px solid" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Pre 2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;1.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;6&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;1,660,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;1.15&amp;#x2014;5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;5&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;256,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Common Stock Warrants to Series B Stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;718,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2016 Common Stock Warrants to Service Providers&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;1.15&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;40,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.40&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.25&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;480,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2017 Common Stock Warrants to Service Provider&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.41&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2018 Emerald Financing Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span id="xbrl_20191107101846769"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;7,500,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;2019 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;0.35&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;5&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;8,000,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;strong&gt;Total warrants vested and outstanding as of June 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;strong&gt;22,304,750&lt;/strong&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200810095519736">P6Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200810095638117">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200810160320633">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200810095646181">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember" id="Fxbrl_20191101125125139">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20191101140300168">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="Fxbrl_20191101140457103">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="Fxbrl_20191101140706851">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20191101140714179">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" id="Fxbrl_20191107103627372">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20191101172324097">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" id="Fxbrl_20200506171055008">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20180201to20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_202008101104590470">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_20200810110459047">P5Y</embi:TermOfWarrant>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember" decimals="INF" id="F10939" unitRef="shares">1660000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember" decimals="INF" id="F10962" unitRef="shares">256000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember" decimals="INF" id="F11010" unitRef="shares">718750</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="F11033" unitRef="shares">40000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="INF" id="F11056" unitRef="shares">125000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="INF" id="F11079" unitRef="shares">480000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="F11102" unitRef="shares">125000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="F11125" unitRef="shares">3400000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="F11148" unitRef="shares">7500000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20200506171102006" unitRef="shares">8000000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200630" decimals="INF" id="F11176_57943250" unitRef="shares">22304750</embi:WarrantsVestedAndOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20190630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="F11185_5000000" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200506190554150" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190630_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="F11185_1830573" unitRef="USD">1830573</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506162036611" unitRef="USD">-90797</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506162054372" unitRef="USD">76708</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506162107929" unitRef="USD">4539</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506162119109" unitRef="USD">-9550</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100806844_xbrl_20200506172705585" unitRef="USD">-219134</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100806860_xbrl_20200506164300542" unitRef="USD">-4887929</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100806875_xbrl_20200506164309192" unitRef="USD">-44061</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810100806886_xbrl_20200506164413240" unitRef="USD">-5151124</us-gaap:FairValueAdjustmentOfWarrants>
  <embi:FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fb4deb6d1-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;At&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;strong&gt;Issuance&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;91.6&amp;#x2014;92.1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;2.23&amp;#x2014;2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;5.0&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;0.33&amp;#x2014;0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</embi:FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20191101141525787" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="1" id="Fxbrl_20200810094654756" unitRef="Percent">91.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="1" id="Fxbrl_20200810094659742" unitRef="Percent">92.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="Fxbrl_20200810095150545" unitRef="Percent">2.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20200810095202009" unitRef="Percent">2.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200506145117729" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200506145325597" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="1" id="Fxbrl_20200506145134245" unitRef="Percent">82.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="1" id="Fxbrl_20200506145317424" unitRef="Percent">79.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200506145142390" unitRef="Percent">0.17</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200506145306258" unitRef="Percent">1.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200506142947213" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200506143011880" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="1" id="Fxbrl_20200506143031812" unitRef="Percent">104.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="1" id="Fxbrl_20200506143049096" unitRef="Percent">79.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20200506143111295" unitRef="Percent">0.16</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20200506143126941" unitRef="Percent">1.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20191101172810291">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_20200507044651821">P2Y7M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_20200506145234609">P3Y1M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200630_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" id="Fxbrl_20200506143149497">P0Y1M20D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" id="Fxbrl_20200506143246008">P0Y7M20D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" id="Fxbrl_20200810121320350">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" id="Fxbrl_20200812032608760">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200630_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="Fxbrl_20200810095932743" unitRef="USD_per_Share">0.33</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200630_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20200810095936765" unitRef="USD_per_Share">0.69</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200630_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200506145205245" unitRef="USD_per_Share">0.16</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200506145256042" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200630_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200506143208292" unitRef="USD_per_Share">0.16</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200506143224958" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200810101652749">&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six Months Ended June 30, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair value of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;to Equity &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:left"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Financing - warrant liability &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;76,708&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;352,732&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Series B - warrant liability &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;4,539&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(26,563&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;112,555&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(9,550&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(26,563&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;465,287&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;465,287&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="text-align:left"&gt;&amp;#160; &amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Six Months Ended June 30, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;516,058&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(219,134&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;516,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Emerald Financing - warrant liability (2)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(4,887,929&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,363,484&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Series B - warrant liability (3)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(44,061&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(144,375&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;299,064&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(5,151,124&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(144,375&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;11,178,925&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(516,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;10,662,548&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506151738328" unitRef="USD">90797</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506162919091" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506151757349" unitRef="USD">276024</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506162930332" unitRef="USD">352732</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506151809908" unitRef="USD">134579</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506162943171" unitRef="USD">112555</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506151821933" unitRef="USD">501400</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200630" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506162955205" unitRef="USD">465287</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100806844_xbrl_20200506172638702" unitRef="USD">219453</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100806844_xbrl_20200506172720201" unitRef="USD">516377</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100806860_xbrl_20200506164212355" unitRef="USD">15251413</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100806860_xbrl_20200506164337940" unitRef="USD">10363484</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100806875_xbrl_20200506164223242" unitRef="USD">487500</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100806875_xbrl_20200506164346159" unitRef="USD">299064</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231" decimals="0" id="Fxbrl_20200810100806886_xbrl_20200506164357066" unitRef="USD">15958366</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190630" decimals="0" id="Fxbrl_20200810100806886_xbrl_20200506164435986" unitRef="USD">11178925</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123713273" unitRef="USD">204102</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124449833" unitRef="USD">516058</us-gaap:DerivativeLiabilities>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506161519971" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506161535400" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506161554205" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506161618939" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100806844_xbrl_20200506172648672" unitRef="USD">516058</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100806860_xbrl_20200506164238992" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100806875_xbrl_20200506164249140" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810100806886_xbrl_20200506164404505" unitRef="USD">516058</embi:FairValueOfWarrantsIssued>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506162752874" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506162211890" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506162146359" unitRef="USD">-26563</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506162129574" unitRef="USD">-26563</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100806844_xbrl_20200506172713519" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190630_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100806860_xbrl_20200506164318857" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100806875_xbrl_20200506164328141" unitRef="USD">-144375</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810100806886_xbrl_20200506164426888" unitRef="USD">-144375</embi:ReclassificationOfDerivativesToEquity>
  <embi:AggregateExercisePriceOfOutstandingCreditAgreement contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="0" id="Fxbrl_20200810110513593" unitRef="USD">4080000</embi:AggregateExercisePriceOfOutstandingCreditAgreement>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_20200506144715073">&lt;div&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30, &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;82.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20200630_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" id="Fxbrl_20200506142023739">&lt;div&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;104.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.14&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="2" id="Fxbrl_20200506141821975" unitRef="USD_per_Share">0.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="2" id="Fxbrl_20200810101503583" unitRef="USD_per_Share">0.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <embi:ValueOfCommonStockCalledByWarrants contextRef="C_20200630_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200506190632335" unitRef="USD">26563</embi:ValueOfCommonStockCalledByWarrants>
  <us-gaap:DebtDisclosureTextBlock contextRef="C_20200101to20200630" id="Fb4c22e23-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;4. Debt&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Multi-Draw Credit Agreement- Related Party&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Company&amp;#x2019;s Debt with Emerald Health Sciences consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Conversion&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,358,687&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,622,344&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(4,352&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(5,086&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Carrying value of total convertible debt - related party&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;651,461&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of non-convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Total carrying value of advances under the multi-draw credit agreement&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;1,101,461&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 7). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, dated October 5, 2018. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the &lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amended&lt;/span&gt;&lt;/span&gt;&amp;#160;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&amp;#x2019; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of June 30, 2020, the unused portion of the credit facility is $13,550,000. The drawdowns are subject to approval by the Company&amp;#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. As such, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place, however, there is no guarantee of continued funding.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% &amp;#160;of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&amp;#x2019;s stockholders (See Note 3).&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&amp;#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&amp;#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;During the six months ended June 30, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income for the six months ended June 30, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;During the three months ended June 30, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. The Lender has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and gave notice to the Company that no warrants will be issued in connection with the advances.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. As of June 30, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 2.27 years. The fair value of the shares underlying the convertible advances under the Amended Credit agreement was $790,691 at June 30, 2020. As of June 30, 2020, the if-converted value did not exceed the principal balance.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;PPP Loan&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;&amp;#160;&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing seven months from the date of funding. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and seven-month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;Interest Expense&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Company&amp;#x2019;s interest expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Six Months Ended&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Related party interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;37,726&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;106,167&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;73,371&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;165,277&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;PPP loan interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;133,310&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;184,313&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;263,657&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;238,293&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;3,485&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;6,458&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;171,625&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;293,965&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;337,980&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;410,028&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506122639460">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Conversion&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,358,687&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,622,344&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(4,352&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(5,086&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Carrying value of total convertible debt - related party&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;651,461&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of non-convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Total carrying value of advances under the multi-draw credit agreement&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;1,101,461&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122019355" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122038961" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20200630" decimals="0" id="Fxbrl_20200810110145735" unitRef="USD">790691</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122058212" unitRef="USD">1358687</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810161952946" unitRef="USD">1622344</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122129394" unitRef="USD">4352</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810162135954" unitRef="USD">5086</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122158922" unitRef="USD">651461</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122211977" unitRef="USD">387070</us-gaap:ConvertibleDebtCurrent>
  <embi:CurrentConvertibleDebtExcludingNoncurrentPortion contextRef="C_20200630_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122258993" unitRef="USD">1101461</embi:CurrentConvertibleDebtExcludingNoncurrentPortion>
  <embi:CurrentConvertibleDebtExcludingNoncurrentPortion contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122312128" unitRef="USD">387070</embi:CurrentConvertibleDebtExcludingNoncurrentPortion>
  <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="C_20181001to20181005_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810103034545" unitRef="USD">5000000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
  <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease contextRef="C_20181001to20181005_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="3" id="Fxbrl_20200810102506832" unitRef="USD_per_Share">0.25</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
  <us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="C_20200101to20200630_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123359355" unitRef="USD">13550000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
  <embi:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506123310924" unitRef="pure">0.50</embi:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase>
  <us-gaap:WarrantExercisePriceDecrease contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200810103639279" unitRef="USD_per_Share">0.35</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="C_20181030to20181101_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123543243" unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123600157" unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124312402" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <embi:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123619970" unitRef="USD">1684920</embi:AllocationOfDebtOnBasisOfRelativeFairValue>
  <embi:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124427672" unitRef="USD">3283890</embi:AllocationOfDebtOnBasisOfRelativeFairValue>
  <embi:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123639937" unitRef="USD">315080</embi:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <embi:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124438921" unitRef="USD">716110</embi:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_Custom_31_Oct_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123657089" unitRef="USD">90080</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="C_20190101to20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506235637465" unitRef="USD">1584850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="C_20190630_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124141212" unitRef="USD">2000000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:ProceedsFromWarrantExercises contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506125842036" unitRef="USD">3985500</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506130129184" unitRef="USD">725425</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <embi:CreditFacilityEffectedFourthAdvances contextRef="C_20200401to20200630_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200810105619047" unitRef="USD">150000</embi:CreditFacilityEffectedFourthAdvances>
  <embi:CreditFacilityEffectedFifthAdvances contextRef="C_20200401to20200630_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200810105740715" unitRef="USD">300000</embi:CreditFacilityEffectedFifthAdvances>
  <embi:ConvertibleMultiDrawCreditAgreementIssuanceCosts contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810110021274" unitRef="USD">63007</embi:ConvertibleMultiDrawCreditAgreementIssuanceCosts>
  <embi:UnamortizedDebtDiscountPeriod contextRef="C_20200101to20200630" id="Fxbrl_20200808132952699">P2Y3M7D</embi:UnamortizedDebtDiscountPeriod>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="4" id="Fxbrl_20200810115254769" unitRef="pure">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <embi:PayrollCostsExcludeCompensation contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="0" id="Fxbrl_20200810121822737" unitRef="USD">100000</embi:PayrollCostsExcludeCompensation>
  <embi:PercentageOfForgivenessAmountForNonPayrollCosts contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="2" id="Fxbrl_20200810121954268" unitRef="pure">0.25</embi:PercentageOfForgivenessAmountForNonPayrollCosts>
  <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="0" id="Fxbrl_20200810122000811" unitRef="USD">100000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
  <embi:PercentageOfReductionInAnnualSalary contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="2" id="Fxbrl_20200810121957395" unitRef="pure">0.25</embi:PercentageOfReductionInAnnualSalary>
  <embi:ScheduleOfInterestExpenseTableTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200808130814632">&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Six Months Ended&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Related party interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;37,726&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;106,167&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;73,371&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;165,277&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;PPP loan interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;133,310&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;184,313&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;263,657&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;238,293&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;3,485&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;6,458&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;171,625&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;293,965&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;337,980&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;410,028&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</embi:ScheduleOfInterestExpenseTableTextBlock>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">37726</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">106167</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">73371</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">165277</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseDebt contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">218</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">0</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">218</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">0</us-gaap:InterestExpenseDebt>
  <embi:AmortizationOfDebtDiscount contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">133310</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">184313</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">263657</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">238293</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfTransactionCosts contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810100659344_xbrl_20200506122454825" unitRef="USD">371</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20200810100659344_xbrl_20200506122523430" unitRef="USD">3485</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_20200810100813355_xbrl_20200810100659344_xbrl_20200506122454825" unitRef="USD">734</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="C_20190101to20190630" decimals="0" id="Fxbrl_20200810100813355_xbrl_20200810100659344_xbrl_20200506122523430" unitRef="USD">6458</embi:AmortizationOfTransactionCosts>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_20200101to20200630" id="Fb4c25530-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;5. Stock-Based Compensation &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Stock Incentive Plan&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On October 31, 2014, after the closing of the Merger, the Board approved the Company&amp;#x2019;s 2014 Omnibus Incentive Plan (the &amp;#x201c;2014 Plan&amp;#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of June 30, 2020, the Company had 13,159,631 shares available for future grant under the 2014 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Stock Options &lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;There was no option activity under the Company&amp;#x2019;s 2014 Plan during the three and six months ended June 30, 2020.&lt;br/&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Restricted Stock Awards &lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the three and six months ended June 30, 2020, 643,501 restricted stock awards (&amp;#x201c;RSAs&amp;#x201d;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. At June 30, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Awards Granted Outside the 2014 Plan&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Options&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;During the three and six months ended June 30, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&amp;#x2019;s former CFO. At June 30, 2020 there are 869,144 options vested and outstanding with a weighted average exercise price of $0.25 and a weighted average remaining life of 0.13 years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&amp;#160;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Restricted Stock Awards&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following is a summary of RSA activity outside of the Company&amp;#x2019;s 2014 Plan during the six months ended June 30, 2020:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average Grant &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Date Fair Value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;0.19&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Released&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(450,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Unvested, June 30, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Stock-Based Compensation Expense&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company recognizes compensation expense using the straight-line method over the requisite service period. &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;For the three months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt; $28,709 and $173,084, &lt;/span&gt;&lt;/span&gt;(including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income.&amp;#160;For the six months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of $92,851 and $344,577, respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income.&amp;#160;&lt;span&gt;&lt;span&gt;The total amount of unrecognized compensation cost was $164,798 as of June 30, 2020. This amount will be recognized over a weighted average period of 2.18 years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="INF" id="Fxbrl_20200506100939949" unitRef="shares">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="C_20200630_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="INF" id="Fxbrl_20200506101132881" unitRef="shares">13159631</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <embi:PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="2" id="Fxbrl_20200506101055802" unitRef="pure">0.10</embi:PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_202008101030349860" unitRef="shares">643501</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="C_20200401to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200810103034986" unitRef="shares">643501</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="C_20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20200810103048668" unitRef="USD_per_Share">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="C_20200101to20200630" decimals="0" id="Fxbrl_202008101211066060" unitRef="shares">325929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20200810121106606" unitRef="shares">325929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="C_20200101to20200630" decimals="2" id="Fxbrl_202008101211459910" unitRef="USD_per_Share">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="C_20200401to20200630" decimals="2" id="Fxbrl_20200810121145991" unitRef="USD_per_Share">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="C_20200630" decimals="0" id="Fxbrl_20200810121255557" unitRef="shares">869144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="C_20200630" decimals="2" id="Fxbrl_20200810121305294" unitRef="USD_per_Share">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_20200101to20200630" id="Fxbrl_20200810121332817">P0Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="C_20200101to20200630" id="Fxbrl_20200506101729193">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average Grant &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Date Fair Value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;0.19&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Released&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;(450,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Unvested, June 30, 2020&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20200506101522497" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20200506101553399" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20200506101357853" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200506101423369" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20200506101607879" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20200506101502348" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20200506101540114" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20200630_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20200506101440651" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="C_20200630" decimals="0" id="Fxbrl_20200506101936290" unitRef="USD">164798</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20200101to20200630" id="Fxbrl_20200506101956354">P2Y2M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <embi:SignificantContractsTextBlock contextRef="C_20200101to20200630" id="Fb4c25531-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6. Significant Contracts - University of Mississippi&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;UM 5050 Pro-Drug and UM 8930 Analog Agreements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (&amp;#x201c;THC&amp;#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&amp;#x201c;CBD&amp;#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &amp;#x201c;all fields of use&amp;#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &amp;#x201c;License Agreements&amp;#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;i)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;ii)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;iii)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&amp;#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&amp;#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&amp;#x2019;s dissolution or cessation of operations, the Company&amp;#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&amp;#x2019;s control, or the Company&amp;#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As of June 30, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;UM 5070 License Agreement&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&amp;#x201c;UM 5070&amp;#x201d;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&amp;#x201c;MRSA&amp;#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&amp;#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&amp;#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&amp;#x2019;s control. The Company may terminate the license agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;As of June 30, 2020, none of the milestones under this license agreement have been met.&lt;/p&gt;</embi:SignificantContractsTextBlock>
  <embi:AnnualMaintenanceFeePayable contextRef="C_20200630" decimals="0" id="Fxbrl_20200506102529475" unitRef="USD">75000</embi:AnnualMaintenanceFeePayable>
  <embi:PaymentForUpfrontFees contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506102551587" unitRef="USD">100000</embi:PaymentForUpfrontFees>
  <embi:PaymentForUpfrontFees contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506102608923" unitRef="USD">200000</embi:PaymentForUpfrontFees>
  <embi:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506102725019" unitRef="USD">200000</embi:AnnualFeesForLicenseAgreement>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member" decimals="0" id="Fxbrl_20200506102819457" unitRef="USD">100000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member" decimals="0" id="Fxbrl_20200506102850433" unitRef="USD">200000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member" decimals="0" id="Fxbrl_20200506102921857" unitRef="USD">400000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506103029010" unitRef="USD">700000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member" id="Fxbrl_20200506102837001">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member" id="Fxbrl_20200506102903805">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member" id="Fxbrl_20200506102935274">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" id="Fxbrl_20200506103205600">P1Y</embi:TermOfAgreement>
  <embi:NoticePeriodForTermination contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" id="Fxbrl_20200506103131657">P60D</embi:NoticePeriodForTermination>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20200101to20200630" id="Fb4c27c40-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;7. Related Party Matters&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&lt;em&gt;Emerald Health Sciences&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&amp;#x2019;s Chief Executive Officer and Emerald Health Sciences&amp;#x2019; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of June 30, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three and six months ended June 30, 2020. Under this agreement, for the three and six months ended June 30, 2019, the Company incurred expenses of $150,000 and $300,000, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&amp;#x2019;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&amp;#x2019; prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon&amp;#x2019;s consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. Under this agreement, for the three and six months ended June 30, 2020, the Company incurred fees of $36,387 and $66,387, respectively. As of June 30, 2020, the Company has accrued $70,258 in expense related to the Independent Contractor Services Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#x200e;As of the date of this filing Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc.&amp;#160;Jim Heppell is also a board member of Emerald Health Sciences, Inc. Additionally, the Company shares the same office location as Emerald Health Pharmaceuticals.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <embi:InitialTermOfAgreement contextRef="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" id="Fxbrl_20200506114236417">P10Y</embi:InitialTermOfAgreement>
  <embi:AccruedExpenseUnderAgreement contextRef="C_20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506114257085" unitRef="USD">7032</embi:AccruedExpenseUnderAgreement>
  <embi:AccruedExpenseUnderAgreement contextRef="C_20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114901777" unitRef="USD">70258</embi:AccruedExpenseUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506114314106" unitRef="USD">150000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="C_20190101to20190630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810093551296" unitRef="USD">300000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:MonthlyFee contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114528458" unitRef="USD">10000</embi:MonthlyFee>
  <embi:MonthlyFeePaidEachMonthInExchangeOfServices contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114534476" unitRef="USD">5000</embi:MonthlyFeePaidEachMonthInExchangeOfServices>
  <embi:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114537898" unitRef="USD">5000</embi:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices>
  <embi:PercentageOfAccruedConsultingFees contextRef="C_20200301to20200330_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="2" id="Fxbrl_20200506114839400" unitRef="pure">1</embi:PercentageOfAccruedConsultingFees>
  <embi:PercentageOfBonusForAccruedConsultingFees contextRef="C_20200301to20200330_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="2" id="Fxbrl_20200506114844164" unitRef="pure">0.10</embi:PercentageOfBonusForAccruedConsultingFees>
  <embi:TotalFeesIncurredUnderAgreement contextRef="C_20200401to20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200810095241152" unitRef="USD">36387</embi:TotalFeesIncurredUnderAgreement>
  <embi:TotalFeesIncurredUnderAgreement contextRef="C_20200101to20200630_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200810095334198" unitRef="USD">66387</embi:TotalFeesIncurredUnderAgreement>
  <us-gaap:SubsequentEventsTextBlock contextRef="C_20200101to20200630" id="Fb4c27c41-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;8. Subsequent Events&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&lt;strong&gt;&lt;em&gt;August 2020 Financing&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;On July 31, 2020, the Company entered into a Securities Purchase Agreement with institutional investors with H.C. Wainwright &amp;amp; Co., LLC acting as the placement agent, pursuant to which the Company sold&lt;/span&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt; 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The common units and pre-funded units were sold a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively, The term of the common stock warrants is five years&amp;#160;and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The exercise price and number of shares of Common Stock underlying the Warrants are subject to adjustment upon the issuance by the Company of stock dividends, stock splits, and similar proportionately applied changes affecting the Company&amp;#x2019;s outstanding Common Stock. Holders of the Warrants will be entitled to participate in any dividends or other distribution of the Company&amp;#x2019;s assets declared or made to holders of the Company&amp;#x2019;s Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;In connection with the registered public offering, the Company incurred issuance costs&lt;/span&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt; of $825,698, for net proceeds of $6,113,969. &lt;/span&gt;&lt;span style="color:#000000"&gt;Additionally, the Company has issued 8,166,667 common stock warrants to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years. The offering closed on August 4, 2020. The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&lt;strong&gt;&lt;em&gt;Management and Board Deferral Agreements&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;Upon the closing of the August 2020 financing, the Company&amp;#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees including&amp;#160;the retention bonus to management and the Board in the aggregate amount of $293,078.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&lt;strong&gt;&lt;em&gt;Exercise Price Adjustment to Emerald Financing Warrants&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;Upon entering into the August 2020 Financing, the Company entered into an agreement with a holder of the Emerald Financing Warrants to permanently set the exercise price of such holder&amp;#x2019;s remaining Emerald Financing warrants to&lt;/span&gt;&lt;span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt; $0.10 and waive such holder&amp;#x2019;s rights to anti-dilution protection upon subsequent issuances or sales of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;strong&gt;&lt;em&gt;Stock Option Grants&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;In August 2020, 22,750,000 stock options with an exercise price of $0.045 were granted to certain directors, officers, employees and consultants of the Company under the 2014 Plan. The stock options will vest 10% on the grant date and 90% in equal semi-annual installments over the vesting schedules as set forth by the Company&amp;#x2019;s Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;On August 7, 2020, the Board approved an Amendment No. 2 to the 2014 Plan. The amendment removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year.&lt;/span&gt;&amp;#160;&lt;span style="color:#000000"&gt;In connection with the option grants the Company will register an additional 18,486,435 common shares as required under the 2014 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;strong&gt;&lt;em&gt;Separation of Chief Executive Officer, Chief Medical Officer and Member of the Board&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;On August 7, 2020, the effective date, Company entered into a Separation and Release Agreement (the &amp;#x201c;Separation Agreement&amp;#x201d;) with Dr. Brian Murphy, Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;Pursuant to the Separation Agreement, Dr. Murphy has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Dr. Murphy compensation and benefits as follows: (i) a gross payment of $195,000 in consideration for the restrictive covenants contained in the Separation Agreement, to be paid over six months; and (ii) a continuation of health insurance benefits for a period of six months following the Separation Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="color:#000000"&gt;&lt;strong&gt;&lt;em&gt;Appointment of Chief Executive Officer&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="text-align:justify;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"&gt;On August 7, 2020, Punit Dhillon resigned his position as the Chair of the Audit Committee and member of the Compensation, Nomination and Corporate Governance Committees and was appointed as the Chief Executive Officer of the Company. Mr. Dhillon remains as the Chairman of the Board and Chairman of the Finance and Business Development Committee. Mr. Dhillon will be eligible to receive a minimum of 6 months&amp;#x2019; severance if he is terminated by the Company without cause and will receive 12-months&amp;#x2019; severance if he is employed by the Company for at least 12 months commencing on August 10, 2020, or a 24 months&amp;#x2019; severance if he is employed by the Company for at least 24 months commencing on August 10, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <embi:CommonUnitsSoldPricePerUnit contextRef="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="2" id="Fxbrl_20200810121121597" unitRef="USD_per_Share">0.06</embi:CommonUnitsSoldPricePerUnit>
  <embi:PreFundedUnitsSoldPricePerUnit contextRef="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="3" id="Fxbrl_20200810121136397" unitRef="USD_per_Share">0.059</embi:PreFundedUnitsSoldPricePerUnit>
  <embi:GrossProceedsOfUnitsSold contextRef="C_20200701to20200731_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="0" id="Fxbrl_20200810121243098" unitRef="USD">6939667</embi:GrossProceedsOfUnitsSold>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="C_20200801to20200804_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20200810122516154" unitRef="USD">6113969</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid contextRef="C_20200801to20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiManagementDeferralAgreementMember" decimals="0" id="Fxbrl_20200813095937213" unitRef="USD">293078</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
  <embi:ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances contextRef="C_20200831_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsMember" decimals="2" id="Fxbrl_20200810124753893" unitRef="USD_per_Share">0.10</embi:ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20200801to20200812_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20200812033904955" unitRef="shares">22750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200801to20200812_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="3" id="Fxbrl_20200812033911831" unitRef="USD_per_Share">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="C_20200801to20200812_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20200812034021334" unitRef="shares">18486435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <embi:PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement contextRef="C_20200801to20200807_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_embiSeparationAndReleaseAgreementMember" decimals="0" id="Fxbrl_20200812034218236" unitRef="USD">195000</embi:PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>embi-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:embi="http://www.emeraldbio.life/20200630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" targetNamespace="http://www.emeraldbio.life/20200630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals" id="CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" id="CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
        <link:definition>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
        <link:definition>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" id="CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited">
        <link:definition>0007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities" id="NatureOfOperationsAndBusinessActivities">
        <link:definition>0008 - Disclosure - Nature of Operations and Business Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities" id="WarrantsAndDerivativeLiabilities">
        <link:definition>0010 - Disclosure - Warrants and Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty" id="ConvertibleDebtRelatedParty">
        <link:definition>0011 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization" id="StockholdersDeficitAndCapitalization">
        <link:definition>0012 - Disclosure - Stockholders' Deficit and Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0013 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi" id="SignificantContractsUniversityOfMississippi">
        <link:definition>0014 - Disclosure - Significant Contracts - University of Mississippi</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters" id="RelatedPartyMatters">
        <link:definition>0015 - Disclosure - Related Party Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables" id="WarrantsAndDerivativeLiabilitiesTables">
        <link:definition>0019 - Disclosure - Warrants and Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables" id="ConvertibleDebtRelatedPartyTables">
        <link:definition>0020 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>0021 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals" id="NatureOfOperationsAndBusinessActivitiesDetailTextuals">
        <link:definition>0022 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>0023 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals" id="SummaryOfSignificantAccountingPoliciesDetailTextuals">
        <link:definition>0024 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsandDerivativeLiabilitiesDetails" id="WarrantsandDerivativeLiabilitiesDetails">
        <link:definition>0025 - Disclosure - Warrants and Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1" id="WarrantsAndDerivativeLiabilitiesDetails1">
        <link:definition>0026 - Disclosure - Warrants and Derivative Liabilities (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2" id="WarrantsAndDerivativeLiabilitiesDetails2">
        <link:definition>0027 - Disclosure - Warrants and Derivative Liabilities (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4" id="WarrantsAndDerivativeLiabilitiesDetails4">
        <link:definition>0028 - Disclosure - Warrants and Derivative Liabilities (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5" id="WarrantsAndDerivativeLiabilitiesDetails5">
        <link:definition>0029 - Disclosure - Warrants and Derivative Liabilities (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals" id="WarrantsAndDerivativeLiabilitiesDetailTextuals">
        <link:definition>0030 - Disclosure - Warrants and Derivative Liabilities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails" id="ConvertibleDebtRelatedPartyDetails">
        <link:definition>0031 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1" id="ConvertibleDebtRelatedPartyDetails1">
        <link:definition>0032 - Disclosure - Debt (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals" id="ConvertibleDebtRelatedPartyDetailTextuals">
        <link:definition>0033 - Disclosure - Debt (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals" id="StockholdersDeficitAndCapitalizationDetailTextuals">
        <link:definition>0034 - Disclosure - Stockholders' Deficit and Capitalization (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
        <link:definition>0035 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals" id="StockBasedCompensationDetailTextuals">
        <link:definition>0036 - Disclosure - Stock-Based Compensation (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1" id="StockBasedCompensationDetailTextuals1">
        <link:definition>0037 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals" id="SignificantContractsUniversityOfMississippiDetailTextuals">
        <link:definition>0038 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals" id="RelatedPartyMattersDetailTextuals">
        <link:definition>0039 - Disclosure - Related Party Matters (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
        <link:definition>0040 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedExpenseUnderAgreement" id="embi_AccruedExpenseUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdditionalConversionLiability" id="embi_AdditionalConversionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateExercisePriceOfOutstandingCreditAgreement" id="embi_AggregateExercisePriceOfOutstandingCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateMilestonePaymentsIfMilestonesAchieved" id="embi_AggregateMilestonePaymentsIfMilestonesAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregatePrincipalAmount" id="embi_AggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AllocationOfDebtOnBasisOfRelativeFairValue" id="embi_AllocationOfDebtOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AllocationOfWarrantOnBasisOfRelativeFairValue" id="embi_AllocationOfWarrantOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmendedAndRestatedMultiDrawCreditAgreementMember" id="embi_AmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfDebtDiscount" id="embi_AmortizationOfDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmortizationOfTransactionCosts" id="embi_AmortizationOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeeForAgreement" id="embi_AnnualFeeForAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeesForLicenseAgreement" id="embi_AnnualFeesForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualMaintenanceFeePayable" id="embi_AnnualMaintenanceFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AvtarDhillonMember" id="embi_AvtarDhillonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" id="embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CapitalRaise" id="embi_CapitalRaise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CashAndCashEquivalents" id="embi_CashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidDuringPeriodForAbstract" id="embi_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInFairValueOfDerivativeLiabilities" id="embi_ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChangeInFairValueOfWarrantLiability" id="embi_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightWarrantsExercise" id="embi_ClassOfWarrantOrRightWarrantsExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockIssuanceCosts" id="embi_CommonStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CommonStockWarrantsMember" id="embi_CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockWarrantsToSeriesBStockholdersMember" id="embi_CommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonUnitsSoldPricePerUnit" id="embi_CommonUnitsSoldPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingAgreementMember" id="embi_ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionLiabilityIntoCommonStockPerShare" id="embi_ConversionLiabilityIntoCommonStockPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" id="embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" id="embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" id="embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" id="embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" id="embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStock" id="embi_ConversionOfSeriesDPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesDPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesFPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockValue" id="embi_ConversionOfSeriesFPreferredStockToCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionPricePerShare" id="embi_ConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleDebtRelatedPartyTextBlock" id="embi_ConvertibleDebtRelatedPartyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleMultiDrawCreditAgreementIssuanceCosts" id="embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConvertibleMultiDrawCreditFacility" id="embi_ConvertibleMultiDrawCreditFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CouponInterestExpense" id="embi_CouponInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CreditFacilityEffectedFifthAdvances" id="embi_CreditFacilityEffectedFifthAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CreditFacilityEffectedFourthAdvances" id="embi_CreditFacilityEffectedFourthAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrentConvertibleDebtExcludingNoncurrentPortion" id="embi_CurrentConvertibleDebtExcludingNoncurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtForgivenessCARESActDescription" id="embi_DebtForgivenessCARESActDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="December2015Member" id="embi_December2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativeLiabilitiesLineItems" id="embi_DerivativeLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativeLiabilitiesTable" id="embi_DerivativeLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DocumentAndEntityInformationAbstract" id="embi_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DouglasCesarioMember" id="embi_DouglasCesarioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DrawDownsLoansInAggregatePrincipalAmount" id="embi_DrawDownsLoansInAggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EmeraldConvertiblePromissoryNoteConversionLiabilityMember" id="embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingIssuanceCosts" id="embi_EmeraldFinancingIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EmeraldFinancingMember" id="embi_EmeraldFinancingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantLiabilityMember" id="embi_EmeraldFinancingWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantsLiabilityMember" id="embi_EmeraldFinancingWarrantsLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantsMember" id="embi_EmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldHealthSciencesIncMember" id="embi_EmeraldHealthSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" id="embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldWarrantLiabilityMember" id="embi_EmeraldWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityLineItems" id="embi_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityTable" id="embi_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ExerciseOfWarrants" id="embi_ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairMarketValueOfStockOptions" id="embi_FairMarketValueOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueAdjustmentOfDerivativeLiabilities" id="embi_FairValueAdjustmentOfDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" id="embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" id="embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfDerivativeLiabilitiesRollForward" id="embi_FairValueOfDerivativeLiabilitiesRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfDerivativeLiabilityExcessOfProceeds" id="embi_FairValueOfDerivativeLiabilityExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfWarrantLiabilityInExcessOfProceeds" id="embi_FairValueOfWarrantLiabilityInExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssued" id="embi_FairValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssuedInConnectionWithFinancings" id="embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FifthAmendedAndRestatedMultiDrawCreditAgreementMember" id="embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FourthAmendedAndRestatedMultiDrawCreditAgreementMember" id="embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrossProceedsOfUnitsSold" id="embi_GrossProceedsOfUnitsSold" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseAccruedInterestDueToRelatedParty" id="embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IndependentContractorAgreementMember" id="embi_IndependentContractorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InitialTermOfAgreement" id="embi_InitialTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="K2CIncMember" id="embi_K2CIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LegalReimbursementFees" id="embi_LegalReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LicenseAgreementMember" id="embi_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LumpSumPaymentInAgreement" id="embi_LumpSumPaymentInAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ManagementDeferralAgreementMember" id="embi_ManagementDeferralAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone1Member" id="embi_Milestone1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone2Member" id="embi_Milestone2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone3Member" id="embi_Milestone3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentsPayableAxis" id="embi_MilestonePaymentsPayableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MilestonePaymentsPayableDomain" id="embi_MilestonePaymentsPayableDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonteCarloSimulationsMember" id="embi_MonteCarloSimulationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthAndYearOfAgreementAxis" id="embi_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MonthAndYearOfAgreementDomain" id="embi_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthlyFee" id="embi_MonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" id="embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MonthlyFeePaidEachMonthInExchangeOfServices" id="embi_MonthlyFeePaidEachMonthInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MultiDrawCreditAgreementMember" id="embi_MultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MultidrawCreditAgreementRelatedPartyNoncurrent" id="embi_MultidrawCreditAgreementRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NatureOfOperationsAndBusinessActivitiesAbstract" id="embi_NatureOfOperationsAndBusinessActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesLineItems" id="embi_NatureOfOperationsAndBusinessActivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesTable" id="embi_NatureOfOperationsAndBusinessActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" id="embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" id="embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities" id="embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NonCashInterestExpenseAbstract" id="embi_NonCashInterestExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoramcoAgreementMember" id="embi_NoramcoAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoticePeriodForTermination" id="embi_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonStockUnitsSold" id="embi_NumberOfCommonStockUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfLicenseAgreements" id="embi_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfPreFundedUnitsSold" id="embi_NumberOfPreFundedUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OctoberTwoThousandFifteenMember" id="embi_OctoberTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OmnibusIncentivePlan2014Member" id="embi_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionAgreementMember" id="embi_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaycheckProtectionProgramMember" id="embi_PaycheckProtectionProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaycheckProtectionProgramPromissoryNoteMember" id="embi_PaycheckProtectionProgramPromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentForUpfrontFees" id="embi_PaymentForUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" id="embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PayrollCostsExcludeCompensation" id="embi_PayrollCostsExcludeCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PercentageOfAccruedConsultingFees" id="embi_PercentageOfAccruedConsultingFees" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAccruedInterestOnOutstandingBalance" id="embi_PercentageOfAccruedInterestOnOutstandingBalance" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" id="embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfBonusForAccruedConsultingFees" id="embi_PercentageOfBonusForAccruedConsultingFees" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfForgivenessAmountForNonPayrollCosts" id="embi_PercentageOfForgivenessAmountForNonPayrollCosts" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfReductionInAnnualSalary" id="embi_PercentageOfReductionInAnnualSalary" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" id="embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" id="embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Pre2015CommonStockWarrantsMember" id="embi_Pre2015CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreferredStockPutOptionLiability" id="embi_PreferredStockPutOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PreFundedUnitsSoldPricePerUnit" id="embi_PreFundedUnitsSoldPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrefundedWarrantsMember" id="embi_PrefundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelAxis" id="embi_PricingModelAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="PricingModelDomain" id="embi_PricingModelDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelMember" id="embi_PricingModelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" id="embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromConvertibleMultiDrawCreditAgreement" id="embi_ProceedsFromConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" id="embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProvisionForConversionOfPreferredStock" id="embi_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReclassificationOfDerivativesToEquity" id="embi_ReclassificationOfDerivativesToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReducedFixedConversionPriceOfCommonStock" id="embi_ReducedFixedConversionPriceOfCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" id="embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RemainingFundsFromPromissoryNote" id="embi_RemainingFundsFromPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RestrictedStockAgreementsMember" id="embi_RestrictedStockAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAndUncertaintiesPolicyTextBlock" id="embi_RisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" id="embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfInterestExpenseTableTextBlock" id="embi_ScheduleOfInterestExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuredPromissoryNoteAndSecurityAgreementMember" id="embi_SecuredPromissoryNoteAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementMember" id="embi_SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" id="embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeniorManagementCompensationPlanDescription" id="embi_SeniorManagementCompensationPlanDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAgreementMember" id="embi_SeparationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAndReleaseAgreementMember" id="embi_SeparationAndReleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBPreferredStockConversionLiabilityMember" id="embi_SeriesBPreferredStockConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantMember" id="embi_SeriesBWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantsMember" id="embi_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesFPreferredStockPutOptionLiabilityMember" id="embi_SeriesFPreferredStockPutOptionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssuanceCosts" id="embi_ShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SignificantContractsAbstract" id="embi_SignificantContractsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantContractsTextBlock" id="embi_SignificantContractsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockholdersDeficitAndCapitalizationTextBlock" id="embi_StockholdersDeficitAndCapitalizationTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" id="embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNetOfIssuanceCosts" id="embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesSeriesBWarrantExercises" id="embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodValueNetOfIssuanceCosts" id="embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueSeriesBWarrantExercises" id="embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockOptions2014PlanMember" id="embi_StockOptions2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsequentFinancingPurchasePriceDescription" id="embi_SubsequentFinancingPurchasePriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementalRestrictedCash" id="embi_SupplementalRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TermOfAgreement" id="embi_TermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrant" id="embi_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrants" id="embi_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermsOfAgreementRenewed" id="embi_TermsOfAgreementRenewed" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" id="embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalCashEquivalentsAndRestrictedCashShownInConsolidated" id="embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalExpenseIncurredUnderAgreement" id="embi_TotalExpenseIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalFeesIncurredUnderAgreement" id="embi_TotalFeesIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TwoThousandEighteenEmeraldFinancingWarrantsMember" id="embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenCommonStockWarrantsMember" id="embi_TwoThousandFifteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" id="embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" id="embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandNineteenCommonStockWarrantsMember" id="embi_TwoThousandNineteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5050ProDrugAndUm8930AnalogAgreementsMember" id="embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5070LicenseAgreementMember" id="embi_Um5070LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnamortizedDebtDiscountPeriod" id="embi_UnamortizedDebtDiscountPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsAbstract" id="embi_UniversityOfMississippiAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsLineItems" id="embi_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsTable" id="embi_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="UniversityOfMississippiMember" id="embi_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnrestrictedCashPositionDecreased" id="embi_UnrestrictedCashPositionDecreased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ValueOfCommonStockCalledByWarrants" id="embi_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndDerivativeLiabilitiesAbstract" id="embi_WarrantsAndDerivativeLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndDerivativeLiabilitiesTextBlock" id="embi_WarrantsAndDerivativeLiabilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" id="embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsVestedAndOutstanding" id="embi_WarrantsVestedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantToPurchaseNumberOfCommonStockPricePerShare" id="embi_WarrantToPurchaseNumberOfCommonStockPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WorkingCapitalDeficit" id="embi_WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>embi-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultidrawCreditAgreementRelatedPartyNoncurrent" xlink:label="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_Liabilities_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LiabilitiesCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_ShortTermBorrowings_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_12" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_13" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LongTermDebt_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LongTermNotesPayable_17" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_18" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_19" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5" xlink:to="loc_embi_ChangeInFairValueOfDerivativeLiabilities_5" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5" xlink:to="loc_us-gaap_InterestExpense_7" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" xlink:label="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_16"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_13" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_16" order="10" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>embi-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsandDerivativeLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/WarrantsandDerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails5" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockholdersDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#RelatedPartyMattersDetailTextuals" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_StockholdersEquity_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_SharesIssued_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_SeriesBWarrantMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_15" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeniorManagementCompensationPlanDescription" xlink:label="loc_embi_SeniorManagementCompensationPlanDescription_34"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_MultiDrawCreditAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8" xlink:to="loc_us-gaap_SubsequentEventMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_12" xlink:to="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_12" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_embi_CommonStockWarrantsMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_16" xlink:to="loc_embi_PrefundedWarrantsMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_WorkingCapitalDeficit_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_SeniorManagementCompensationPlanDescription_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_GrossProceedsOfUnitsSold_37" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_TermOfWarrants_39" order="180" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5" xlink:to="loc_us-gaap_WarrantMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_RestrictedStockMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsandDerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_Pre2015CommonStockWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_TermOfWarrant_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_WarrantsVestedAndOutstanding_22" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_9" xlink:to="loc_embi_PricingModelMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_SeriesBWarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_embi_EmeraldFinancingMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilities_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_embi_FairValueOfWarrantsIssued_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_MonteCarloSimulationsMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_embi_EmeraldFinancingMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MinimumMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_9" xlink:to="loc_embi_PricingModelMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_embi_SeriesBWarrantMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregateExercisePriceOfOutstandingCreditAgreement" xlink:label="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldWarrantLiabilityMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_SeriesBWarrantsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_us-gaap_WarrantMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_14" xlink:to="loc_dei_EntityDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_14" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_14" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_ValueOfCommonStockCalledByWarrants_20" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_TermOfWarrant_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_24" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_25" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_26" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_27" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_28" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_29" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_16" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaycheckProtectionProgramMember" xlink:label="loc_embi_PaycheckProtectionProgramMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CreditFacilityEffectedFourthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFourthAdvances_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CreditFacilityEffectedFifthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFifthAdvances_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_39"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_40"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_41"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_43"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_44"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PayrollCostsExcludeCompensation" xlink:label="loc_embi_PayrollCostsExcludeCompensation_45"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfForgivenessAmountForNonPayrollCosts" xlink:label="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_46"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_47"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfReductionInAnnualSalary" xlink:label="loc_embi_PercentageOfReductionInAnnualSalary_48"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_embi_MultiDrawCreditAgreementMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_embi_IndependentContractorAgreementMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_10" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_10" xlink:to="loc_embi_PaycheckProtectionProgramMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_10" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_14" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_14" xlink:to="loc_us-gaap_SubsequentEventMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_14" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_20" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_22" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_24" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_25" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_27" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_28" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_29" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_30" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_31" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_CreditFacilityEffectedFourthAdvances_32" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_CreditFacilityEffectedFifthAdvances_33" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_34" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilities_35" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_36" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_37" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_38" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_39" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_UnamortizedDebtDiscountPeriod_40" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_41" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_42" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_43" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_44" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PayrollCostsExcludeCompensation_45" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_46" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_47" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfReductionInAnnualSalary_48" order="300" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LegalReimbursementFees" xlink:label="loc_embi_LegalReimbursementFees_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_33"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_BridgeLoanMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_12" xlink:to="loc_us-gaap_InvestorMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_BridgeLoan_22" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_23" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_24" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_25" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_SubsequentFinancingPurchasePriceDescription_27" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_TermOfWarrants_28" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_LegalReimbursementFees_29" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_EmeraldFinancingIssuanceCosts_30" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_31" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_32" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_33" order="170" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_30"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_RestrictedStockMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_embi_FairMarketValueOfStockOptions_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_25" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_26" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_28" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_29" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_RestrictedStockExpense_30" order="200" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_embi_UniversityOfMississippiAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_33"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_embi_UniversityOfMississippiAgreementsLineItems_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_OptionAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_LicenseAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5070LicenseAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_UniversityOfMississippiMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_11" xlink:to="loc_us-gaap_IntellectualPropertyMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MonthAndYearOfAgreementAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_15" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_15" xlink:to="loc_embi_December2015Member_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_15" xlink:to="loc_embi_OctoberTwoThousandFifteenMember_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_15" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MilestonePaymentsPayableAxis_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_MilestonePaymentsPayableAxis_20" xlink:to="loc_embi_MilestonePaymentsPayableDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_20" xlink:to="loc_embi_Milestone1Member_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_20" xlink:to="loc_embi_Milestone2Member_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_20" xlink:to="loc_embi_Milestone3Member_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_MilestonePaymentsPayableAxis_20" xlink:to="loc_embi_MilestonePaymentsPayableDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_AnnualMaintenanceFeePayable_27" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_TermOfAgreement_28" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_PaymentForUpfrontFees_29" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_NumberOfLicenseAgreements_30" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_NoticePeriodForTermination_31" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_AnnualFeesForLicenseAgreement_32" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_1" xlink:to="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_33" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAccruedConsultingFees" xlink:label="loc_embi_PercentageOfAccruedConsultingFees_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfBonusForAccruedConsultingFees" xlink:label="loc_embi_PercentageOfBonusForAccruedConsultingFees_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalFeesIncurredUnderAgreement" xlink:label="loc_embi_TotalFeesIncurredUnderAgreement_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_IndependentContractorAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_embi_AvtarDhillonMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_InitialTermOfAgreement_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_TotalExpenseIncurredUnderAgreement_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFee_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_16" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_17" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_PercentageOfAccruedConsultingFees_18" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_PercentageOfBonusForAccruedConsultingFees_19" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_TotalFeesIncurredUnderAgreement_20" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_AccruedExpenseUnderAgreement_21" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ManagementDeferralAgreementMember" xlink:label="loc_embi_ManagementDeferralAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsMember" xlink:label="loc_embi_EmeraldFinancingWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockOptions2014PlanMember" xlink:label="loc_embi_StockOptions2014PlanMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonUnitsSoldPricePerUnit" xlink:label="loc_embi_CommonUnitsSoldPricePerUnit_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PreFundedUnitsSoldPricePerUnit" xlink:label="loc_embi_PreFundedUnitsSoldPricePerUnit_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" xlink:label="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" xlink:label="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_37"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_ManagementDeferralAgreementMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_SeparationAndReleaseAgreementMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_embi_CommonStockWarrantsMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_embi_PrefundedWarrantsMember_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_embi_EmeraldFinancingWarrantsMember_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_17" xlink:to="loc_us-gaap_PlanNameDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_17" xlink:to="loc_embi_StockOptions2014PlanMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_17" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_CommonUnitsSoldPricePerUnit_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_PreFundedUnitsSoldPricePerUnit_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_GrossProceedsOfUnitsSold_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_29" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_30" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_31" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_32" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_33" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_35" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_36" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_37" order="160" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>embi-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AdditionalConversionLiability" xlink:label="loc_embi_AdditionalConversionLiability_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregateExercisePriceOfOutstandingCreditAgreement" xlink:label="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregatePrincipalAmount" xlink:label="loc_embi_AggregatePrincipalAmount_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmortizationOfDebtDiscount" xlink:label="loc_embi_AmortizationOfDebtDiscount_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmortizationOfTransactionCosts" xlink:label="loc_embi_AmortizationOfTransactionCosts_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualFeeForAgreement" xlink:label="loc_embi_AnnualFeeForAgreement_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_34"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CapitalRaise" xlink:label="loc_embi_CapitalRaise_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CashAndCashEquivalents" xlink:label="loc_embi_CashAndCashEquivalents_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_37"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_38"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ChangeInFairValueOfWarrantLiability" xlink:label="loc_embi_ChangeInFairValueOfWarrantLiability_39"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_40"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockIssuanceCosts" xlink:label="loc_embi_CommonStockIssuanceCosts_41"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_42"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_43"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonUnitsSoldPricePerUnit" xlink:label="loc_embi_CommonUnitsSoldPricePerUnit_44"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConsultingAgreementMember" xlink:label="loc_embi_ConsultingAgreementMember_45"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionLiabilityIntoCommonStockPerShare" xlink:label="loc_embi_ConversionLiabilityIntoCommonStockPerShare_46"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_47"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_48"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_49"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_50"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_51"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStock" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_52"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_53"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_54"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockValue" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_55"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConversionPricePerShare" xlink:label="loc_embi_ConversionPricePerShare_56"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConvertibleDebtRelatedPartyTextBlock" xlink:label="loc_embi_ConvertibleDebtRelatedPartyTextBlock_57"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_58"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConvertibleMultiDrawCreditFacility" xlink:label="loc_embi_ConvertibleMultiDrawCreditFacility_59"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CouponInterestExpense" xlink:label="loc_embi_CouponInterestExpense_60"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CreditFacilityEffectedFifthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFifthAdvances_61"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CreditFacilityEffectedFourthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFourthAdvances_62"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_63"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DebtForgivenessCARESActDescription" xlink:label="loc_embi_DebtForgivenessCARESActDescription_64"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_65"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_66"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_67"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DocumentAndEntityInformationAbstract" xlink:label="loc_embi_DocumentAndEntityInformationAbstract_68"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DouglasCesarioMember" xlink:label="loc_embi_DouglasCesarioMember_69"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_70"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_71"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_72"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_73"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantLiabilityMember_74"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_75"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsMember" xlink:label="loc_embi_EmeraldFinancingWarrantsMember_76"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_77"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_78"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_79"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_80"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_81"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_82"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_83"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_84"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_85"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_86"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_87"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_88"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_90"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" xlink:label="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_91"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_92"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_93"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_94"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" xlink:label="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_95"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_96"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_97"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_98"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LegalReimbursementFees" xlink:label="loc_embi_LegalReimbursementFees_99"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_100"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LumpSumPaymentInAgreement" xlink:label="loc_embi_LumpSumPaymentInAgreement_101"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ManagementDeferralAgreementMember" xlink:label="loc_embi_ManagementDeferralAgreementMember_102"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_103"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_104"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_105"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_106"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_107"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_108"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_109"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_110"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_111"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_112"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_113"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_114"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultidrawCreditAgreementRelatedPartyNoncurrent" xlink:label="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_115"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_116"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_117"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_118"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_119"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_120"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities" xlink:label="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NonCashInterestExpenseAbstract" xlink:label="loc_embi_NonCashInterestExpenseAbstract_122"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NoramcoAgreementMember" xlink:label="loc_embi_NoramcoAgreementMember_123"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_124"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_125"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_126"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_127"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_128"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_129"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_130"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaycheckProtectionProgramMember" xlink:label="loc_embi_PaycheckProtectionProgramMember_131"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_132"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_133"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" xlink:label="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_134"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PayrollCostsExcludeCompensation" xlink:label="loc_embi_PayrollCostsExcludeCompensation_135"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAccruedConsultingFees" xlink:label="loc_embi_PercentageOfAccruedConsultingFees_136"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAccruedInterestOnOutstandingBalance" xlink:label="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_137"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_138"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfBonusForAccruedConsultingFees" xlink:label="loc_embi_PercentageOfBonusForAccruedConsultingFees_139"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfForgivenessAmountForNonPayrollCosts" xlink:label="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_140"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfReductionInAnnualSalary" xlink:label="loc_embi_PercentageOfReductionInAnnualSalary_141"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_142"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" xlink:label="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_143"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_144"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PreferredStockPutOptionLiability" xlink:label="loc_embi_PreferredStockPutOptionLiability_145"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PreFundedUnitsSoldPricePerUnit" xlink:label="loc_embi_PreFundedUnitsSoldPricePerUnit_146"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_147"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_148"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_149"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_150"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_151"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_152"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_153"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ProvisionForConversionOfPreferredStock" xlink:label="loc_embi_ProvisionForConversionOfPreferredStock_154"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_155"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReducedFixedConversionPriceOfCommonStock" xlink:label="loc_embi_ReducedFixedConversionPriceOfCommonStock_156"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_157"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_RemainingFundsFromPromissoryNote" xlink:label="loc_embi_RemainingFundsFromPromissoryNote_158"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_159"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_embi_RisksAndUncertaintiesPolicyTextBlock_160"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" xlink:label="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_161"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_embi_ScheduleOfInterestExpenseTableTextBlock_162"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_163"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_164"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_165"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeniorManagementCompensationPlanDescription" xlink:label="loc_embi_SeniorManagementCompensationPlanDescription_166"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeparationAgreementMember" xlink:label="loc_embi_SeparationAgreementMember_167"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_168"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_169"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_170"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_171"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesFPreferredStockPutOptionLiabilityMember" xlink:label="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_172"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ShareIssuanceCosts" xlink:label="loc_embi_ShareIssuanceCosts_173"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_174"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SignificantContractsTextBlock" xlink:label="loc_embi_SignificantContractsTextBlock_175"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockholdersDeficitAndCapitalizationTextBlock" xlink:label="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_176"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" xlink:label="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_177"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_178"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_179"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_180"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_181"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockOptions2014PlanMember" xlink:label="loc_embi_StockOptions2014PlanMember_182"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_183"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SupplementalRestrictedCash" xlink:label="loc_embi_SupplementalRestrictedCash_184"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_185"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_186"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_187"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermsOfAgreementRenewed" xlink:label="loc_embi_TermsOfAgreementRenewed_188"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" xlink:label="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_189"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:label="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_190"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_191"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalFeesIncurredUnderAgreement" xlink:label="loc_embi_TotalFeesIncurredUnderAgreement_192"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_193"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_194"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_195"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_196"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_197"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_198"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_199"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_200"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_201"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_202"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_203"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_204"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_205"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_embi_UniversityOfMississippiAgreementsAbstract_206"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_207"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_208"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_209"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UnrestrictedCashPositionDecreased" xlink:label="loc_embi_UnrestrictedCashPositionDecreased_210"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_211"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_212"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_213"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_214"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_215"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_216"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantToPurchaseNumberOfCommonStockPricePerShare" xlink:label="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_217"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_218"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_219"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_220"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_221"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_222"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_223"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_224"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_225"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_226"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_227"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_228"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_229"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_230"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_231"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_232"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_233"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_234"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvancesFairValueDisclosure" xlink:label="loc_us-gaap_AdvancesFairValueDisclosure_235"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_236"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_237"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_238"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_240"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_241"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_242"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_243"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_244"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_245"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_246"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_247"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_248"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_249"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_250"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_251"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_252"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_253"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_254"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_255"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_256"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_257"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_258"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_260"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_261"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_262"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_263"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_264"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_265"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_266"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_267"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_268"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_269"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_270"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_271"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_272"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_273"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_274"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_275"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_276"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_277"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_278"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_279"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_280"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_281"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_282"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_283"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_284"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_285"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_286"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_287"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_288"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_289"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_290"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_291"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_292"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_293"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_294"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_295"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_296"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_297"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_298"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_299"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_300"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_301"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_302"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_303"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_304"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_305"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_307"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_308"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_309"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_310"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_311"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_312"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_313"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_314"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_315"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_316"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_317"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_318"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_319"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_320"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_321"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_322"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_323"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_324"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_325"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_326"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_327"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_328"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_329"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_330"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_331"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_332"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_333"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_334"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_335"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_336"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_337"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_338"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_339"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_340"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_341"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_342"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_343"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_344"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_345"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_346"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_347"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_348"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_349"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_350"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_351"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_352"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_353"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_354"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_355"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_356"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_357"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_358"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_359"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_360"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_361"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_362"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_363"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_364"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_365"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_366"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_367"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_368"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_369"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_370"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_371"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_372"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_373"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_374"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_375"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_376"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_377"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_378"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_379"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_380"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_381"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_382"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_383"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_384"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_385"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_386"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_387"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_388"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_389"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_390"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_391"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_392"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_393"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_394"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_395"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_396"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_397"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_398"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_399"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_400"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_401"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_402"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_404"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_405"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_406"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_407"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_408"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_409"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_410"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_411"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_412"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_413"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_414"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_415"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_416"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_417"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_418"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_419"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_420"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_421"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_423"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_424"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_425"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_426"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_427"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_428"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_430"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_431"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_432"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_433"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_434"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_435"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_436"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_437"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_438"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_439"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_440"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_441"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_442"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_443"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_444"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_445"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_446"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_447"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_448"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_449"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_450"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_451"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_454"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_455"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_456"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_457"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_458"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_459"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_460"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_461"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_462"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_464"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_465"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_466"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_467"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_468"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_469"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_470"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_471"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_472"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_473"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_474"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_475"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_476"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_478"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_479"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_480"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_481"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_482"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_483"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_484"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_485"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_486"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_487"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_488"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_489"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_490"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_491"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_492"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_493"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_494"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_495"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_496"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_497"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_498"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_499"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_500"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_501"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_502"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_503"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_504"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_505"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_506"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_507"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_508"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_509"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_510"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_511"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_512"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_513"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_514"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_515"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_516"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_517"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag_1" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate_1" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus_1" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus_1" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate_1" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType_1" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey_1" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory_1" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName_1" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_LegalEntityAxis_1" xml:lang="en-US">UM 5050 Pro-Drug and UM 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol_1" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AccruedExpenseUnderAgreement_0" xml:lang="en-US">Represents total accrued expense under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AccruedExpenseUnderAgreement_1" xml:lang="en-US">Accrued Expense Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AccruedExpenseUnderAgreement_2" xml:lang="en-US">Accrued expense under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AdditionalConversionLiability_0" xml:lang="en-US">Threshold number of specified trading days that common stock price to additional conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AdditionalConversionLiability_1" xml:lang="en-US">Additional Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AdditionalConversionLiability_2" xml:lang="en-US">Additional conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_0" xml:lang="en-US">Information about aggregate exercise price of outstanding credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_1" xml:lang="en-US">Aggregate Exercise Price Of outstanding Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_2" xml:lang="en-US">Aggregate exercise price of outstanding credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_0" xml:lang="en-US">This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_1" xml:lang="en-US">Aggregate Milestone Payments If Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_2" xml:lang="en-US">Aggregate milestone payments if milestones achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregatePrincipalAmount_0" xml:lang="en-US">Represents aggregate principal amount .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregatePrincipalAmount_1" xml:lang="en-US">Aggregate Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of debt on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Debt On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of debt on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of warrant on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Warrant On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of warrant on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents information of amended and restated multi draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmortizationOfDebtDiscount_0" xml:lang="en-US">Amount of amortization expense attributable to debt discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmortizationOfDebtDiscount_1" xml:lang="en-US">Amortization Of Debt Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AmortizationOfDebtDiscount_2" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmortizationOfTransactionCosts_0" xml:lang="en-US">Amount of amortization of transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmortizationOfTransactionCosts_1" xml:lang="en-US">Amortization Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AmortizationOfTransactionCosts_2" xml:lang="en-US">Amortization of transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualFeeForAgreement_0" xml:lang="en-US">Represents amount of annual fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualFeeForAgreement_1" xml:lang="en-US">Annual Fee For Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AnnualFeeForAgreement_2" xml:lang="en-US">Annual fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_0" xml:lang="en-US">Represents annual fees for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_1" xml:lang="en-US">Annual Fees For License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_2" xml:lang="en-US">Annual fees for license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualMaintenanceFeePayable_0" xml:lang="en-US">Represents the amount of annual maintenance fee payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualMaintenanceFeePayable_1" xml:lang="en-US">Annual maintenance fee payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AvtarDhillonMember_0" xml:lang="en-US">Name of board member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AvtarDhillonMember_1" xml:lang="en-US">Avtar Dhillon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AvtarDhillonMember_2" xml:lang="en-US">Dr. Avtar Dhillon</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Beneficial conversion feature on convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CapitalRaise_0" xml:lang="en-US">Represents amount of capital raise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CapitalRaise_1" xml:lang="en-US">Capital Raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CashAndCashEquivalents_0" xml:lang="en-US">Represents amount of Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CashAndCashEquivalents_1" xml:lang="en-US">Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CashAndCashEquivalents_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_0" xml:lang="en-US">Cash Paid During Period For Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_1" xml:lang="en-US">Cash paid during the period for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_2" xml:lang="en-US">Cash paid during the period for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_0" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_2" xml:lang="en-US">Change In Fair Value Of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_3" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_0" xml:lang="en-US">Amount of expense (income) related to warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_1" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_2" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_0" xml:lang="en-US">Class Of Warrant Or Right Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_1" xml:lang="en-US">Represents number of warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_2" xml:lang="en-US">Warrants exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockIssuanceCosts_0" xml:lang="en-US">Amount of common stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockIssuanceCosts_1" xml:lang="en-US">Common Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CommonStockIssuanceCosts_2" xml:lang="en-US">Common stock issuance costs paid of $7,778</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockWarrantsMember_0" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockWarrantsMember_1" xml:lang="en-US">Common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonStockWarrantsMember_2" xml:lang="en-US">Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Represents common stock warrants to series B stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Common Stock Warrants To Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonUnitsSoldPricePerUnit_0" xml:lang="en-US">Common Units Sold Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonUnitsSoldPricePerUnit_1" xml:lang="en-US">Represents the price per unit of common units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonUnitsSoldPricePerUnit_2" xml:lang="en-US">Common units sold price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConsultingAgreementMember_0" xml:lang="en-US">Consulting Agreement that involves two or more parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConsultingAgreementMember_1" xml:lang="en-US">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConsultingAgreementMember_2" xml:lang="en-US">Consulting Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_0" xml:lang="en-US">Represents conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_1" xml:lang="en-US">Conversion Liability Into Common Stock Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_2" xml:lang="en-US">Conversion liability into common stock per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0" xml:lang="en-US">Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1" xml:lang="en-US">Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2" xml:lang="en-US">Conversion of outstanding preferred stock subject to redemption into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.80 and $0.40 per share for December 31, 2016 and $0.25 and $0.15 per share for December 31, 2017 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3" xml:lang="en-US">Conversion of Series A and Series B Preferred Stock and conversion liability into common stock at $0.80 per share and $0.80 and $0.40 per share for 2015 and 2016, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion of series D preferred stock to common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock,Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_0" xml:lang="en-US">Number of shares of series F preferred stock converted during the period into common stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_0" xml:lang="en-US">Value of shares of series F preferred stock converted into common stocks during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionPricePerShare_0" xml:lang="en-US">Represents the value related to conversion of Series A Preferred Stock and conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionPricePerShare_1" xml:lang="en-US">Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionPricePerShare_2" xml:lang="en-US">Conversion of preferred stock price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_0" xml:lang="en-US">The entire disclosure for convertible debt - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_1" xml:lang="en-US">Convertible Debt Related Party [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_2" xml:lang="en-US">Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1" xml:lang="en-US">Convertible Multi Draw Credit Agreement Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2" xml:lang="en-US">Convertible multi-draw credit agreement issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_0" xml:lang="en-US">The carrying value of convertible multi- draw credit facility - related party as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_2" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_3" xml:lang="en-US">Convertible Multi Draw Credit Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_4" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_5" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CouponInterestExpense_0" xml:lang="en-US">Amount of interest expense classified as coupon interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CouponInterestExpense_1" xml:lang="en-US">Coupon Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CouponInterestExpense_2" xml:lang="en-US">Interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CreditFacilityEffectedFifthAdvances_0" xml:lang="en-US">Credit Facility Effected Fifth Advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CreditFacilityEffectedFifthAdvances_1" xml:lang="en-US">Represents credit facility fifth advances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CreditFacilityEffectedFourthAdvances_0" xml:lang="en-US">Credit Facility Effected Fourth Advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CreditFacilityEffectedFourthAdvances_1" xml:lang="en-US">Represents fourth credit facility advances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_0" xml:lang="en-US">The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_1" xml:lang="en-US">Current Convertible Debt Excluding Noncurrent Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_2" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_3" xml:lang="en-US">Total carrying value of advances under the multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DebtForgivenessCARESActDescription_0" xml:lang="en-US">Represents information of debt forgiveness under The Coronavirus Aid, Relief, and Economic Security Act ("the CARES Act").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DebtForgivenessCARESActDescription_1" xml:lang="en-US">Debt Forgiveness CARES Act Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DebtForgivenessCARESActDescription_2" xml:lang="en-US">Debt forgiveness, CARES Act, description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_December2015Member_0" xml:lang="en-US">Represents December 2015 as agreement month and year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_December2015Member_1" xml:lang="en-US">December 2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_December2015Member_2" xml:lang="en-US">December 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DerivativeLiabilitiesLineItems_0" xml:lang="en-US">Line item represents derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DerivativeLiabilitiesLineItems_1" xml:lang="en-US">Derivative Liabilities Line Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DerivativeLiabilitiesTable_0" xml:lang="en-US">A table or schedule providing information about derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DerivativeLiabilitiesTable_1" xml:lang="en-US">Derivative Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DouglasCesarioMember_0" xml:lang="en-US">Represents the Douglas Cesario.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DouglasCesarioMember_1" xml:lang="en-US">Douglas Cesario [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_DouglasCesarioMember_2" xml:lang="en-US">Douglas Cesario, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_0" xml:lang="en-US">Represents draw downs loans in aggregate principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_1" xml:lang="en-US">Draw Downs Loans In Aggregate Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_2" xml:lang="en-US">Draw downs loans In aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0" xml:lang="en-US">Information about emerald convertible promissory note - conversion liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3" xml:lang="en-US">Emerald Convertible Promissory Note - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_0" xml:lang="en-US">Cost incurred for Emerald Financing, issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_1" xml:lang="en-US">Emerald Financing Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_2" xml:lang="en-US">Emerald financing issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingMember_0" xml:lang="en-US">Represents Emerald financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingMember_1" xml:lang="en-US">Emerald Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingMember_2" xml:lang="en-US">Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingMember_3" xml:lang="en-US">Emerald Financing - Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingWarrantLiabilityMember_0" xml:lang="en-US">Information regarding Emerald Financing Warrant Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingWarrantLiabilityMember_1" xml:lang="en-US">Emerald Financing Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingWarrantLiabilityMember_2" xml:lang="en-US">Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingWarrantsLiabilityMember_0" xml:lang="en-US">Information regarding Emerald Financing Warrants Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingWarrantsLiabilityMember_1" xml:lang="en-US">Emerald Financing Warrants Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingWarrantsLiabilityMember_2" xml:lang="en-US">Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingWarrantsMember_0" xml:lang="en-US">Emerald Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingWarrantsMember_1" xml:lang="en-US">Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingWarrantsMember_2" xml:lang="en-US">Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_0" xml:lang="en-US">Represents information about Emerald Health Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_1" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_2" xml:lang="en-US">Emerald Health Sciences Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_3" xml:lang="en-US">Emerald Health Sciences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0" xml:lang="en-US">Information regarding emerald multi-draw credit agreement compound derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Compound Derivative Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Compound Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_0" xml:lang="en-US">Represents the information about Emerald Warrant Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_1" xml:lang="en-US">Emerald Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_2" xml:lang="en-US">Emerald Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_3" xml:lang="en-US">Emerald Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EquityLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EquityLineItems_1" xml:lang="en-US">Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EquityTable_0" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EquityTable_1" xml:lang="en-US">Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ExerciseOfWarrants_0" xml:lang="en-US">The amount express exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ExerciseOfWarrants_1" xml:lang="en-US">Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ExerciseOfWarrants_2" xml:lang="en-US">Reclassification of warrant liabilities to equity from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairMarketValueOfStockOptions_0" xml:lang="en-US">Represents the fair market value of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairMarketValueOfStockOptions_1" xml:lang="en-US">Fair Market Value Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairMarketValueOfStockOptions_2" xml:lang="en-US">Fair market value of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_0" xml:lang="en-US">It represents fair value adjustment of derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_2" xml:lang="en-US">Fair Value Adjustment Of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_3" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of derivative asset and liability measured on recurring and nonrecurring basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_1" xml:lang="en-US">Fair Value Measurement Inputs And Valuation Techniques Derivative Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_2" xml:lang="en-US">Schedule of input and valuation technique used to value derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_0" xml:lang="en-US">Represents the amount of derivative liabilities at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_1" xml:lang="en-US">Fair Value Of Derivative Liabilities [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_0" xml:lang="en-US">It represents fair value of derivative liability excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_1" xml:lang="en-US">Fair Value Of Derivative Liability Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_2" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_0" xml:lang="en-US">Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_1" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_2" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_3" xml:lang="en-US">Fair Value Of Warrant Liability In Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_5" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantsIssued_0" xml:lang="en-US">The fair value of warrants issued in noncash investing or financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_1" xml:lang="en-US">Initial Fair Value of Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantsIssued_2" xml:lang="en-US">Fair Value Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_3" xml:lang="en-US">Fair value of warrants issued in connection with financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_4" xml:lang="en-US">Fair Value of Derivative Liabilities Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_0" xml:lang="en-US">Amount of fair value of warrants issued in connection with financings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_1" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_2" xml:lang="en-US">Fair value of warrants issued in connection with financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Fifth Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Represents Fifth Amended And Restated Multi Draw Credit Agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Fifth amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Fourth Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Represents Fourth Amended And Restated Multi Draw Credit Agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">fourth amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_GrossProceedsOfUnitsSold_0" xml:lang="en-US">Gross Proceeds Of Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_GrossProceedsOfUnitsSold_1" xml:lang="en-US">Represents the amount of gross proceeds of units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_GrossProceedsOfUnitsSold_2" xml:lang="en-US">Gross proceeds of units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_0" xml:lang="en-US">Represents increase decrease in accrued interest due to related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_1" xml:lang="en-US">Increase Decrease Accrued Interest Due To Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_2" xml:lang="en-US">Accrued interest related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IndependentContractorAgreementMember_0" xml:lang="en-US">Represents name of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IndependentContractorAgreementMember_1" xml:lang="en-US">Independent Contractor Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IndependentContractorAgreementMember_2" xml:lang="en-US">Independent contractor agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_InitialTermOfAgreement_0" xml:lang="en-US">Represents the initial term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_InitialTermOfAgreement_1" xml:lang="en-US">Initial Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_InitialTermOfAgreement_2" xml:lang="en-US">Initial term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_K2CIncMember_0" xml:lang="en-US">Represents name of party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_K2CIncMember_1" xml:lang="en-US">K2C Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_K2CIncMember_2" xml:lang="en-US">K2C, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LegalReimbursementFees_0" xml:lang="en-US">Represent legal reimburse fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LegalReimbursementFees_1" xml:lang="en-US">Legal Reimbursement Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_LegalReimbursementFees_2" xml:lang="en-US">Legal reimbursement fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LicenseAgreementMember_0" xml:lang="en-US">Represents license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LicenseAgreementMember_1" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_LicenseAgreementMember_2" xml:lang="en-US">UM 8930 analogue agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LicenseAgreementMember_3" xml:lang="en-US">License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LumpSumPaymentInAgreement_0" xml:lang="en-US">The amount related to lump sum payment in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LumpSumPaymentInAgreement_1" xml:lang="en-US">Lump Sum Payment In Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LumpSumPaymentInAgreement_2" xml:lang="en-US">Lump sum payment in agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ManagementDeferralAgreementMember_0" xml:lang="en-US">Management Deferral Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ManagementDeferralAgreementMember_1" xml:lang="en-US">Management Deferral Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ManagementDeferralAgreementMember_2" xml:lang="en-US">Management Deferral Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone1Member_0" xml:lang="en-US">It represents milestone 1 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone1Member_1" xml:lang="en-US">Milestone 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone1Member_2" xml:lang="en-US">Milestone 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone2Member_0" xml:lang="en-US">It represents milestone 2 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone2Member_1" xml:lang="en-US">Milestone 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone2Member_2" xml:lang="en-US">Milestone 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone3Member_0" xml:lang="en-US">It represents milestone 3 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone3Member_1" xml:lang="en-US">Milestone 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone3Member_2" xml:lang="en-US">Milestone 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MilestonePaymentsPayableAxis_0" xml:lang="en-US">It represents milestone payments payable axis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MilestonePaymentsPayableAxis_1" xml:lang="en-US">Milestone Payments Payable [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MilestonePaymentsPayableDomain_0" xml:lang="en-US">It represents milestone payments payable domain.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MilestonePaymentsPayableDomain_1" xml:lang="en-US">Milestone Payments Payable [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonteCarloSimulationsMember_0" xml:lang="en-US">Represents monte carlo simulations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonteCarloSimulationsMember_1" xml:lang="en-US">Monte Carlo Simulations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonteCarloSimulationsMember_2" xml:lang="en-US">Monte Carlo simulations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthAndYearOfAgreementAxis_0" xml:lang="en-US">Information regarding month and year of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthAndYearOfAgreementAxis_1" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthAndYearOfAgreementDomain_0" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthAndYearOfAgreementDomain_1" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFee_0" xml:lang="en-US">Represents amount of monthly fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFee_1" xml:lang="en-US">Monthly Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonthlyFee_2" xml:lang="en-US">Monthly fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0" xml:lang="en-US">Represents amount of monthly fees accruing from the effective date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1" xml:lang="en-US">Monthly Fee Accruing From Effective Date In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2" xml:lang="en-US">Monthly fee accruing from effective date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_0" xml:lang="en-US">Represents amount of monthly fee paid in exchange of services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_1" xml:lang="en-US">Monthly Fee Paid Each Month In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_2" xml:lang="en-US">Monthly fee paid each month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents the information about Multi-Draw Credit Agreement (the "Credit Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MultiDrawCreditAgreementMember_1" xml:lang="en-US">Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MultiDrawCreditAgreementMember_2" xml:lang="en-US">Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_0" xml:lang="en-US">Multidraw Credit Agreement Related Party Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_1" xml:lang="en-US">Represents the multidraw credit agreement related party noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_2" xml:lang="en-US">Multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_1" xml:lang="en-US">Nature Of Operations And Business Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_1" xml:lang="en-US">Nature Of Operations And Business Activities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xml:lang="en-US">Nature Of Operations And Business Activities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_1" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_2" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_0" xml:lang="en-US">Represents Tabular disclosure of nature of operations, business activities and Summary of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_0" xml:lang="en-US">Represents net loss available to common shareholders, adjusted as appropriate for gains or losses from dilutive securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_1" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_2" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_3" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_4" xml:lang="en-US">Net Loss Available To Common Shareholders Adjusted As Appropriate For Gains Or Losses From Dilutive Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_5" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_6" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_7" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NonCashInterestExpenseAbstract_0" xml:lang="en-US">Non Cash Interest Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_NonCashInterestExpenseAbstract_1" xml:lang="en-US">Non-cash interest expense:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NoramcoAgreementMember_0" xml:lang="en-US">It represents Noramco Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NoramcoAgreementMember_1" xml:lang="en-US">Noramco Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NoramcoAgreementMember_2" xml:lang="en-US">Noramco Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NoticePeriodForTermination_0" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NoticePeriodForTermination_1" xml:lang="en-US">Notice Period For Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NoticePeriodForTermination_2" xml:lang="en-US">Notice period for termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfCommonStockUnitsSold_0" xml:lang="en-US">Number Of Common Stock Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfCommonStockUnitsSold_1" xml:lang="en-US">Represents the number of common stock units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfCommonStockUnitsSold_2" xml:lang="en-US">Number of common stock units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfLicenseAgreements_0" xml:lang="en-US">Represents number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfLicenseAgreements_1" xml:lang="en-US">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfLicenseAgreements_2" xml:lang="en-US">Number of license agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfPreFundedUnitsSold_0" xml:lang="en-US">Number Of Pre Funded Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfPreFundedUnitsSold_1" xml:lang="en-US">Number of pre funded units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfPreFundedUnitsSold_2" xml:lang="en-US">Number of pre-funded units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_0" xml:lang="en-US">Represents agreement date of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_1" xml:lang="en-US">October Two Thousand Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_2" xml:lang="en-US">October 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_0" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_1" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_2" xml:lang="en-US">2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_3" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OptionAgreementMember_0" xml:lang="en-US">Represents information regarding option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OptionAgreementMember_1" xml:lang="en-US">Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OptionAgreementMember_2" xml:lang="en-US">UM 5050 pro-drug agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OptionAgreementMember_3" xml:lang="en-US">Option Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaycheckProtectionProgramMember_0" xml:lang="en-US">Paycheck Protection Program[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaycheckProtectionProgramMember_1" xml:lang="en-US">PaycheckProtectionProgram.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaycheckProtectionProgramMember_2" xml:lang="en-US">Paycheck Protection Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_0" xml:lang="en-US">Represents information of Paycheck protection program promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_1" xml:lang="en-US">Paycheck Protection Program Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_2" xml:lang="en-US">Paycheck Protection Program Promissory Note (PPP Note)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaymentForUpfrontFees_0" xml:lang="en-US">It represents payment for upfront fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaymentForUpfrontFees_1" xml:lang="en-US">Payment For Upfront Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaymentForUpfrontFees_2" xml:lang="en-US">Payment for upfront fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_0" xml:lang="en-US">Represents amount of payment in consideration for restrictive covenants in separation agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_1" xml:lang="en-US">Payment in consideration for restrictive covenants in Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_2" xml:lang="en-US">Payment in consideration for restrictive covenants in Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PayrollCostsExcludeCompensation_0" xml:lang="en-US">Payroll Costs Exclude Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PayrollCostsExcludeCompensation_1" xml:lang="en-US">Represents the amount of payroll costs exclude compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAccruedConsultingFees_0" xml:lang="en-US">Represents percentage of accrued consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAccruedConsultingFees_1" xml:lang="en-US">Percentage of accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PercentageOfAccruedConsultingFees_2" xml:lang="en-US">Percentage of accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_0" xml:lang="en-US">Represents percentage of interest on accrued the outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_1" xml:lang="en-US">Percentage Of Accrued Interest On Outstanding Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_2" xml:lang="en-US">Percentage of accrued interest on outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0" xml:lang="en-US">Percentage of amount need to be issued against warrant purchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1" xml:lang="en-US">Percentage Of Amount Need To Be Issued Against Warrant Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2" xml:lang="en-US">Warrant coverage on the debt facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfBonusForAccruedConsultingFees_0" xml:lang="en-US">Represents percentage of bonus for accrued consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfBonusForAccruedConsultingFees_1" xml:lang="en-US">Percentage of bonus for accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfBonusForAccruedConsultingFees_2" xml:lang="en-US">Percentage of bonus for accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_0" xml:lang="en-US">Percentage Of Forgiveness Amount For Non Payroll Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_1" xml:lang="en-US">Represents the percentage of forgiveness amount for non payroll costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_2" xml:lang="en-US">Percentage of forgiveness amount for nonpayroll costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfReductionInAnnualSalary_0" xml:lang="en-US">Percentage Of Reduction In Annual Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfReductionInAnnualSalary_1" xml:lang="en-US">Percentage of reduction in annual salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfReductionInAnnualSalary_2" xml:lang="en-US">Percentage of reduction in annual salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_0" xml:lang="en-US">Percentage of share reserve of the number of issued and outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_1" xml:lang="en-US">Percentage Of Share Reserve Of Number Of Issued And Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_2" xml:lang="en-US">Percentage of share reserve of the number of issued and outstanding shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1" xml:lang="en-US">Period Of Discretionary Annual Bonus Payable To Contractor After Each Fiscal Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_0" xml:lang="en-US">Represents Pre 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_1" xml:lang="en-US">Pre 2015 Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_2" xml:lang="en-US">Pre 2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PreferredStockPutOptionLiability_0" xml:lang="en-US">Represents the value of preferred stock put option liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PreferredStockPutOptionLiability_1" xml:lang="en-US">Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PreferredStockPutOptionLiability_2" xml:lang="en-US">Series F put option liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PreFundedUnitsSoldPricePerUnit_0" xml:lang="en-US">Pre Funded Units Sold Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PreFundedUnitsSoldPricePerUnit_1" xml:lang="en-US">Represents the price per unit of pre-funded units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PreFundedUnitsSoldPricePerUnit_2" xml:lang="en-US">Pre-funded units sold price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PrefundedWarrantsMember_0" xml:lang="en-US">Prefunded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PrefundedWarrantsMember_1" xml:lang="en-US">Prefunded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PrefundedWarrantsMember_2" xml:lang="en-US">Pre-funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelAxis_0" xml:lang="en-US">Pricing Model [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelDomain_0" xml:lang="en-US">Pricing Model [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PricingModelMember_0" xml:lang="en-US">Represents option pricing model,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelMember_1" xml:lang="en-US">Pricing Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PricingModelMember_2" xml:lang="en-US">Pricing Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds From Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_3" xml:lang="en-US">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs for the June 30, 2020 and June 30, 2019 periods, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0" xml:lang="en-US">Represents the amount related to proceeds from financing between the conversion liability and the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1" xml:lang="en-US">Proceeds From Financing Between Conversion Liability And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2" xml:lang="en-US">Proceeds from financing between conversion liability and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_0" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_1" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_2" xml:lang="en-US">Fair value of the conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_3" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_0" xml:lang="en-US">Amount of reclassification of derivatives to equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_1" xml:lang="en-US">Reclassification Of Derivatives To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_2" xml:lang="en-US">Reclassification of Derivatives to Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReducedFixedConversionPriceOfCommonStock_0" xml:lang="en-US">Represents amount of reduced fixed conversion price of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReducedFixedConversionPriceOfCommonStock_1" xml:lang="en-US">Reduced Fixed Conversion Price Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ReducedFixedConversionPriceOfCommonStock_2" xml:lang="en-US">Reduced fixed conversion price of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_0" xml:lang="en-US">Amount of reduction to APIC from the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_1" xml:lang="en-US">Reduction To Additional Paid In Capital From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_2" xml:lang="en-US">Reduction to APIC from the issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RemainingFundsFromPromissoryNote_0" xml:lang="en-US">Represents amount of remaining funds from promissory note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RemainingFundsFromPromissoryNote_1" xml:lang="en-US">Remaining Funds From Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_RemainingFundsFromPromissoryNote_2" xml:lang="en-US">Remaining funds from promissory note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RestrictedStockAgreementsMember_0" xml:lang="en-US">Information of Restricted Stock Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RestrictedStockAgreementsMember_1" xml:lang="en-US">Restricted Stock Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_RestrictedStockAgreementsMember_2" xml:lang="en-US">Restricted Stock Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_0" xml:lang="en-US">Represents policy for Risks and Uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_1" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_2" xml:lang="en-US">Risks and Uncertainties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0" xml:lang="en-US">Represent Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1" xml:lang="en-US">Schedule Of Adjustment For Difference Between Fair Value Of Warrant Liabilities And Total Proceeds Received Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2" xml:lang="en-US">Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_0" xml:lang="en-US">Tabular disclosure of interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_1" xml:lang="en-US">Schedule Of Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_2" xml:lang="en-US">Schedule of interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_0" xml:lang="en-US">Represents Secured Promissory Note and Security Agreement for a convertible loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_1" xml:lang="en-US">Secured Promissory Note And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_2" xml:lang="en-US">Secured promissory note and security agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_0" xml:lang="en-US">Represents information regarding securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_1" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_2" xml:lang="en-US">Securities purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_0" xml:lang="en-US">Securities Purchase Agreement With H C Wainwright And Co LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_1" xml:lang="en-US">Securities Purchase Agreement with H C Wainwright And Co LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_2" xml:lang="en-US">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeniorManagementCompensationPlanDescription_0" xml:lang="en-US">Represents description of senior management compensation plan description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeniorManagementCompensationPlanDescription_1" xml:lang="en-US">Senior Management Compensation Plan Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeniorManagementCompensationPlanDescription_2" xml:lang="en-US">Description of senior management's compensation plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeparationAgreementMember_0" xml:lang="en-US">Represents information of separation agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeparationAgreementMember_1" xml:lang="en-US">Separation Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeparationAgreementMember_2" xml:lang="en-US">Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_0" xml:lang="en-US">Represents separation and release agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_1" xml:lang="en-US">Separation And Release Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_2" xml:lang="en-US">Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_3" xml:lang="en-US">Separation and release agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_0" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_1" xml:lang="en-US">Series B Preferred Stock Conversion Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_2" xml:lang="en-US">Series B Preferred Stock - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_3" xml:lang="en-US">Series B conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBWarrantMember_0" xml:lang="en-US">Represents information regarding Series B warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBWarrantMember_1" xml:lang="en-US">Series B Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeriesBWarrantMember_2" xml:lang="en-US">Series B Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBWarrantMember_3" xml:lang="en-US">Series B warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBWarrantsMember_0" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBWarrantsMember_1" xml:lang="en-US">Series B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBWarrantsMember_2" xml:lang="en-US">Series B Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_0" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_1" xml:lang="en-US">Series F Preferred Stock Put Option Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_2" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ShareIssuanceCosts_0" xml:lang="en-US">Represents costs related to issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ShareIssuanceCosts_1" xml:lang="en-US">Share Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ShareIssuanceCosts_2" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsAbstract_0" xml:lang="en-US">Significant Contracts [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SignificantContractsTextBlock_0" xml:lang="en-US">The entire disclosure for Significant Contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsTextBlock_1" xml:lang="en-US">Significant Contracts [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SignificantContractsTextBlock_2" xml:lang="en-US">Significant Contracts - University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_0" xml:lang="en-US">The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity which includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and the accumulated deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_1" xml:lang="en-US">Stockholders Deficit And Capitalization [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_2" xml:lang="en-US">Stockholders' Deficit and Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0" xml:lang="en-US">Number of shares issued in lieu of cash for Stock based compensation expense contributed to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1" xml:lang="en-US">Stock Issued During Period Shares Issued For Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2" xml:lang="en-US">Stock based compensation expense (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0" xml:lang="en-US">Number of shares of stock issued during the period net of issuance costs value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0" xml:lang="en-US">Number of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Shares Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0" xml:lang="en-US">Value of shares of common stock issued during the period net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0" xml:lang="en-US">Value of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Value Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockOptions2014PlanMember_0" xml:lang="en-US">Stock Options 2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockOptions2014PlanMember_1" xml:lang="en-US">This member stands for 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockOptions2014PlanMember_2" xml:lang="en-US">2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_0" xml:lang="en-US">Represents subsequent financing purchase price description to protect against anti-dilution.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_1" xml:lang="en-US">Subsequent Financing Purchase Price Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_2" xml:lang="en-US">Subsequent financing purchase price, description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SupplementalRestrictedCash_0" xml:lang="en-US">Represents amount of supplemental restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SupplementalRestrictedCash_1" xml:lang="en-US">Supplemental Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SupplementalRestrictedCash_2" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfAgreement_0" xml:lang="en-US">Represents time to pay, after milestone is met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfAgreement_1" xml:lang="en-US">Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TermOfAgreement_2" xml:lang="en-US">Term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfWarrant_0" xml:lang="en-US">Represents term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfWarrant_1" xml:lang="en-US">Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermOfWarrant_2" xml:lang="en-US">Term of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TermOfWarrant_3" xml:lang="en-US">Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfWarrants_0" xml:lang="en-US">Represents term of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfWarrants_1" xml:lang="en-US">Term Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermOfWarrants_2" xml:lang="en-US">Term of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermsOfAgreementRenewed_0" xml:lang="en-US">Represents tem of agreement renewed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermsOfAgreementRenewed_1" xml:lang="en-US">Terms Of Agreement Renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermsOfAgreementRenewed_2" xml:lang="en-US">Terms of agreement renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_0" xml:lang="en-US">Threshold Exercise Price Of Warrants To Waive Rights To Anti Dilution Protection Upon Subsequent Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_1" xml:lang="en-US">Threshold exercise price of warrants to waive rights to anti dilution protection upon subsequent issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_2" xml:lang="en-US">Threshold exercise price of warrants to waive rights to anti dilution protection upon subsequent issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_0" xml:lang="en-US">Represents amount of total cash, cash equivalents and restricted cash shown in the consolidated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_1" xml:lang="en-US">Total Cash Equivalents And Restricted Cash Shown In Consolidated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_2" xml:lang="en-US">Total cash and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_0" xml:lang="en-US">Represents total expense incurred under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_1" xml:lang="en-US">Total Expense Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_2" xml:lang="en-US">Expense incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_3" xml:lang="en-US">Total expense incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalFeesIncurredUnderAgreement_0" xml:lang="en-US">Total Fees Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalFeesIncurredUnderAgreement_1" xml:lang="en-US">Represents the total fees incurred under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TotalFeesIncurredUnderAgreement_2" xml:lang="en-US">Fees incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_0" xml:lang="en-US">Represents 2018 Emerald Financing Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_1" xml:lang="en-US">Two Thousand Eighteen Emerald Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_2" xml:lang="en-US">2018 Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0" xml:lang="en-US">Information about 2018 emerald multi-draw credit agreement warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement - compound derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2" xml:lang="en-US">Two Thousand Eighteen Emerald Multi Draw Credit Agreement Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" xml:lang="en-US">2018 Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_0" xml:lang="en-US">Represents 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_2" xml:lang="en-US">2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Common Stock Warrants to Series B Stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Common Stock Warrants To Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2" xml:lang="en-US">2015 Series B financing Placement Agent Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_3" xml:lang="en-US">Need to Delete from Editor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_0" xml:lang="en-US">Information about 2019 common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Nineteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_2" xml:lang="en-US">2019 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand seventeen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Seventeen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2017 Common Stock Warrants to Service Provider</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand sixteen Series D Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Seventeen Series D Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2" xml:lang="en-US">2017 Series D Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand sixteen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Sixteen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2016 Common Stock Warrants to Service Providers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents 2016 Series C Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Sixteen Series C Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2" xml:lang="en-US">2016 Series C Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_0" xml:lang="en-US">It represents UM 5050 Pro-Drug and UM 8930 Analog Agreements member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_1" xml:lang="en-US">Um 5050 Pro Drug And Um 8930 Analog Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_2" xml:lang="en-US">Um 5050 Pro-Drug And Um 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Um5070LicenseAgreementMember_0" xml:lang="en-US">UM 5070 license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Um5070LicenseAgreementMember_1" xml:lang="en-US">Um 5070 License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Um5070LicenseAgreementMember_2" xml:lang="en-US">UM 5070 license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_0" xml:lang="en-US">Period of unamortized discount of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_1" xml:lang="en-US">Unamortized Debt Discount Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_2" xml:lang="en-US">Unamortized debt discount period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsAbstract_0" xml:lang="en-US">University Of Mississippi Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiAgreementsLineItems_0" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsLineItems_1" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiAgreementsTable_0" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsTable_1" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiMember_0" xml:lang="en-US">Represents information regarding university of Mississippi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiMember_1" xml:lang="en-US">University Of Mississippi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_UniversityOfMississippiMember_2" xml:lang="en-US">University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UnrestrictedCashPositionDecreased_0" xml:lang="en-US">Represents amount of unrestricted cash position decreased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UnrestrictedCashPositionDecreased_1" xml:lang="en-US">Unrestricted cash position decreased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_0" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_1" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_2" xml:lang="en-US">Value of common stock called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xml:lang="en-US">Warrants And Derivative Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_0" xml:lang="en-US">The entire disclosure for Warrants and Derivative Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1" xml:lang="en-US">Warrants And Derivative Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_2" xml:lang="en-US">Warrants and Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents warrants issued in connection with convertible multi draw credit agreement related party value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Warrants issued in connection with convertible multi draw credit agreement related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_3" xml:lang="en-US">Warrants issued in connection with convertible multi-draw credit agreement, related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0" xml:lang="en-US">Warrants Issued in Connection with Financings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1" xml:lang="en-US">Warrants Issued In Connection With Financings [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2" xml:lang="en-US">Warrants Issued in Connection with Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsVestedAndOutstanding_0" xml:lang="en-US">Represents warrants vested and outstanding as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsVestedAndOutstanding_1" xml:lang="en-US">Warrants Vested And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WarrantsVestedAndOutstanding_2" xml:lang="en-US">Amount Vested and Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_0" xml:lang="en-US">Represents warrant to purchase number of common stock price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_1" xml:lang="en-US">Warrant To Purchase Number Of Common Stock Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_2" xml:lang="en-US">Warrant to purchase number of shares of Common Stock equal to dollar amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WorkingCapitalDeficit_0" xml:lang="en-US">Represent working capital deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_WorkingCapitalDeficit_1" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WorkingCapitalDeficit_2" xml:lang="en-US">Working Capital Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WorkingCapitalDeficit_3" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_1" xml:lang="en-US">Elizabeth Berecz, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_2" xml:lang="en-US">Douglas Cesario</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_2" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_2" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_0" xml:lang="en-US">Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_1" xml:lang="en-US">Accrued and accounts payable - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_2" xml:lang="en-US">Accrued interest due to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_0" xml:lang="en-US">Accrued Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_1" xml:lang="en-US">Amount of salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional paid-in-capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional Paid-In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xml:lang="en-US">Stock based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvancesFairValueDisclosure_0" xml:lang="en-US">Advances, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdvancesFairValueDisclosure_1" xml:lang="en-US">Fair value of advances under the Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Recognized stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Recognized additional stock based compensation expense of restricted stock and option awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_1" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Anti-dilutive excluded from the calculation of diluted loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent_2" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoan_0" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoan_1" xml:lang="en-US">Maximum aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BridgeLoan_2" xml:lang="en-US">Aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoanMember_0" xml:lang="en-US">Bridge Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoanMember_1" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BridgeLoanMember_2" xml:lang="en-US">Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1" xml:lang="en-US">Reconciliation of cash and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Net (decrease) increase in cash and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US">Supplemental disclosures of non-cash financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants to purchase an aggregate shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US">Number of common stock called by warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xml:lang="en-US">Total number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US">Number of warrant issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">Commitments and contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US">Number of shares reserved for future grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Par value of common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3" xml:lang="en-US">Common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Common stock, $0.001 par value; 500,000,000 shares authorized; 183,207,747 and 182,895,247 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_1" xml:lang="en-US">Stock-Based Compensation for Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_2" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_1" xml:lang="en-US">Conversion of outstanding preferred stock into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleCommonStockMember_0" xml:lang="en-US">Convertible Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleCommonStockMember_1" xml:lang="en-US">Common shares underlying convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_0" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_2" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_3" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_4" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember_0" xml:lang="en-US">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember_1" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_0" xml:lang="en-US">Less, noncurrent portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_2" xml:lang="en-US">Convertible multi-draw credit agreement - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_1" xml:lang="en-US">Schedule of convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_2" xml:lang="en-US">Schedule of convertible and non-convertible advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1" xml:lang="en-US">Fair value of common stock issued in extinguishment of convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_2" xml:lang="en-US">Number of shares issued in conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1" xml:lang="en-US">Number of common shares issued in conversion of bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_1" xml:lang="en-US">Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis_0" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1" xml:lang="en-US">Beneficial conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1" xml:lang="en-US">Carrying value of the equity component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2" xml:lang="en-US">Total principal value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2" xml:lang="en-US">Conversion price, per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3" xml:lang="en-US">Initial conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1" xml:lang="en-US">Reduction in conversion price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_2" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1" xml:lang="en-US">Number of trading days as of financing close date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0" xml:lang="en-US">Draw downs in aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_2" xml:lang="en-US">Principal amount of promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xml:lang="en-US">Effective interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2" xml:lang="en-US">Bridge loan interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US">Bridge loan maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_2" xml:lang="en-US">Maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US">Debt Issuance Costs and Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_0" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_1" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_3" xml:lang="en-US">Issuance costs related to warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Distribution Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_1" xml:lang="en-US">Amount of deferral agreements paid to certain senior members of management</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_0" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_1" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_2" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_0" xml:lang="en-US">Derivative Contract [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_0" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_0" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_1" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities_2" xml:lang="en-US">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_3" xml:lang="en-US">Derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_0" xml:lang="en-US">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_1" xml:lang="en-US">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_2" xml:lang="en-US">Current balance of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_3" xml:lang="en-US">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1" xml:lang="en-US">Derivative liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2" xml:lang="en-US">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3" xml:lang="en-US">Derivative liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_4" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_1" xml:lang="en-US">Convertible Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">Stock-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract_1" xml:lang="en-US">(Loss) earnings per common share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">Net loss per share - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_0" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_1" xml:lang="en-US">Basic net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2" xml:lang="en-US">Net loss per share - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_0" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_1" xml:lang="en-US">Diluted net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">(Loss) Earnings Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Recognized weighted average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" xml:lang="en-US">Recognized period of non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2" xml:lang="en-US">Stock Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract_0" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityAbstract_1" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain_1" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1" xml:lang="en-US">Change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2" xml:lang="en-US">Change in fair market of the warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3" xml:lang="en-US">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_4" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_5" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_6" xml:lang="en-US">Change in Fair value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" xml:lang="en-US">Schedule of input and valuation technique used to value warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1" xml:lang="en-US">Fair Value Measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_0" xml:lang="en-US">Loss on disposal of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0" xml:lang="en-US">Loss on extinguishment of secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2" xml:lang="en-US">Loss on extinguishment of secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">(Loss) income before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract_1" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_0" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_0" xml:lang="en-US">Increase (Decrease) in Notes Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_1" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1" xml:lang="en-US">Changes in assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember_0" xml:lang="en-US">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntellectualPropertyMember_1" xml:lang="en-US">Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense_1" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense_2" xml:lang="en-US">Net income (loss) and comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpense_3" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt_0" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt_1" xml:lang="en-US">PPP loan interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseRelatedParty_0" xml:lang="en-US">Interest Expense, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseRelatedParty_1" xml:lang="en-US">Related party interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOther_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther_1" xml:lang="en-US">Interest Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther_2" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet_0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet_1" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_0" xml:lang="en-US">Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_1" xml:lang="en-US">Accrued interest on outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestorMember_0" xml:lang="en-US">Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestorMember_1" xml:lang="en-US">Accredited investor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and stockholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">Noncurrent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_2" xml:lang="en-US">Noncurrent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1" xml:lang="en-US">Maximum amount that can be borrowed over the life of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_2" xml:lang="en-US">Credit facility advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1" xml:lang="en-US">Unused portion of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xml:lang="en-US">Principal amounts of borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1" xml:lang="en-US">Fair value of advance under credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_1" xml:lang="en-US">Amount of capital raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1" xml:lang="en-US">Interest rate percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2" xml:lang="en-US">Interest rates per annum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_0" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_1" xml:lang="en-US">Principal amount of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US">Maximum borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2" xml:lang="en-US">Maximum borrowing capacity of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Maximum Month-end Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_1" xml:lang="en-US">Credit facility advances per month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt_0" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt_1" xml:lang="en-US">PPP loan non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1" xml:lang="en-US">Benchmarked yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_1" xml:lang="en-US">Remaining term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_2" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_0" xml:lang="en-US">Measurement Input, Offered Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_1" xml:lang="en-US">Weighted-average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_1" xml:lang="en-US">Volatility factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_2" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xml:lang="en-US">Cash flows provided from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_5" xml:lang="en-US">Net (loss) income and comprehensive (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_6" xml:lang="en-US">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Total other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">Total other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_4" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1" xml:lang="en-US">Other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_0" xml:lang="en-US">Nonoperating Income (Expense) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_1" xml:lang="en-US">Non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_2" xml:lang="en-US">Non-operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_3" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_4" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_5" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" xml:lang="en-US">Nature of Operations and Business Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_2" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent_0" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_0" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_1" xml:lang="en-US">Warrant liability, issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_2" xml:lang="en-US">Payments of Derivative Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_3" xml:lang="en-US">Warrant liability, issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_4" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2" xml:lang="en-US">Private placement stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xml:lang="en-US">Purchases of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2" xml:lang="en-US">Preferred stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_2" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue_0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue_1" xml:lang="en-US">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US">Proceeds from secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs for the June 30, 2020 and June 30, 2019 periods, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Less: Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Common stock gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Less: Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US">Proceeds from issuance of private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_1" xml:lang="en-US">Proceeds from PPP loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_0" xml:lang="en-US">Proceeds from Other Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_1" xml:lang="en-US">Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_1" xml:lang="en-US">Proceeds from related party debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_2" xml:lang="en-US">Proceeds from Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US">Net equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">Related Party Matters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_0" xml:lang="en-US">Funding of remaining bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_1" xml:lang="en-US">Issuance costs from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_2" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_3" xml:lang="en-US">Payments received from convertible bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_4" xml:lang="en-US">Funds received under the Secured Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development Expenses and Licensed Technology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockExpense_0" xml:lang="en-US">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockExpense_1" xml:lang="en-US">Stock compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember_0" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_1" xml:lang="en-US">Unvested restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_2" xml:lang="en-US">Restricted stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3" xml:lang="en-US">Retained earnings during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of outstanding shares of common stock equivalents were excluded from the computation of diluted earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xml:lang="en-US">Schedule of the activity of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1" xml:lang="en-US">Schedule of RSA activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of summary of stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of fair value assumptions of stock option granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_0" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US">Schedule of warrants vested and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_1" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_2" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_1" xml:lang="en-US">Convertible Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_2" xml:lang="en-US">Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_1" xml:lang="en-US">Convertible Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_2" xml:lang="en-US">Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_0" xml:lang="en-US">Series F Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_1" xml:lang="en-US">Convertible Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_2" xml:lang="en-US">Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_2" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1" xml:lang="en-US">Description of stock option agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xml:lang="en-US">Number of restricted common stock granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Unvested, June 30, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Unvested, June 30, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2" xml:lang="en-US">Number of unrestricted stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3" xml:lang="en-US">Number of restricted common stock vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xml:lang="en-US">Additional common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Exercisable, September 30, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable, September 30, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted-average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1" xml:lang="en-US">Number of forfeiture of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted average exercise price of forfeiture of shares (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Balance, September 30, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Balance, December 31, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Balance, September 30, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Balance, December 31, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value of the awards expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xml:lang="en-US">Aggregate intrinsic value of options exercisable, and vested and expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price of vested and outstanding (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted average remaining life (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xml:lang="en-US">Number of option vested and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average grant date fair value (Price per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US">Number of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1" xml:lang="en-US">Over a one-year period commencing on the date of grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2" xml:lang="en-US">November 21, 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">Each of the next thirty-six months thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2" xml:lang="en-US">October 20, 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued_2" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued_3" xml:lang="en-US">Number of additional shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_1" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_2" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_3" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings_0" xml:lang="en-US">Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings_1" xml:lang="en-US">PPP loan non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems_0" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_0" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_1" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_4" xml:lang="en-US">Total stockholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">Stockholders' (deficit) equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1" xml:lang="en-US">Number of notes converted into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3" xml:lang="en-US">Number of common shares issued to individual investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates_2" xml:lang="en-US">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_1" xml:lang="en-US">Decrease in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_2" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_2" xml:lang="en-US">Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_1" xml:lang="en-US">Value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1" xml:lang="en-US">Warrants and rights outstanding measurement input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1" xml:lang="en-US">Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2" xml:lang="en-US">Warrants and rights outstanding term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted average common shares outstanding - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average common shares outstanding - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1" xml:lang="en-US">Weighted average shares of common stock outstanding used to compute earnings per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1" xlink:to="lab_dei_AmendmentFlag_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2" xlink:to="lab_dei_CurrentFiscalYearEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3" xlink:to="lab_dei_DocumentFiscalPeriodFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4" xlink:to="lab_dei_DocumentFiscalYearFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5" xlink:to="lab_dei_DocumentPeriodEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6" xlink:to="lab_dei_DocumentType_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7" xlink:to="lab_dei_EntityCentralIndexKey_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_9" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_10" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_11" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_12" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_12" xlink:to="lab_dei_EntityFilerCategory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_13" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_14" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_14" xlink:to="lab_dei_EntityRegistrantName_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_15" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_16" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="lab_dei_LegalEntityAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_18" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_18" xlink:to="lab_dei_TradingSymbol_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_19" xlink:to="lab_embi_AccruedExpenseUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_19" xlink:to="lab_embi_AccruedExpenseUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_19" xlink:to="lab_embi_AccruedExpenseUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_20" xlink:to="lab_embi_AdditionalConversionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_20" xlink:to="lab_embi_AdditionalConversionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_20" xlink:to="lab_embi_AdditionalConversionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21" xlink:to="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21" xlink:to="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21" xlink:to="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregatePrincipalAmount_23" xlink:to="lab_embi_AggregatePrincipalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregatePrincipalAmount_23" xlink:to="lab_embi_AggregatePrincipalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26" xlink:to="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26" xlink:to="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26" xlink:to="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_27" xlink:to="lab_embi_AmortizationOfDebtDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_27" xlink:to="lab_embi_AmortizationOfDebtDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_27" xlink:to="lab_embi_AmortizationOfDebtDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_28" xlink:to="lab_embi_AmortizationOfTransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_28" xlink:to="lab_embi_AmortizationOfTransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_28" xlink:to="lab_embi_AmortizationOfTransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_29" xlink:to="lab_embi_AnnualFeeForAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_29" xlink:to="lab_embi_AnnualFeeForAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_29" xlink:to="lab_embi_AnnualFeeForAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_30" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_30" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_30" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualMaintenanceFeePayable_31" xlink:to="lab_embi_AnnualMaintenanceFeePayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualMaintenanceFeePayable_31" xlink:to="lab_embi_AnnualMaintenanceFeePayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_32" xlink:to="lab_embi_AvtarDhillonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_32" xlink:to="lab_embi_AvtarDhillonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_32" xlink:to="lab_embi_AvtarDhillonMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_34" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_34" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_34" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CapitalRaise_35" xlink:to="lab_embi_CapitalRaise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CapitalRaise_35" xlink:to="lab_embi_CapitalRaise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashAndCashEquivalents_36" xlink:to="lab_embi_CashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashAndCashEquivalents_36" xlink:to="lab_embi_CashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashAndCashEquivalents_36" xlink:to="lab_embi_CashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_37" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_37" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_37" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_38" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_38" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_38" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_38" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_39" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_39" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_39" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_40" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_40" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_40" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuanceCosts_41" xlink:to="lab_embi_CommonStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuanceCosts_41" xlink:to="lab_embi_CommonStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuanceCosts_41" xlink:to="lab_embi_CommonStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsMember_42" xlink:to="lab_embi_CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsMember_42" xlink:to="lab_embi_CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsMember_42" xlink:to="lab_embi_CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_43" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_43" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_43" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonUnitsSoldPricePerUnit_44" xlink:to="lab_embi_CommonUnitsSoldPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonUnitsSoldPricePerUnit_44" xlink:to="lab_embi_CommonUnitsSoldPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonUnitsSoldPricePerUnit_44" xlink:to="lab_embi_CommonUnitsSoldPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_45" xlink:to="lab_embi_ConsultingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_45" xlink:to="lab_embi_ConsultingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_45" xlink:to="lab_embi_ConsultingAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_46" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_46" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_46" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_47" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_47" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_47" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_48" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_48" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_48" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_48" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_49" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_49" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_49" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_49" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_50" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_50" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_50" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_51" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_51" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_51" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_52" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_52" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_52" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_52" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_53" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_53" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_53" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_53" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_54" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_54" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_54" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_55" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_55" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_55" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_56" xlink:to="lab_embi_ConversionPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_56" xlink:to="lab_embi_ConversionPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_56" xlink:to="lab_embi_ConversionPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_57" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_57" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_57" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_58" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_58" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_58" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_59" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_59" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_59" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_59" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_59" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_59" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_60" xlink:to="lab_embi_CouponInterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_60" xlink:to="lab_embi_CouponInterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_60" xlink:to="lab_embi_CouponInterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFifthAdvances_61" xlink:to="lab_embi_CreditFacilityEffectedFifthAdvances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFifthAdvances_61" xlink:to="lab_embi_CreditFacilityEffectedFifthAdvances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFourthAdvances_62" xlink:to="lab_embi_CreditFacilityEffectedFourthAdvances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFourthAdvances_62" xlink:to="lab_embi_CreditFacilityEffectedFourthAdvances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_63" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DebtForgivenessCARESActDescription_64" xlink:to="lab_embi_DebtForgivenessCARESActDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DebtForgivenessCARESActDescription_64" xlink:to="lab_embi_DebtForgivenessCARESActDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DebtForgivenessCARESActDescription_64" xlink:to="lab_embi_DebtForgivenessCARESActDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_65" xlink:to="lab_embi_December2015Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_65" xlink:to="lab_embi_December2015Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_65" xlink:to="lab_embi_December2015Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_66" xlink:to="lab_embi_DerivativeLiabilitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_66" xlink:to="lab_embi_DerivativeLiabilitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesTable_67" xlink:to="lab_embi_DerivativeLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesTable_67" xlink:to="lab_embi_DerivativeLiabilitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_68" xlink:to="lab_embi_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_68" xlink:to="lab_embi_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_69" xlink:to="lab_embi_DouglasCesarioMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_69" xlink:to="lab_embi_DouglasCesarioMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_69" xlink:to="lab_embi_DouglasCesarioMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_70" xlink:to="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_70" xlink:to="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_70" xlink:to="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_71" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_71" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_71" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_71" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_72" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_72" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_72" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_73" xlink:to="lab_embi_EmeraldFinancingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_73" xlink:to="lab_embi_EmeraldFinancingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_73" xlink:to="lab_embi_EmeraldFinancingMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_73" xlink:to="lab_embi_EmeraldFinancingMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantLiabilityMember_74" xlink:to="lab_embi_EmeraldFinancingWarrantLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantLiabilityMember_74" xlink:to="lab_embi_EmeraldFinancingWarrantLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantLiabilityMember_74" xlink:to="lab_embi_EmeraldFinancingWarrantLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsLiabilityMember_75" xlink:to="lab_embi_EmeraldFinancingWarrantsLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsLiabilityMember_75" xlink:to="lab_embi_EmeraldFinancingWarrantsLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsLiabilityMember_75" xlink:to="lab_embi_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsMember_76" xlink:to="lab_embi_EmeraldFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsMember_76" xlink:to="lab_embi_EmeraldFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsMember_76" xlink:to="lab_embi_EmeraldFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_77" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_77" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_77" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_77" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_78" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_78" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_78" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_79" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_79" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_79" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_79" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityLineItems_80" xlink:to="lab_embi_EquityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityLineItems_80" xlink:to="lab_embi_EquityLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityTable_81" xlink:to="lab_embi_EquityTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityTable_81" xlink:to="lab_embi_EquityTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_82" xlink:to="lab_embi_ExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_82" xlink:to="lab_embi_ExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_82" xlink:to="lab_embi_ExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_83" xlink:to="lab_embi_FairMarketValueOfStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_83" xlink:to="lab_embi_FairMarketValueOfStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_83" xlink:to="lab_embi_FairMarketValueOfStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_84" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_84" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_84" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_84" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_85" xlink:to="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_85" xlink:to="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_85" xlink:to="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_86" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_86" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_86" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_87" xlink:to="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_87" xlink:to="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_88" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_88" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_88" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_89" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_90" xlink:to="lab_embi_FairValueOfWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_90" xlink:to="lab_embi_FairValueOfWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_90" xlink:to="lab_embi_FairValueOfWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_90" xlink:to="lab_embi_FairValueOfWarrantsIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_90" xlink:to="lab_embi_FairValueOfWarrantsIssued_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_91" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_91" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_91" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_92" xlink:to="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_92" xlink:to="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_92" xlink:to="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_93" xlink:to="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_93" xlink:to="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_93" xlink:to="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfUnitsSold_94" xlink:to="lab_embi_GrossProceedsOfUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfUnitsSold_94" xlink:to="lab_embi_GrossProceedsOfUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfUnitsSold_94" xlink:to="lab_embi_GrossProceedsOfUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_95" xlink:to="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_95" xlink:to="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_95" xlink:to="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_96" xlink:to="lab_embi_IndependentContractorAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_96" xlink:to="lab_embi_IndependentContractorAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_96" xlink:to="lab_embi_IndependentContractorAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_97" xlink:to="lab_embi_InitialTermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_97" xlink:to="lab_embi_InitialTermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_97" xlink:to="lab_embi_InitialTermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_98" xlink:to="lab_embi_K2CIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_98" xlink:to="lab_embi_K2CIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_98" xlink:to="lab_embi_K2CIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LegalReimbursementFees_99" xlink:to="lab_embi_LegalReimbursementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LegalReimbursementFees_99" xlink:to="lab_embi_LegalReimbursementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LegalReimbursementFees_99" xlink:to="lab_embi_LegalReimbursementFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_100" xlink:to="lab_embi_LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_100" xlink:to="lab_embi_LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_100" xlink:to="lab_embi_LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_100" xlink:to="lab_embi_LicenseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_101" xlink:to="lab_embi_LumpSumPaymentInAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_101" xlink:to="lab_embi_LumpSumPaymentInAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_101" xlink:to="lab_embi_LumpSumPaymentInAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ManagementDeferralAgreementMember_102" xlink:to="lab_embi_ManagementDeferralAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ManagementDeferralAgreementMember_102" xlink:to="lab_embi_ManagementDeferralAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ManagementDeferralAgreementMember_102" xlink:to="lab_embi_ManagementDeferralAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_103" xlink:to="lab_embi_Milestone1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_103" xlink:to="lab_embi_Milestone1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_103" xlink:to="lab_embi_Milestone1Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_104" xlink:to="lab_embi_Milestone2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_104" xlink:to="lab_embi_Milestone2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_104" xlink:to="lab_embi_Milestone2Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_105" xlink:to="lab_embi_Milestone3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_105" xlink:to="lab_embi_Milestone3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_105" xlink:to="lab_embi_Milestone3Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableAxis_106" xlink:to="lab_embi_MilestonePaymentsPayableAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableAxis_106" xlink:to="lab_embi_MilestonePaymentsPayableAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableDomain_107" xlink:to="lab_embi_MilestonePaymentsPayableDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableDomain_107" xlink:to="lab_embi_MilestonePaymentsPayableDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_108" xlink:to="lab_embi_MonteCarloSimulationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_108" xlink:to="lab_embi_MonteCarloSimulationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_108" xlink:to="lab_embi_MonteCarloSimulationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_109" xlink:to="lab_embi_MonthAndYearOfAgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_109" xlink:to="lab_embi_MonthAndYearOfAgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_110" xlink:to="lab_embi_MonthAndYearOfAgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_110" xlink:to="lab_embi_MonthAndYearOfAgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_111" xlink:to="lab_embi_MonthlyFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_111" xlink:to="lab_embi_MonthlyFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_111" xlink:to="lab_embi_MonthlyFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_112" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_112" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_112" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_113" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_113" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_113" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_114" xlink:to="lab_embi_MultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_114" xlink:to="lab_embi_MultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_114" xlink:to="lab_embi_MultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_115" xlink:to="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_115" xlink:to="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_115" xlink:to="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_116" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_116" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_117" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_117" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_118" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_118" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_119" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_119" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_119" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_120" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_120" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_121" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_7"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NonCashInterestExpenseAbstract_122" xlink:to="lab_embi_NonCashInterestExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NonCashInterestExpenseAbstract_122" xlink:to="lab_embi_NonCashInterestExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_123" xlink:to="lab_embi_NoramcoAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_123" xlink:to="lab_embi_NoramcoAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_123" xlink:to="lab_embi_NoramcoAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_124" xlink:to="lab_embi_NoticePeriodForTermination_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_124" xlink:to="lab_embi_NoticePeriodForTermination_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_124" xlink:to="lab_embi_NoticePeriodForTermination_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockUnitsSold_125" xlink:to="lab_embi_NumberOfCommonStockUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockUnitsSold_125" xlink:to="lab_embi_NumberOfCommonStockUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockUnitsSold_125" xlink:to="lab_embi_NumberOfCommonStockUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_126" xlink:to="lab_embi_NumberOfLicenseAgreements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_126" xlink:to="lab_embi_NumberOfLicenseAgreements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_126" xlink:to="lab_embi_NumberOfLicenseAgreements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfPreFundedUnitsSold_127" xlink:to="lab_embi_NumberOfPreFundedUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfPreFundedUnitsSold_127" xlink:to="lab_embi_NumberOfPreFundedUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfPreFundedUnitsSold_127" xlink:to="lab_embi_NumberOfPreFundedUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_128" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_128" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_128" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_129" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_129" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_129" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_129" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_130" xlink:to="lab_embi_OptionAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_130" xlink:to="lab_embi_OptionAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_130" xlink:to="lab_embi_OptionAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_130" xlink:to="lab_embi_OptionAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramMember_131" xlink:to="lab_embi_PaycheckProtectionProgramMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramMember_131" xlink:to="lab_embi_PaycheckProtectionProgramMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramMember_131" xlink:to="lab_embi_PaycheckProtectionProgramMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_132" xlink:to="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_132" xlink:to="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_132" xlink:to="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_133" xlink:to="lab_embi_PaymentForUpfrontFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_133" xlink:to="lab_embi_PaymentForUpfrontFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_133" xlink:to="lab_embi_PaymentForUpfrontFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_134" xlink:to="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_134" xlink:to="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_134" xlink:to="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PayrollCostsExcludeCompensation_135" xlink:to="lab_embi_PayrollCostsExcludeCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PayrollCostsExcludeCompensation_135" xlink:to="lab_embi_PayrollCostsExcludeCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedConsultingFees_136" xlink:to="lab_embi_PercentageOfAccruedConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedConsultingFees_136" xlink:to="lab_embi_PercentageOfAccruedConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedConsultingFees_136" xlink:to="lab_embi_PercentageOfAccruedConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_137" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_137" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_137" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_138" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_138" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_138" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfBonusForAccruedConsultingFees_139" xlink:to="lab_embi_PercentageOfBonusForAccruedConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfBonusForAccruedConsultingFees_139" xlink:to="lab_embi_PercentageOfBonusForAccruedConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfBonusForAccruedConsultingFees_139" xlink:to="lab_embi_PercentageOfBonusForAccruedConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_140" xlink:to="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_140" xlink:to="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_140" xlink:to="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfReductionInAnnualSalary_141" xlink:to="lab_embi_PercentageOfReductionInAnnualSalary_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfReductionInAnnualSalary_141" xlink:to="lab_embi_PercentageOfReductionInAnnualSalary_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfReductionInAnnualSalary_141" xlink:to="lab_embi_PercentageOfReductionInAnnualSalary_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_142" xlink:to="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_142" xlink:to="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_142" xlink:to="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_143" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_143" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_143" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_144" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_144" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_144" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_145" xlink:to="lab_embi_PreferredStockPutOptionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_145" xlink:to="lab_embi_PreferredStockPutOptionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_145" xlink:to="lab_embi_PreferredStockPutOptionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreFundedUnitsSoldPricePerUnit_146" xlink:to="lab_embi_PreFundedUnitsSoldPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreFundedUnitsSoldPricePerUnit_146" xlink:to="lab_embi_PreFundedUnitsSoldPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreFundedUnitsSoldPricePerUnit_146" xlink:to="lab_embi_PreFundedUnitsSoldPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PrefundedWarrantsMember_147" xlink:to="lab_embi_PrefundedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PrefundedWarrantsMember_147" xlink:to="lab_embi_PrefundedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PrefundedWarrantsMember_147" xlink:to="lab_embi_PrefundedWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelAxis_148" xlink:to="lab_embi_PricingModelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelDomain_149" xlink:to="lab_embi_PricingModelDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_150" xlink:to="lab_embi_PricingModelMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_150" xlink:to="lab_embi_PricingModelMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_150" xlink:to="lab_embi_PricingModelMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_151" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_151" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_151" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_152" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_152" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_152" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_152" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_153" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_153" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_153" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_154" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_154" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_154" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_154" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_155" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_155" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_155" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReducedFixedConversionPriceOfCommonStock_156" xlink:to="lab_embi_ReducedFixedConversionPriceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReducedFixedConversionPriceOfCommonStock_156" xlink:to="lab_embi_ReducedFixedConversionPriceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReducedFixedConversionPriceOfCommonStock_156" xlink:to="lab_embi_ReducedFixedConversionPriceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_157" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_157" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_157" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RemainingFundsFromPromissoryNote_158" xlink:to="lab_embi_RemainingFundsFromPromissoryNote_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RemainingFundsFromPromissoryNote_158" xlink:to="lab_embi_RemainingFundsFromPromissoryNote_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RemainingFundsFromPromissoryNote_158" xlink:to="lab_embi_RemainingFundsFromPromissoryNote_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_159" xlink:to="lab_embi_RestrictedStockAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_159" xlink:to="lab_embi_RestrictedStockAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_159" xlink:to="lab_embi_RestrictedStockAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_160" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_160" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_160" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_161" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_161" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_161" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_162" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_162" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_162" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_163" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_163" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_163" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_164" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_164" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_164" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_165" xlink:to="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_165" xlink:to="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_165" xlink:to="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeniorManagementCompensationPlanDescription_166" xlink:to="lab_embi_SeniorManagementCompensationPlanDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeniorManagementCompensationPlanDescription_166" xlink:to="lab_embi_SeniorManagementCompensationPlanDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeniorManagementCompensationPlanDescription_166" xlink:to="lab_embi_SeniorManagementCompensationPlanDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAgreementMember_167" xlink:to="lab_embi_SeparationAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAgreementMember_167" xlink:to="lab_embi_SeparationAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAgreementMember_167" xlink:to="lab_embi_SeparationAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_168" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_168" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_168" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_168" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_169" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_169" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_169" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_169" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_170" xlink:to="lab_embi_SeriesBWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_170" xlink:to="lab_embi_SeriesBWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_170" xlink:to="lab_embi_SeriesBWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_170" xlink:to="lab_embi_SeriesBWarrantMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_171" xlink:to="lab_embi_SeriesBWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_171" xlink:to="lab_embi_SeriesBWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_171" xlink:to="lab_embi_SeriesBWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_172" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_172" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_172" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_173" xlink:to="lab_embi_ShareIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_173" xlink:to="lab_embi_ShareIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_173" xlink:to="lab_embi_ShareIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsAbstract_174" xlink:to="lab_embi_SignificantContractsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_175" xlink:to="lab_embi_SignificantContractsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_175" xlink:to="lab_embi_SignificantContractsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_175" xlink:to="lab_embi_SignificantContractsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_176" xlink:to="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_176" xlink:to="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_176" xlink:to="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_177" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_177" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_177" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_178" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_178" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_178" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_179" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_179" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_179" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_180" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_180" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_180" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_181" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_181" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_181" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockOptions2014PlanMember_182" xlink:to="lab_embi_StockOptions2014PlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockOptions2014PlanMember_182" xlink:to="lab_embi_StockOptions2014PlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockOptions2014PlanMember_182" xlink:to="lab_embi_StockOptions2014PlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_183" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_183" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_183" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SupplementalRestrictedCash_184" xlink:to="lab_embi_SupplementalRestrictedCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SupplementalRestrictedCash_184" xlink:to="lab_embi_SupplementalRestrictedCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SupplementalRestrictedCash_184" xlink:to="lab_embi_SupplementalRestrictedCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_185" xlink:to="lab_embi_TermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_185" xlink:to="lab_embi_TermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_185" xlink:to="lab_embi_TermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_186" xlink:to="lab_embi_TermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_186" xlink:to="lab_embi_TermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_186" xlink:to="lab_embi_TermOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_186" xlink:to="lab_embi_TermOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_187" xlink:to="lab_embi_TermOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_187" xlink:to="lab_embi_TermOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_187" xlink:to="lab_embi_TermOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_188" xlink:to="lab_embi_TermsOfAgreementRenewed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_188" xlink:to="lab_embi_TermsOfAgreementRenewed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_188" xlink:to="lab_embi_TermsOfAgreementRenewed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_189" xlink:to="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_189" xlink:to="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_189" xlink:to="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_190" xlink:to="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_190" xlink:to="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_190" xlink:to="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_191" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_191" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_191" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_191" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalFeesIncurredUnderAgreement_192" xlink:to="lab_embi_TotalFeesIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalFeesIncurredUnderAgreement_192" xlink:to="lab_embi_TotalFeesIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalFeesIncurredUnderAgreement_192" xlink:to="lab_embi_TotalFeesIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_193" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_193" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_193" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_194" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_194" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_194" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_194" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_194" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_195" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_195" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_195" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_196" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_196" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_196" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_197" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_197" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_197" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_197" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_198" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_198" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_198" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_199" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_199" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_199" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_200" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_200" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_200" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_201" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_201" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_201" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_202" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_202" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_202" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_203" xlink:to="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_203" xlink:to="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_203" xlink:to="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_204" xlink:to="lab_embi_Um5070LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_204" xlink:to="lab_embi_Um5070LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_204" xlink:to="lab_embi_Um5070LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_205" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_205" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_205" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsAbstract_206" xlink:to="lab_embi_UniversityOfMississippiAgreementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_207" xlink:to="lab_embi_UniversityOfMississippiAgreementsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_207" xlink:to="lab_embi_UniversityOfMississippiAgreementsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_208" xlink:to="lab_embi_UniversityOfMississippiAgreementsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_208" xlink:to="lab_embi_UniversityOfMississippiAgreementsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_209" xlink:to="lab_embi_UniversityOfMississippiMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_209" xlink:to="lab_embi_UniversityOfMississippiMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_209" xlink:to="lab_embi_UniversityOfMississippiMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnrestrictedCashPositionDecreased_210" xlink:to="lab_embi_UnrestrictedCashPositionDecreased_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnrestrictedCashPositionDecreased_210" xlink:to="lab_embi_UnrestrictedCashPositionDecreased_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_211" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_211" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_211" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_212" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_213" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_213" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_213" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_214" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_214" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_214" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_214" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_215" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_215" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_215" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_216" xlink:to="lab_embi_WarrantsVestedAndOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_216" xlink:to="lab_embi_WarrantsVestedAndOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_216" xlink:to="lab_embi_WarrantsVestedAndOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_217" xlink:to="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_217" xlink:to="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_217" xlink:to="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_218" xlink:to="lab_embi_WorkingCapitalDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_218" xlink:to="lab_embi_WorkingCapitalDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_218" xlink:to="lab_embi_WorkingCapitalDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_218" xlink:to="lab_embi_WorkingCapitalDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_219" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_219" xlink:to="lab_srt_ChiefFinancialOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_219" xlink:to="lab_srt_ChiefFinancialOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_220" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_220" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_220" xlink:to="lab_srt_MaximumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_221" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_221" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_221" xlink:to="lab_srt_MinimumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_222" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_223" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_224" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_225" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_225" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_226" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_226" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_227" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_227" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_228" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_228" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_229" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_229" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_229" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_230" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_230" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_231" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_231" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_232" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_232" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_233" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_233" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_233" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_233" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_234" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_234" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvancesFairValueDisclosure_235" xlink:to="lab_us-gaap_AdvancesFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvancesFairValueDisclosure_235" xlink:to="lab_us-gaap_AdvancesFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_236" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_236" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_236" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_237" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_237" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_238" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_238" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_240" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_240" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_241" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_241" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_242" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_242" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_242" xlink:to="lab_us-gaap_AssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_243" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_243" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_244" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_245" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_245" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_246" xlink:to="lab_us-gaap_BridgeLoan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_246" xlink:to="lab_us-gaap_BridgeLoan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_246" xlink:to="lab_us-gaap_BridgeLoan_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_247" xlink:to="lab_us-gaap_BridgeLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_247" xlink:to="lab_us-gaap_BridgeLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_247" xlink:to="lab_us-gaap_BridgeLoanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_248" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_248" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_248" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_248" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_248" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_249" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_249" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_249" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_249" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_250" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_250" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_251" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_251" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_252" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_252" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_253" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_254" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_255" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_256" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_256" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_256" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_256" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_257" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_258" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_258" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_259" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_260" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_260" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_261" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_262" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_262" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_263" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_263" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_264" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_264" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_265" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_265" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_265" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_266" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_266" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_267" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_267" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_268" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_268" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_268" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_268" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_268" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_269" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_269" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_270" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_270" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_270" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_271" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_271" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleCommonStockMember_272" xlink:to="lab_us-gaap_ConvertibleCommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleCommonStockMember_272" xlink:to="lab_us-gaap_ConvertibleCommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_273" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_273" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_273" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_273" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_273" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_274" xlink:to="lab_us-gaap_ConvertibleDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_274" xlink:to="lab_us-gaap_ConvertibleDebtMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_275" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_275" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_275" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_276" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_276" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_276" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_277" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_277" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_277" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_278" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_278" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_279" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_280" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_280" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_281" xlink:to="lab_us-gaap_DebtInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_282" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_282" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_283" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_283" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_283" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_284" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_284" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_284" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_284" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_285" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_285" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_285" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_286" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_286" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_287" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_287" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_287" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_288" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_288" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_289" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_289" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_289" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_290" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_291" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_291" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_291" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_292" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_293" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_294" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_294" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_294" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_295" xlink:to="lab_us-gaap_DebtPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_295" xlink:to="lab_us-gaap_DebtPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_296" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_296" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_296" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_296" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_297" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_297" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_298" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_298" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_298" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_299" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_299" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_300" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_301" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_302" xlink:to="lab_us-gaap_DerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_302" xlink:to="lab_us-gaap_DerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_302" xlink:to="lab_us-gaap_DerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_302" xlink:to="lab_us-gaap_DerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_303" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_303" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_303" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_303" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_304" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_304" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_304" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_304" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_304" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_305" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_305" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_306" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_307" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_307" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_308" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_308" xlink:to="lab_us-gaap_EarningsPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_309" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_309" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_309" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_310" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_310" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_311" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_311" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_311" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_312" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_312" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_313" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_313" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_314" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_314" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_314" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_315" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_315" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_315" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_316" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_316" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_316" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_317" xlink:to="lab_us-gaap_EquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_317" xlink:to="lab_us-gaap_EquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_318" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_318" xlink:to="lab_us-gaap_EquityComponentDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_319" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_320" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_320" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_321" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_321" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_322" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_323" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_324" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_324" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_325" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_325" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_325" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_325" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_325" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_326" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_326" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_326" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_326" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_327" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_327" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_328" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_328" xlink:to="lab_us-gaap_IncomeStatementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_329" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_330" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_331" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_331" xlink:to="lab_us-gaap_IncomeTaxesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_332" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_332" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_333" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_333" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_334" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_334" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_335" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_336" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_336" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_337" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_337" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_338" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_338" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_339" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_339" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_340" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_340" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_341" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_342" xlink:to="lab_us-gaap_IntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_342" xlink:to="lab_us-gaap_IntellectualPropertyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_343" xlink:to="lab_us-gaap_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_343" xlink:to="lab_us-gaap_InterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_343" xlink:to="lab_us-gaap_InterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_343" xlink:to="lab_us-gaap_InterestExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_344" xlink:to="lab_us-gaap_InterestExpenseDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_344" xlink:to="lab_us-gaap_InterestExpenseDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty_345" xlink:to="lab_us-gaap_InterestExpenseRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty_345" xlink:to="lab_us-gaap_InterestExpenseRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_346" xlink:to="lab_us-gaap_InterestIncomeOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_346" xlink:to="lab_us-gaap_InterestIncomeOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_346" xlink:to="lab_us-gaap_InterestIncomeOther_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_347" xlink:to="lab_us-gaap_InterestPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_347" xlink:to="lab_us-gaap_InterestPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_348" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_348" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_349" xlink:to="lab_us-gaap_InvestorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_349" xlink:to="lab_us-gaap_InvestorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_350" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_350" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_351" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_351" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_351" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_352" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_352" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_353" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_353" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_354" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_354" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_355" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_355" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_355" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_356" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_356" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_356" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_357" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_357" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_358" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_358" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_359" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_359" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_360" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_360" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_361" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_361" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_361" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_362" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_362" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_363" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_363" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_363" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_364" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_364" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_365" xlink:to="lab_us-gaap_LongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_365" xlink:to="lab_us-gaap_LongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_366" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_366" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_366" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_367" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_367" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_367" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_368" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_368" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_369" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_369" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_369" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_370" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_370" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_370" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_371" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_372" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_373" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_373" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_373" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_374" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_374" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_375" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_375" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_375" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_376" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_376" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_377" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_377" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_377" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_377" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_378" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_378" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_379" xlink:to="lab_us-gaap_NetIncomeLoss_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_380" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_380" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_381" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_381" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_381" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_381" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_381" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_382" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_382" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_383" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_383" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_383" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_384" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_384" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_384" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_385" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_385" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_386" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_386" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_386" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_386" xlink:to="lab_us-gaap_OperatingIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_386" xlink:to="lab_us-gaap_OperatingIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_386" xlink:to="lab_us-gaap_OperatingIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_387" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_387" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_388" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_388" xlink:to="lab_us-gaap_OtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_388" xlink:to="lab_us-gaap_OtherAssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent_389" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_390" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_390" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_390" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_390" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_390" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_391" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_391" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_391" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_392" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_392" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_392" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_393" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_394" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_395" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_395" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_395" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_396" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_396" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_396" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_397" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_397" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_398" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_398" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_399" xlink:to="lab_us-gaap_PreferredStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_399" xlink:to="lab_us-gaap_PreferredStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_400" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_400" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_401" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_401" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_402" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_402" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_403" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_404" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_404" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_405" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_405" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_405" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_405" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_406" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_406" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_407" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_407" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_408" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_408" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_409" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_409" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_409" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_410" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_410" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_410" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_410" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_411" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_413" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_414" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_415" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_415" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_416" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_416" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_416" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_416" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_416" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_417" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_417" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_417" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_417" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_418" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_418" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_419" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_419" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_420" xlink:to="lab_us-gaap_RestrictedStockExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_420" xlink:to="lab_us-gaap_RestrictedStockExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_421" xlink:to="lab_us-gaap_RestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_421" xlink:to="lab_us-gaap_RestrictedStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_421" xlink:to="lab_us-gaap_RestrictedStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_422" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_423" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_423" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_424" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_424" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_425" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_425" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_426" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_426" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_427" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_427" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_428" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_429" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_430" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_430" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_431" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_431" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_432" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_433" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_433" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_434" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_434" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_434" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_435" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_435" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_435" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_436" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_436" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_436" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_437" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_437" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_437" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_438" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_438" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_438" xlink:to="lab_us-gaap_ShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_439" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_439" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_440" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_440" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_441" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_441" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_441" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_442" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_442" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_443" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_443" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_443" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_444" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_444" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_445" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_445" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_445" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_446" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_446" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_447" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_447" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_447" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_447" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_448" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_448" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_449" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_449" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_450" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_450" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_451" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_451" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_452" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_453" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_454" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_454" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_455" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_455" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_456" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_456" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_457" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_457" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_458" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_458" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_458" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_459" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_459" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_459" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_460" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_460" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_461" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_461" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_462" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_462" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_463" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_464" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_464" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_465" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_465" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_465" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_466" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_466" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_467" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_467" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_468" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_468" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_468" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_469" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_469" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_470" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_470" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_471" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_471" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_472" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_472" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_473" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_473" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_474" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_475" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_475" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_476" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_476" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_478" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_478" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_478" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_479" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_479" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_479" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_480" xlink:to="lab_us-gaap_SharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_480" xlink:to="lab_us-gaap_SharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_480" xlink:to="lab_us-gaap_SharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_480" xlink:to="lab_us-gaap_SharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_481" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_481" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_481" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_481" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings_482" xlink:to="lab_us-gaap_ShortTermBorrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings_482" xlink:to="lab_us-gaap_ShortTermBorrowings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_483" xlink:to="lab_us-gaap_ShortTermDebtLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_484" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_485" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_486" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_486" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_487" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_488" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_488" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_489" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_490" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_490" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_491" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_491" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_492" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_493" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_494" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_494" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_494" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_494" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_494" xlink:to="lab_us-gaap_StockholdersEquity_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_495" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_495" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_496" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_496" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_497" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_497" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_497" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_497" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_498" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_499" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_499" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_500" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_501" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_501" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_502" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_503" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_504" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_505" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_505" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_506" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_506" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_507" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_508" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_508" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_508" xlink:to="lab_us-gaap_UseOfEstimates_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_509" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_509" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_509" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_510" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_510" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_510" xlink:to="lab_us-gaap_WarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_511" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_512" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_512" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_512" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_513" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_513" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_513" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_514" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_514" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_514" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_515" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_515" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_515" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_516" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_516" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_516" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_517" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_517" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>embi-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#DocumentAndEntityInformation" roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#NatureOfOperationsAndBusinessActivities" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilities" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedParty" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockholdersDeficitAndCapitalization" roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensation" roleURI="http://www.emeraldbio.life/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SignificantContractsUniversityOfMississippi" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#RelatedPartyMatters" roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SubsequentEvents" roleURI="http://www.emeraldbio.life/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedPartyTables" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensationTables" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsandDerivativeLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/WarrantsandDerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetails5" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#WarrantsAndDerivativeLiabilitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedPartyDetails1" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockholdersDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#RelatedPartyMattersDetailTextuals" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DocumentAndEntityInformationAbstract" xlink:label="loc_embi_DocumentAndEntityInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityShellCompany_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultidrawCreditAgreementRelatedPartyNoncurrent" xlink:label="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_ShortTermBorrowings_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_LongTermDebt_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_Liabilities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_PreferredStockValue_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommonStockValue_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquity_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InterestExpense_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" xlink:label="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CashAndCashEquivalents" xlink:label="loc_embi_CashAndCashEquivalents_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SupplementalRestrictedCash" xlink:label="loc_embi_SupplementalRestrictedCash_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:label="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_34"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_24" xlink:to="loc_embi_CashAndCashEquivalents_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_24" xlink:to="loc_embi_SupplementalRestrictedCash_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_24" xlink:to="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24" xlink:to="loc_embi_CashPaidDuringPeriodForAbstract_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_28" xlink:to="loc_us-gaap_InterestPaidNet_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_28" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_24" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_31" xlink:to="loc_embi_ExerciseOfWarrants_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_31" xlink:to="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_31" xlink:to="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_31" xlink:to="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_SharesIssued_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockholdersEquity_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_SharesIssued_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockholdersDeficitAndCapitalizationTextBlock" xlink:label="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SignificantContractsTextBlock" xlink:label="loc_embi_SignificantContractsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_SignificantContractsAbstract_0" xlink:to="loc_embi_SignificantContractsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMatters">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_embi_RisksAndUncertaintiesPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_RisksAndUncertaintiesPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_SeriesBWarrantMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_9" xlink:to="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_9" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_embi_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_ScheduleOfInterestExpenseTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeniorManagementCompensationPlanDescription" xlink:label="loc_embi_SeniorManagementCompensationPlanDescription_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_35"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_MultiDrawCreditAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8" xlink:to="loc_us-gaap_SubsequentEventMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_11" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_11" xlink:to="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_14" xlink:to="loc_embi_CommonStockWarrantsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_14" xlink:to="loc_embi_PrefundedWarrantsMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_StockholdersEquity_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_WorkingCapitalDeficit_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_SeniorManagementCompensationPlanDescription_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_GrossProceedsOfUnitsSold_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_18" xlink:to="loc_embi_TermOfWarrants_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_RestrictedStockMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsandDerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_Pre2015CommonStockWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_embi_TermOfWarrant_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_embi_WarrantsVestedAndOutstanding_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_PricingModelMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_SeriesBWarrantMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldFinancingMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_8" xlink:to="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_embi_FairValueOfWarrantsIssued_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilities_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_7" xlink:to="loc_embi_PricingModelDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_7" xlink:to="loc_embi_MonteCarloSimulationsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_embi_EmeraldFinancingMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_PricingModelMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_embi_SeriesBWarrantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregateExercisePriceOfOutstandingCreditAgreement" xlink:label="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_25"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldWarrantLiabilityMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_SeriesBWarrantsMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_WarrantMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_embi_ValueOfCommonStockCalledByWarrants_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_embi_TermOfWarrant_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NonCashInterestExpenseAbstract" xlink:label="loc_embi_NonCashInterestExpenseAbstract_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmortizationOfDebtDiscount" xlink:label="loc_embi_AmortizationOfDebtDiscount_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AmortizationOfTransactionCosts" xlink:label="loc_embi_AmortizationOfTransactionCosts_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseDebt_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_NonCashInterestExpenseAbstract_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_3" xlink:to="loc_embi_AmortizationOfDebtDiscount_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_3" xlink:to="loc_embi_AmortizationOfTransactionCosts_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpense_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaycheckProtectionProgramMember" xlink:label="loc_embi_PaycheckProtectionProgramMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CreditFacilityEffectedFourthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFourthAdvances_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CreditFacilityEffectedFifthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFifthAdvances_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_40"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PayrollCostsExcludeCompensation" xlink:label="loc_embi_PayrollCostsExcludeCompensation_41"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfForgivenessAmountForNonPayrollCosts" xlink:label="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_43"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfReductionInAnnualSalary" xlink:label="loc_embi_PercentageOfReductionInAnnualSalary_44"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_MultiDrawCreditAgreementMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_IndependentContractorAgreementMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9" xlink:to="loc_embi_PaycheckProtectionProgramMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_12" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_12" xlink:to="loc_us-gaap_SubsequentEventMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_27" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_CreditFacilityEffectedFourthAdvances_28" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_CreditFacilityEffectedFifthAdvances_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DerivativeLiabilities_31" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_32" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_33" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_34" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_35" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_UnamortizedDebtDiscountPeriod_36" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_37" order="220" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_38" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_39" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_40" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_PayrollCostsExcludeCompensation_41" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_42" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_43" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15" xlink:to="loc_embi_PercentageOfReductionInAnnualSalary_44" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LegalReimbursementFees" xlink:label="loc_embi_LegalReimbursementFees_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7" xlink:to="loc_us-gaap_BridgeLoanMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_10" xlink:to="loc_us-gaap_RelatedPartyDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_us-gaap_InvestorMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_embi_EquityLineItems_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_BridgeLoan_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_embi_SubsequentFinancingPurchasePriceDescription_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_embi_TermOfWarrants_24" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_embi_LegalReimbursementFees_25" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_embi_EmeraldFinancingIssuanceCosts_26" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_27" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_28" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_BridgeLoan_29" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_30" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_13" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_31" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_27"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_RestrictedStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensation_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_embi_FairMarketValueOfStockOptions_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_RestrictedStockExpense_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensation_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_embi_UniversityOfMississippiAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_embi_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_OptionAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_LicenseAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5070LicenseAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_UniversityOfMississippiMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:to="loc_us-gaap_IntellectualPropertyMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MonthAndYearOfAgreementAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_13" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_13" xlink:to="loc_embi_December2015Member_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_13" xlink:to="loc_embi_OctoberTwoThousandFifteenMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MilestonePaymentsPayableAxis_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableAxis_17" xlink:to="loc_embi_MilestonePaymentsPayableDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone1Member_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone2Member_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone3Member_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_UniversityOfMississippiAgreementsLineItems_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AnnualMaintenanceFeePayable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_TermOfAgreement_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_PaymentForUpfrontFees_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_NumberOfLicenseAgreements_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_NoticePeriodForTermination_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AnnualFeesForLicenseAgreement_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfAccruedConsultingFees" xlink:label="loc_embi_PercentageOfAccruedConsultingFees_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PercentageOfBonusForAccruedConsultingFees" xlink:label="loc_embi_PercentageOfBonusForAccruedConsultingFees_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_TotalFeesIncurredUnderAgreement" xlink:label="loc_embi_TotalFeesIncurredUnderAgreement_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_IndependentContractorAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_embi_AvtarDhillonMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_InitialTermOfAgreement_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_TotalExpenseIncurredUnderAgreement_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_MonthlyFee_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_PercentageOfAccruedConsultingFees_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_PercentageOfBonusForAccruedConsultingFees_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_TotalFeesIncurredUnderAgreement_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_embi_AccruedExpenseUnderAgreement_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ManagementDeferralAgreementMember" xlink:label="loc_embi_ManagementDeferralAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_EmeraldFinancingWarrantsMember" xlink:label="loc_embi_EmeraldFinancingWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_StockOptions2014PlanMember" xlink:label="loc_embi_StockOptions2014PlanMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_CommonUnitsSoldPricePerUnit" xlink:label="loc_embi_CommonUnitsSoldPricePerUnit_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PreFundedUnitsSoldPricePerUnit" xlink:label="loc_embi_PreFundedUnitsSoldPricePerUnit_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" xlink:label="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200630.xsd#embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" xlink:label="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_ManagementDeferralAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_SeparationAndReleaseAgreementMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_CommonStockWarrantsMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_PrefundedWarrantsMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_EmeraldFinancingWarrantsMember_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14" xlink:to="loc_us-gaap_PlanNameDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_14" xlink:to="loc_embi_StockOptions2014PlanMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_CommonUnitsSoldPricePerUnit_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_PreFundedUnitsSoldPricePerUnit_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_GrossProceedsOfUnitsSold_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_17" xlink:to="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvancesFairValueDisclosure" xlink:label="loc_us-gaap_AdvancesFairValueDisclosure_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_AdvancesFairValueDisclosure_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702193503688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Emerald Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,541,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189702200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 102,524<span></span>
</td>
<td class="nump">$ 1,829,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">152,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,643<span></span>
</td>
<td class="nump">7,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">225,955<span></span>
</td>
<td class="nump">1,994,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">227,207<span></span>
</td>
<td class="nump">1,996,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,096,283<span></span>
</td>
<td class="nump">129,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">77,290<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest due to related party</a></td>
<td class="nump">37,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">PPP loan non-current</a></td>
<td class="nump">51,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">426,884<span></span>
</td>
<td class="nump">420,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">465,287<span></span>
</td>
<td class="nump">410,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,155,123<span></span>
</td>
<td class="nump">970,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">PPP loan non-current</a></td>
<td class="nump">65,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MultidrawCreditAgreementRelatedPartyNoncurrent', window );">Multi-draw credit agreement - related party</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">651,461<span></span>
</td>
<td class="nump">387,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,321,631<span></span>
</td>
<td class="nump">1,448,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 500,000,000 shares authorized; 183,207,747 and 182,895,247 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">183,208<span></span>
</td>
<td class="nump">182,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">32,657,546<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(35,935,178)<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(3,094,424)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">$ 227,207<span></span>
</td>
<td class="nump">$ 1,996,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MultidrawCreditAgreementRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the multidraw credit agreement related party noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MultidrawCreditAgreementRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189687016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702196158856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 428,529<span></span>
</td>
<td class="nump">$ 688,041<span></span>
</td>
<td class="nump">$ 1,228,141<span></span>
</td>
<td class="nump">$ 1,009,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">792,129<span></span>
</td>
<td class="nump">1,082,846<span></span>
</td>
<td class="nump">2,203,725<span></span>
</td>
<td class="nump">2,276,928<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,220,658<span></span>
</td>
<td class="nump">1,770,887<span></span>
</td>
<td class="nump">3,431,866<span></span>
</td>
<td class="nump">3,285,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(1,220,658)<span></span>
</td>
<td class="num">(1,770,887)<span></span>
</td>
<td class="num">(3,431,866)<span></span>
</td>
<td class="num">(3,285,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">26,353<span></span>
</td>
<td class="num">(17,971,742)<span></span>
</td>
<td class="num">(9,550)<span></span>
</td>
<td class="num">(5,151,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">171,625<span></span>
</td>
<td class="nump">293,965<span></span>
</td>
<td class="nump">337,980<span></span>
</td>
<td class="nump">410,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense (income), net</a></td>
<td class="nump">197,978<span></span>
</td>
<td class="num">(17,677,777)<span></span>
</td>
<td class="nump">328,430<span></span>
</td>
<td class="num">(4,418,452)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(1,418,636)<span></span>
</td>
<td class="nump">15,906,890<span></span>
</td>
<td class="num">(3,760,296)<span></span>
</td>
<td class="nump">1,132,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income and comprehensive (loss) income</a></td>
<td class="num">$ (1,420,236)<span></span>
</td>
<td class="nump">$ 15,905,290<span></span>
</td>
<td class="num">$ (3,761,896)<span></span>
</td>
<td class="nump">$ 1,130,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>(Loss) earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares of common stock outstanding used to compute earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">183,052,175<span></span>
</td>
<td class="nump">132,923,037<span></span>
</td>
<td class="nump">182,654,571<span></span>
</td>
<td class="nump">132,826,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">183,052,175<span></span>
</td>
<td class="nump">189,094,958<span></span>
</td>
<td class="nump">182,654,571<span></span>
</td>
<td class="nump">172,058,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702193547176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (3,761,896)<span></span>
</td>
<td class="nump">$ 1,130,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">92,851<span></span>
</td>
<td class="nump">344,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueAdjustmentOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(9,550)<span></span>
</td>
<td class="num">(5,151,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilityExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">264,391<span></span>
</td>
<td class="nump">244,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">38,445<span></span>
</td>
<td class="num">(169,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">966,474<span></span>
</td>
<td class="nump">57,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">67,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty', window );">Accrued interest related party</a></td>
<td class="nump">37,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">6,478<span></span>
</td>
<td class="nump">182,494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,294,153)<span></span>
</td>
<td class="num">(3,036,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from PPP loan</a></td>
<td class="nump">116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs for the June 30, 2020 and June 30, 2019 periods, respectively</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">3,990,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">566,700<span></span>
</td>
<td class="nump">3,990,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and restricted cash</a></td>
<td class="num">(1,727,453)<span></span>
</td>
<td class="nump">954,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, beginning of period</a></td>
<td class="nump">1,834,515<span></span>
</td>
<td class="nump">1,857,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, end of period</a></td>
<td class="nump">107,062<span></span>
</td>
<td class="nump">2,812,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">102,524<span></span>
</td>
<td class="nump">2,807,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SupplementalRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated', window );">Total cash and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">107,062<span></span>
</td>
<td class="nump">2,812,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ExerciseOfWarrants', window );">Reclassification of warrant liabilities to equity from exercise of warrants</a></td>
<td class="nump">$ 26,563<span></span>
</td>
<td class="nump">144,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement', window );">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement', window );">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement', window );">Beneficial conversion feature on convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,584,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of Cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount express exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueAdjustmentOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents fair value adjustment of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueAdjustmentOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilityExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents fair value of derivative liability excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilityExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase decrease in accrued interest due to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_IncreaseDecreaseAccruedInterestDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SupplementalRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of supplemental restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SupplementalRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of total cash, cash equivalents and restricted cash shown in the consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702193438024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190251960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">$ 17,528,947<span></span>
</td>
<td class="num">$ (33,225,107)<span></span>
</td>
<td class="num">$ (15,562,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi-draw credit agreement, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,774,392)<span></span>
</td>
<td class="num">(14,774,392)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">20,001,400<span></span>
</td>
<td class="num">(47,999,499)<span></span>
</td>
<td class="num">(27,864,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">17,528,947<span></span>
</td>
<td class="num">(33,225,107)<span></span>
</td>
<td class="num">(15,562,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,130,898<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 134,095<span></span>
</td>
<td class="nump">20,318,672<span></span>
</td>
<td class="num">(32,094,209)<span></span>
</td>
<td class="num">(11,641,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">134,095,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">20,001,400<span></span>
</td>
<td class="num">(47,999,499)<span></span>
</td>
<td class="num">(27,864,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">144,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,905,290<span></span>
</td>
<td class="nump">15,905,290<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 134,095<span></span>
</td>
<td class="nump">20,318,672<span></span>
</td>
<td class="num">(32,094,209)<span></span>
</td>
<td class="num">(11,641,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">134,095,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 182,895<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,341,660)<span></span>
</td>
<td class="num">(2,341,660)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">32,628,837<span></span>
</td>
<td class="num">(34,514,942)<span></span>
</td>
<td class="num">(1,702,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 182,895<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,761,896)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">32,657,546<span></span>
</td>
<td class="num">(35,935,178)<span></span>
</td>
<td class="num">(3,094,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">32,628,837<span></span>
</td>
<td class="num">(34,514,942)<span></span>
</td>
<td class="num">(1,702,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,420,236)<span></span>
</td>
<td class="num">(1,420,236)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">$ 32,657,546<span></span>
</td>
<td class="num">$ (35,935,178)<span></span>
</td>
<td class="num">$ (3,094,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702202122904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Operations and Business Activities</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong>1. Nature of Operations and Business Activities</strong></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><i>Nature of Operations</i></strong></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>Emerald Bioscience, Inc. (the &#x201c;Company&#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#x201c;Merger&#x201d;) pursuant to which Nemus, a California corporation (&#x201c;Nemus Sub&#x201d;), became the Company&#x2019;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus </span></span></span></span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Sub to form a Nevada company.</span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#x201c;Emerald Health Sciences&#x201d;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &#x201c;Emerald Financing&#x201d;). As part of the transaction, the Company&#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#x2019;s Board.&#160;</span></span></span></span></span></span></span>On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company (Note 8).</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On February 11, 2019, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) and majority stockholder unanimously approved an amendment to the Company&#x2019;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&#x2019;s name to Emerald Bioscience, Inc.</span></span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#x201c;EMBI Australia&#x201d;), in order to qualify for the Australian government&#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#x2019;s product candidates.</span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 7 - Related Party Matters for additional information.</span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company is a biopharmaceutical company located in </span></span></span></span></span></span></span>San Diego<span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#x201c;UM&#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</span></span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As of June 30, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so.</p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><i>Liquidity and Going Concern</i></strong></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">The Company has incurred operating losses and negative cash flows from operations since inception and as of June 30, 2020, had an accumulated deficit of $35,935,178, a stockholders&#x2019; deficit of $3,094,424 and a working capital deficit of $1,929,168. The Company anticipates operating losses and negative cash flows from operations into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of June 30, 2020, the Company had unrestricted cash in the amount of $102,524 as compared to $1,829,977 as of December 31, 2019.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company&#x2019;s expected cash requirements, without obtaining additional funding management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&#x2019;s ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt">The Company&#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Emerald Health Sciences (See Note 4).</span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &#x201c;Amended Credit Agreement&#x201d;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt">Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement.</span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">During the three months ended June 30, 2020 the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. The advances bear interest at 7% per annum and mature on October 5, 2022. The Company intends to use the proceeds from the advances for general corporate and working capital purposes. Emerald Health Sciences has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and that no warrants will be issued with the advances.</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#x201c;PPP Loan&#x201d;) from City National Bank (the &#x201c;PPP Loan Lender&#x201d;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) administered by the U.S. Small Business Administration (&#x201c;SBA&#x201d;) (Note 4).</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On July 31, 2020, the Company entered into the August 2020 Financing (Note 8), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction are $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively, The term of the common stock warrants is five years&#160;and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company intends to use the net proceeds of the Offering for general corporate purposes, including working capital.</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely. In August 2020, subsequent to closing the August 2020 Financing, the Board of Directors determined that the Company has been sufficiently financed and authorized the Company to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt">The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt">In December 2019, a novel strain of coronavirus (&#x201c;COVID-19&#x201d;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&#x2019;s ability to raise additional capital and obtain the necessary funds.</span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of NB1111 from the second half of 2020, to the 2021 timeframe.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt">After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702201924600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 1.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2. Summary of Significant Accounting Policies</strong></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Basis of Presentation</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&#x2019;s business and the risks inherent therein.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Use of Estimates</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</span></span></p></div><p style="MARGIN:0px;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Risks and Uncertainties</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#x2019;s ability to attract new funding.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Fair Value Measurements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:6%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></p></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying values of the Company&#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&#x2019;s relatively short term the carrying value approximates fair value.&#160; As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was&#160;$387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Condensed Consolidated Balance Sheets. As of June 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Convertible Instruments</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Warrants Issued in Connection with Financings</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive (Loss) Income .</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Debt Issuance Costs and Interest</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Research and Development Expenses and Licensed Technology</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Stock-Based Compensation Expense </strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%"><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="width:4%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividends - The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></p></td></tr></tbody></table></div><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>(Loss) Earnings Per Common Share</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies FASB ASC No. 260, Earnings per Share in calculating its basic and diluted net (loss) earnings per common share. Basic (loss) earnings per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted (loss) earnings per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss (earnings) per share of common stock for the periods presented because including them would have been anti-dilutive:</span></span></p><div><div><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Three Months </strong></p><p style="MARGIN:0px;text-align:center"><strong>Ended June 30, </strong></p><p style="MARGIN:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Six Months </strong></p><p style="MARGIN:0px;text-align:center"><strong>Ended June 30, </strong></p><p style="MARGIN:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2020</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2019</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2020</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2019</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Stock options</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">4,186,786</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">2,411,846</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">4,186,786</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">2,814,505</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Unvested restricted stock</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">209,055</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">237,798</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Common shares underlying convertible debt</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5,125,364</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5,125,364</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">11,722,222</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">18,844,002</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">20,353,145</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div></div><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recent Accounting Pronouncements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;<em>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.</em> This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes</em> (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702195320872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsAndDerivativeLiabilitiesAbstract', window );"><strong>Warrants And Derivative Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsAndDerivativeLiabilitiesTextBlock', window );">Warrants and Derivative Liabilities</a></td>
<td class="text"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong>3. Warrants and Derivative Liabilities</strong></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><i>Warrants</i></strong></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Warrants vested and outstanding as of June 30, 2020 are summarized as follows:</span></span></span></span></p><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:9%">&#160;</td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:9%">&#160;</td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Number of</strong></p><p style="MARGIN:0px;text-align:center"><strong>Warrants</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Exercise</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Term</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Vested and</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td style="BORDER-BOTTOM:1px solid" valign="bottom"><p style="MARGIN:0px;text-align:justify"><strong>Source</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Price</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>(Years)</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Pre 2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">1.00</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">6&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">1,660,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td>$</td><td><p style="MARGIN:0px;text-align:right">1.15&#x2014;5.00</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">5&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">256,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Common Stock Warrants to Series B Stockholders</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.00</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">718,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2016 Common Stock Warrants to Service Providers</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">1.15</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">10</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">40,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2016 Series C Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.40</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2017 Series D Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.25</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">480,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2017 Common Stock Warrants to Service Provider</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.41</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2018 Emerald Financing Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.10</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">3,400,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Emerald Multi-Draw Credit Agreement Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom"><span id="xbrl_20191107101846769">0.50</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">7,500,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2019 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom">$</td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">0.35</td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">5</td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">8,000,000</td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><strong>Total warrants vested and outstanding as of June 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>22,304,750</strong></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Emerald Multi-Draw Credit Agreement Warrants</em></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the six months ended June 30, 2019, the Company issued<span><span><span><span> 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants were equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions:</span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>At</strong></p><p style="MARGIN:0px;text-align:center"><strong>Issuance</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Dividend yield</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">0.00</td><td style="width:1%;white-space:nowrap" valign="bottom">%</td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Volatility factor</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">91.6&#x2014;92.1</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">%</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Risk-free interest rate</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">2.23&#x2014;2.51</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">%</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Expected term (years)</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5.0</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Underlying common stock price</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td>$</td><td><p style="MARGIN:0px;text-align:right">0.33&#x2014;0.69</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Derivative Liabilities</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following tables summarize the activity of derivative liabilities for the periods indicated:</span></span></p><div><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><div><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30, 2020</strong></span></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities Issued</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Change in</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair value of </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Reclassification</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>of Derivatives</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>to Equity </strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90,797</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(90,797</span></span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Financing - warrant liability <sup>(2)</sup></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">276,024</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">76,708</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">352,732</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series B - warrant liability <sup>(3)</sup></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">134,579</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,539</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(26,563</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">112,555</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>501,400</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(9,550</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(26,563</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>465,287</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less, noncurrent portion of derivative liabilities</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(90,797</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current balance of derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>410,603</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>465,287</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-align:left">&#160; &#160;&#160;</span></span></span></p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30, 2019</strong></span></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Issued</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Change in</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Reclassification</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>of Derivatives</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>to Equity</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">219,453</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">516,058</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(219,134</span></span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">516,377</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Financing - warrant liability (2)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,251,413</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,887,929</span></span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,363,484</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series B - warrant liability (3)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">487,500</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(44,061</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(144,375</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">299,064</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>15,958,366</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>516,058</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(5,151,124</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(144,375</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>11,178,925</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less, noncurrent portion of derivative liabilities</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(219,453</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(516,377</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current balance of derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>15,738,913</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>10,662,548</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160; &#160;</span></span></p></div></div><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes model for each payment period.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. For the three and six months ended June 30, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Emerald Financing Warrant Liability (2)</em></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity</em><em>&#x2019;</em><em>s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s.</span></span></p></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31, </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">82.2</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.5</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.17</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.62</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.63</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Series B Warrant Liability (3)</em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a &#x201c;down-round&#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104.9</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.2</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.60</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.14</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.64</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the six months ended June 30, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#x2019;s common stock on the exercise dates.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsAndDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsAndDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsAndDerivativeLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Warrants and Derivative Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsAndDerivativeLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702202316552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>4. Debt</strong></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Multi-Draw Credit Agreement- Related Party</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company&#x2019;s Debt with Emerald Health Sciences consists of the following:</span></p><div><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Conversion</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Price</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>June 30,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>December 31,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0.40</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,358,687</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,622,344</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt issuance costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(4,352</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(5,086</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Carrying value of total convertible debt - related party</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>651,461</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of non-convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">n/a</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">450,000</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>&#x2014;</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>1,101,461</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><p style="margin:0px">&#160;</p><div><div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 7). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, dated October 5, 2018. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.</span></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amended</span></span>&#160;<span style="font-size:10pt;font-family:Times New Roman, Times, serif">Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&#x2019; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of June 30, 2020, the unused portion of the credit facility is $13,550,000. The drawdowns are subject to approval by the Company&#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. As such, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place, however, there is no guarantee of continued funding.</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.</span></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% &#160;of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#x2019;s stockholders (See Note 3).</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&#x2019;s Condensed Consolidated Balance Sheets.</span></div><div>&#160;</div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">During the six months ended June 30, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income for the six months ended June 30, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p></div></div><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</span></p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify">&#160;</p><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">During the three months ended June 30, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. The Lender has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and gave notice to the Company that no warrants will be issued in connection with the advances.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. As of June 30, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 2.27 years. The fair value of the shares underlying the convertible advances under the Amended Credit agreement was $790,691 at June 30, 2020. As of June 30, 2020, the if-converted value did not exceed the principal balance.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><em>PPP Loan</em></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><em>&#160;</em></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing seven months from the date of funding. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and seven-month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.</span></p><p style="MARGIN:0px;text-align:justify"><br/><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><em>Interest Expense</em></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company&#x2019;s interest expense consists of the following:</span></p><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Three Months Ended<br/>June 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Six Months Ended</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>June 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Related party interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">37,726</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">106,167</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">73,371</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">165,277</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">PPP loan interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">218</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">218</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Non-cash interest expense:</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">133,310</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">184,313</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">263,657</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">238,293</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of transaction costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">371</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3,485</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">734</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6,458</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>171,625</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>293,965</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>337,980</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>410,028</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702195162472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>5. Stock-Based Compensation </strong></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Stock Incentive Plan</strong></em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 31, 2014, after the closing of the Merger, the Board approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of June 30, 2020, the Company had 13,159,631 shares available for future grant under the 2014 Plan.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Stock Options </em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>There was no option activity under the Company&#x2019;s 2014 Plan during the three and six months ended June 30, 2020.<br/>&#160;&#160;</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Restricted Stock Awards </em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the three and six months ended June 30, 2020, 643,501 restricted stock awards (&#x201c;RSAs&#x201d;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. At June 30, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Awards Granted Outside the 2014 Plan</strong></em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Options</em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the three and six months ended June 30, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&#x2019;s former CFO. At June 30, 2020 there are 869,144 options vested and outstanding with a weighted average exercise price of $0.25 and a weighted average remaining life of 0.13 years.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>&#160;</em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Restricted Stock Awards</em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following is a summary of RSA activity outside of the Company&#x2019;s 2014 Plan during the six months ended June 30, 2020:</span></span></span></span></p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Shares</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Average Grant </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Date Fair Value</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Unvested, December 31, 2019</strong></span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>450,000</strong></span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>0.19</strong></span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Released</span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(450,000</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Unvested, June 30, 2020</strong></span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#x2014;</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td><td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#x2014;</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Stock-Based Compensation Expense</strong></em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company recognizes compensation expense using the straight-line method over the requisite service period. </span></span><span><span>For the three months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of</span></span><span><span> $28,709 and $173,084, </span></span>(including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income.&#160;For the six months ended June 30, 2020 and 2019, the Company recognized stock-based compensation expense of $92,851 and $344,577, respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Condensed Consolidated Statements of Comprehensive (Loss) Income.&#160;<span><span>The total amount of unrecognized compensation cost was $164,798 as of June 30, 2020. This amount will be recognized over a weighted average period of 2.18 years.</span></span></span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702201784456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SignificantContractsAbstract', window );"><strong>Significant Contracts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SignificantContractsTextBlock', window );">Significant Contracts - University of Mississippi</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6. Significant Contracts - University of Mississippi</strong></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>UM 5050 Pro-Drug and UM 8930 Analog Agreements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (&#x201c;THC&#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&#x201c;CBD&#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &#x201c;all fields of use&#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &#x201c;License Agreements&#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">i)</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ii)</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">iii)</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#x2019;s dissolution or cessation of operations, the Company&#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#x2019;s control, or the Company&#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#x2019; written notice to UM.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As of June 30, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>UM 5070 License Agreement</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#x201c;UM 5070&#x201d;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&#x201c;MRSA&#x201d;).</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#x2019;s control. The Company may terminate the license agreement upon 60 days&#x2019; written notice to UM.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">As of June 30, 2020, none of the milestones under this license agreement have been met.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SignificantContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SignificantContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SignificantContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Significant Contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SignificantContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702195162472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Matters</a></td>
<td class="text"><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>7. Related Party Matters</strong></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><em>Emerald Health Sciences</em></strong></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&#x2019;s Chief Executive Officer and Emerald Health Sciences&#x2019; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of June 30, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three and six months ended June 30, 2020. Under this agreement, for the three and six months ended June 30, 2019, the Company incurred expenses of $150,000 and $300,000, respectively.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</span></span></p></div></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#x2019;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#x2019; prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon&#x2019;s consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. Under this agreement, for the three and six months ended June 30, 2020, the Company incurred fees of $36,387 and $66,387, respectively. As of June 30, 2020, the Company has accrued $70,258 in expense related to the Independent Contractor Services Agreement.</span></span></p><p style="margin:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#x200e;As of the date of this filing Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc.&#160;Jim Heppell is also a board member of Emerald Health Sciences, Inc. Additionally, the Company shares the same office location as Emerald Health Pharmaceuticals.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702201784456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>8. Subsequent Events</strong></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"><strong><em>August 2020 Financing</em></strong></span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">On July 31, 2020, the Company entered into a Securities Purchase Agreement with institutional investors with H.C. Wainwright &amp; Co., LLC acting as the placement agent, pursuant to which the Company sold</span><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"> 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The common units and pre-funded units were sold a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively, The term of the common stock warrants is five years&#160;and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The exercise price and number of shares of Common Stock underlying the Warrants are subject to adjustment upon the issuance by the Company of stock dividends, stock splits, and similar proportionately applied changes affecting the Company&#x2019;s outstanding Common Stock. Holders of the Warrants will be entitled to participate in any dividends or other distribution of the Company&#x2019;s assets declared or made to holders of the Company&#x2019;s Common Stock.</span></p><p style="margin:0pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">In connection with the registered public offering, the Company incurred issuance costs</span><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"> of $825,698, for net proceeds of $6,113,969. </span><span style="color:#000000">Additionally, the Company has issued 8,166,667 common stock warrants to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years. The offering closed on August 4, 2020. The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital.</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"><strong><em>Management and Board Deferral Agreements</em></strong></span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">Upon the closing of the August 2020 financing, the Company&#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees including&#160;the retention bonus to management and the Board in the aggregate amount of $293,078.</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"><strong><em>Exercise Price Adjustment to Emerald Financing Warrants</em></strong></span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">&#160;</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">Upon entering into the August 2020 Financing, the Company entered into an agreement with a holder of the Emerald Financing Warrants to permanently set the exercise price of such holder&#x2019;s remaining Emerald Financing warrants to</span><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400"> $0.10 and waive such holder&#x2019;s rights to anti-dilution protection upon subsequent issuances or sales of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10.</span></p><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000"><strong><em>Stock Option Grants</em></strong></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">In August 2020, 22,750,000 stock options with an exercise price of $0.045 were granted to certain directors, officers, employees and consultants of the Company under the 2014 Plan. The stock options will vest 10% on the grant date and 90% in equal semi-annual installments over the vesting schedules as set forth by the Company&#x2019;s Board of Directors.</span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">On August 7, 2020, the Board approved an Amendment No. 2 to the 2014 Plan. The amendment removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year.</span>&#160;<span style="color:#000000">In connection with the option grants the Company will register an additional 18,486,435 common shares as required under the 2014 Plan.</span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000"><strong><em>Separation of Chief Executive Officer, Chief Medical Officer and Member of the Board</em></strong></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">On August 7, 2020, the effective date, Company entered into a Separation and Release Agreement (the &#x201c;Separation Agreement&#x201d;) with Dr. Brian Murphy, Chief Executive Officer.</span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000">Pursuant to the Separation Agreement, Dr. Murphy has agreed to certain ongoing cooperation obligations and to provide certain releases and waivers as contained in the Separation Agreement. As consideration under the Separation Agreement, the Company has agreed to provide Dr. Murphy compensation and benefits as follows: (i) a gross payment of $195,000 in consideration for the restrictive covenants contained in the Separation Agreement, to be paid over six months; and (ii) a continuation of health insurance benefits for a period of six months following the Separation Date.</span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="color:#000000"><strong><em>Appointment of Chief Executive Officer</em></strong></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="text-align:justify;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman;font-style:normal;font-weight:400">On August 7, 2020, Punit Dhillon resigned his position as the Chair of the Audit Committee and member of the Compensation, Nomination and Corporate Governance Committees and was appointed as the Chief Executive Officer of the Company. Mr. Dhillon remains as the Chairman of the Board and Chairman of the Finance and Business Development Committee. Mr. Dhillon will be eligible to receive a minimum of 6 months&#x2019; severance if he is terminated by the Company without cause and will receive 12-months&#x2019; severance if he is employed by the Company for at least 12 months commencing on August 10, 2020, or a 24 months&#x2019; severance if he is employed by the Company for at least 24 months commencing on August 10, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190086440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Basis of Presentation</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&#x2019;s business and the risks inherent therein.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Use of Estimates</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Risks and Uncertainties</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#x2019;s ability to attract new funding.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Fair Value Measurements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:6%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></p></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying values of the Company&#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3).&#160;</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&#x2019;s relatively short term the carrying value approximates fair value.&#160; As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was&#160;$387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Condensed Consolidated Balance Sheets. As of June 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Convertible Instruments</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock', window );">Warrants Issued in Connection with Financings</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Warrants Issued in Connection with Financings</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive (Loss) Income .</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Interest</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Debt Issuance Costs and Interest</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Licensed Technology</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Research and Development Expenses and Licensed Technology</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Stock-Based Compensation Expense </strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%"><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="width:4%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividends - The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">(Loss) Earnings Per Common Share</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>(Loss) Earnings Per Common Share</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies FASB ASC No. 260, Earnings per Share in calculating its basic and diluted net (loss) earnings per common share. Basic (loss) earnings per share of common stock is computed by dividing net (loss) income available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted (loss) earnings per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss (earnings) per share of common stock for the periods presented because including them would have been anti-dilutive:</span></span></p><div><div><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Three Months </strong></p><p style="MARGIN:0px;text-align:center"><strong>Ended June 30, </strong></p><p style="MARGIN:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Six Months </strong></p><p style="MARGIN:0px;text-align:center"><strong>Ended June 30, </strong></p><p style="MARGIN:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2020</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2019</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2020</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2019</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Stock options</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">4,186,786</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">2,411,846</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">4,186,786</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">2,814,505</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Unvested restricted stock</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">209,055</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">237,798</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Common shares underlying convertible debt</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5,125,364</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5,125,364</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">11,722,222</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">18,844,002</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">20,353,145</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recent Accounting Pronouncements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;<em>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.</em> This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes</em> (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for Risks and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued in Connection with Financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702195307240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding shares of common stock equivalents were excluded from the computation of diluted earnings per share</a></td>
<td class="text"><div><div><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Three Months </strong></p><p style="MARGIN:0px;text-align:center"><strong>Ended June 30, </strong></p><p style="MARGIN:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Six Months </strong></p><p style="MARGIN:0px;text-align:center"><strong>Ended June 30, </strong></p><p style="MARGIN:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2020</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2019</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2020</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>2019</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Stock options</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">4,186,786</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">2,411,846</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">4,186,786</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">2,814,505</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Unvested restricted stock</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">209,055</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">237,798</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Common shares underlying convertible debt</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5,125,364</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5,125,364</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">11,722,222</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">18,844,002</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">20,353,145</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189553368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants vested and outstanding</a></td>
<td class="text"><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:9%">&#160;</td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:9%">&#160;</td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Number of</strong></p><p style="MARGIN:0px;text-align:center"><strong>Warrants</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Exercise</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Term</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Vested and</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td style="BORDER-BOTTOM:1px solid" valign="bottom"><p style="MARGIN:0px;text-align:justify"><strong>Source</strong></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Price</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>(Years)</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>Outstanding</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Pre 2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">1.00</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">6&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">1,660,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td>$</td><td><p style="MARGIN:0px;text-align:right">1.15&#x2014;5.00</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">5&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">256,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Common Stock Warrants to Series B Stockholders</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.00</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">718,750</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2016 Common Stock Warrants to Service Providers</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">1.15</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">10</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">40,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2016 Series C Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.40</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2017 Series D Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.25</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">480,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2017 Common Stock Warrants to Service Provider</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.41</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2018 Emerald Financing Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom">0.10</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">3,400,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Emerald Multi-Draw Credit Agreement Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom">$</td><td style="text-align:right;width:9%" valign="bottom"><span id="xbrl_20191107101846769">0.50</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">7,500,000</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">2019 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom">$</td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">0.35</td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">5</td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom">8,000,000</td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><strong>Total warrants vested and outstanding as of June 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><strong>22,304,750</strong></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of the activity of derivative liabilities</a></td>
<td class="text"><div><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30, 2020</strong></span></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities Issued</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Change in</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair value of </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Reclassification</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>of Derivatives</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>to Equity </strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90,797</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(90,797</span></span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Financing - warrant liability <sup>(2)</sup></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">276,024</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">76,708</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">352,732</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series B - warrant liability <sup>(3)</sup></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">134,579</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,539</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(26,563</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">112,555</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>501,400</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(9,550</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(26,563</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>465,287</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less, noncurrent portion of derivative liabilities</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(90,797</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current balance of derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>410,603</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>465,287</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-align:left">&#160; &#160;&#160;</span></span></span></p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="18" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Six Months Ended June 30, 2019</strong></span></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Issued</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Change in</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Reclassification</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>of Derivatives</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>to Equity</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fair</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Value of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Derivative Liabilities</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">219,453</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">516,058</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(219,134</span></span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">516,377</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerald Financing - warrant liability (2)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">15,251,413</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,887,929</span></span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,363,484</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Series B - warrant liability (3)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">487,500</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(44,061</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(144,375</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">299,064</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>15,958,366</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>516,058</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(5,151,124</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(144,375</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>11,178,925</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less, noncurrent portion of derivative liabilities</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(219,453</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(516,377</span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current balance of derivative liabilities</strong></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>15,738,913</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>10,662,548</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock', window );">Schedule of input and valuation technique used to value derivative liabilities</a></td>
<td class="text"><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><strong>At</strong></p><p style="MARGIN:0px;text-align:center"><strong>Issuance</strong></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Dividend yield</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">0.00</td><td style="width:1%;white-space:nowrap" valign="bottom">%</td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Volatility factor</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">91.6&#x2014;92.1</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">%</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Risk-free interest rate</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right">2.23&#x2014;2.51</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">%</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Expected term (years)</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom">5.0</td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify">Underlying common stock price</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td>$</td><td><p style="MARGIN:0px;text-align:right">0.33&#x2014;0.69</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_EmeraldFinancingWarrantsLiabilityMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><div><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30, </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31, </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">82.2</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.5</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.17</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.62</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.63</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><div><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>June 30,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2020</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104.9</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.2</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.60</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.14</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.64</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.16</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DerivativeLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DerivativeLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of derivative asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_EmeraldFinancingWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_EmeraldFinancingWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702201745016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible and non-convertible advances</a></td>
<td class="text"><div><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Conversion</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Price</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>June 30,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>December 31,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0.40</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,358,687</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,622,344</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt issuance costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(4,352</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(5,086</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Carrying value of total convertible debt - related party</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>651,461</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of non-convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">n/a</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">450,000</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>&#x2014;</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>1,101,461</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text"><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Three Months Ended<br/>June 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Six Months Ended</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>June 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Related party interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">37,726</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">106,167</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">73,371</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">165,277</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">PPP loan interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">218</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">218</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Non-cash interest expense:</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">133,310</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">184,313</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">263,657</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">238,293</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of transaction costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">371</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3,485</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">734</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">6,458</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>171,625</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>293,965</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>337,980</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>410,028</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702201916072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of RSA activity</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Shares</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Average Grant </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Date Fair Value</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Unvested, December 31, 2019</strong></span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>450,000</strong></span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>0.19</strong></span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Granted</span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Released</span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(450,000</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.19</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Unvested, June 30, 2020</strong></span></span></span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#x2014;</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>$</strong></span></span></span></span></td><td style="BORDER-BOTTOM:3px double;width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>&#x2014;</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702119581048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,935,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,173,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,094,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,702,897)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
<td class="num">$ (11,641,442)<span></span>
</td>
<td class="num">$ (27,864,191)<span></span>
</td>
<td class="num">$ (15,562,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,929,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,829,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SeniorManagementCompensationPlanDescription', window );">Description of senior management's compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramPromissoryNoteMember', window );">Paycheck Protection Program Promissory Note (PPP Note)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SeniorManagementCompensationPlanDescription', window );">Description of senior management's compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In August 2020, subsequent to closing the August 2020 Financing, the Board of Directors determined that the Company has been sufficiently financed and authorized the Company to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_AmendedAndRestatedMultiDrawCreditAgreementMember', window );">Amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Principal amount of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Credit facility advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DrawDownsLoansInAggregatePrincipalAmount', window );">Draw downs loans In aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rates per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember', window );">fourth amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Credit facility advances per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember', window );">Fifth Amended And Restated Multi Draw Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Credit facility advances per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfCommonStockUnitsSold', window );">Number Of Common Stock Units Sold</a></td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfPreFundedUnitsSold', window );">Number Of Pre Funded Units Sold</a></td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_GrossProceedsOfUnitsSold', window );">Gross Proceeds Of Units Sold</a></td>
<td class="nump">$ 6,939,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrants', window );">Term Of Warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Subsequent Event | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Subsequent Event | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DrawDownsLoansInAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents draw downs loans in aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DrawDownsLoansInAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_GrossProceedsOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gross proceeds of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_GrossProceedsOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NatureOfOperationsAndBusinessActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfCommonStockUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfCommonStockUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfPreFundedUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfPreFundedUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SeniorManagementCompensationPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents description of senior management compensation plan description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SeniorManagementCompensationPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum month-end amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_AmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_AmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702193552648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">4,186,786<span></span>
</td>
<td class="nump">2,411,846<span></span>
</td>
<td class="nump">4,186,786<span></span>
</td>
<td class="nump">2,814,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209,055<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">237,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">22,304,750<span></span>
</td>
<td class="nump">18,844,002<span></span>
</td>
<td class="nump">22,304,750<span></span>
</td>
<td class="nump">20,353,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember', window );">Common shares underlying convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">5,125,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,125,364<span></span>
</td>
<td class="nump">11,722,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702202897832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesFairValueDisclosure', window );">Fair value of advances under the Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,877,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">$ 651,461<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of Federal Home Loan Bank (FHLBank) advances carried under the fair value option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189416936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">22,304,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">1,660,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsToSeriesBStockholdersMember', window );">Common Stock Warrants to Series B Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">718,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember', window );">2016 Common Stock Warrants to Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember', window );">2016 Series C Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember', window );">2017 Series D Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">480,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember', window );">2017 Common Stock Warrants to Service Provider</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsVestedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants vested and outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsVestedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsToSeriesBStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsToSeriesBStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189371736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 1) - Pricing Model - Emerald Multi-Draw Credit Agreement Warrants<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_PricingModelMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_PricingModelMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">92.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">2.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">2.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189494088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(9,550)<span></span>
</td>
<td class="num">(5,151,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="num">(26,563)<span></span>
</td>
<td class="num">(144,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">465,287<span></span>
</td>
<td class="nump">11,178,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Less, noncurrent portion of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(516,377)<span></span>
</td>
<td class="num">$ (90,797)<span></span>
</td>
<td class="num">$ (219,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current balance of derivative liabilities</a></td>
<td class="nump">465,287<span></span>
</td>
<td class="nump">10,662,548<span></span>
</td>
<td class="nump">$ 410,603<span></span>
</td>
<td class="nump">$ 15,738,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing - Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">276,024<span></span>
</td>
<td class="nump">15,251,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="nump">76,708<span></span>
</td>
<td class="num">(4,887,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">352,732<span></span>
</td>
<td class="nump">10,363,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement - compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">90,797<span></span>
</td>
<td class="nump">219,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(90,797)<span></span>
</td>
<td class="num">(219,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">134,579<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="nump">4,539<span></span>
</td>
<td class="num">(44,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="num">(26,563)<span></span>
</td>
<td class="num">(144,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">$ 112,555<span></span>
</td>
<td class="nump">$ 299,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ReclassificationOfDerivativesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification of derivatives to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ReclassificationOfDerivativesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190697336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 3) - Monte Carlo simulations - Emerald Financing<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.17<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_MonteCarloSimulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_MonteCarloSimulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189630328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 4) - Pricing Model - Series B warrant<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">104.9<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.16<span></span>
</td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">1 month 20 days<span></span>
</td>
<td class="text">7 months 20 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190763624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,550)<span></span>
</td>
<td class="num">$ (5,151,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsLiabilityMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="nump">44,200,000<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateExercisePriceOfOutstandingCreditAgreement', window );">Aggregate exercise price of outstanding credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price, per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember', window );">Series B Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AggregateExercisePriceOfOutstandingCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about aggregate exercise price of outstanding credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AggregateExercisePriceOfOutstandingCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ValueOfCommonStockCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of common stock called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ValueOfCommonStockCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702189734136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Total principal value</a></td>
<td class="nump">$ 790,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">$ 651,461<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Total principal value</a></td>
<td class="nump">$ 2,014,500<span></span>
</td>
<td class="nump">2,014,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized debt discount</a></td>
<td class="num">(1,358,687)<span></span>
</td>
<td class="num">(1,622,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Unamortized debt issuance costs</a></td>
<td class="num">(4,352)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Carrying value of total convertible debt - related party</a></td>
<td class="nump">651,461<span></span>
</td>
<td class="nump">387,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CurrentConvertibleDebtExcludingNoncurrentPortion', window );">Total carrying value of advances under the multi-draw credit agreement</a></td>
<td class="nump">$ 1,101,461<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CurrentConvertibleDebtExcludingNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CurrentConvertibleDebtExcludingNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702197489240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related party interest expense - stated rate</a></td>
<td class="nump">$ 37,726<span></span>
</td>
<td class="nump">$ 106,167<span></span>
</td>
<td class="nump">$ 73,371<span></span>
</td>
<td class="nump">$ 165,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">PPP loan interest expense - stated rate</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">133,310<span></span>
</td>
<td class="nump">184,313<span></span>
</td>
<td class="nump">263,657<span></span>
</td>
<td class="nump">238,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmortizationOfTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">3,485<span></span>
</td>
<td class="nump">734<span></span>
</td>
<td class="nump">6,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">$ 171,625<span></span>
</td>
<td class="nump">$ 293,965<span></span>
</td>
<td class="nump">$ 337,980<span></span>
</td>
<td class="nump">$ 410,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmortizationOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmortizationOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NonCashInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NonCashInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702119142536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,287<span></span>
</td>
<td class="nump">$ 11,178,925<span></span>
</td>
<td class="nump">$ 465,287<span></span>
</td>
<td class="nump">$ 11,178,925<span></span>
</td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts', window );">Convertible multi-draw credit agreement issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UnamortizedDebtDiscountPeriod', window );">Unamortized debt discount period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 322,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value of the equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramMember', window );">Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 24,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PayrollCostsExcludeCompensation', window );">Payroll Costs Exclude Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfForgivenessAmountForNonPayrollCosts', window );">Percentage of forgiveness amount for nonpayroll costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Amount of salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfReductionInAnnualSalary', window );">Percentage of reduction in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AllocationOfDebtOnBasisOfRelativeFairValue', window );">Allocation of debt on the basis of relative fair value</a></td>
<td class="nump">$ 1,684,920<span></span>
</td>
<td class="nump">$ 1,684,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,283,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,283,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AllocationOfWarrantOnBasisOfRelativeFairValue', window );">Allocation of warrant on the basis of relative fair value</a></td>
<td class="nump">315,080<span></span>
</td>
<td class="nump">315,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 204,102<span></span>
</td>
<td class="nump">$ 204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,985,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,732<span></span>
</td>
<td class="nump">$ 10,363,484<span></span>
</td>
<td class="nump">352,732<span></span>
</td>
<td class="nump">$ 10,363,484<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,251,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Maximum amount that can be borrowed over the life of the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Unused portion of the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase', window );">Warrant coverage on the debt facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc [Member] | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Amount of capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc [Member] | Independent contractor agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CreditFacilityEffectedFourthAdvances', window );">Credit Facility Effected Fourth Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CreditFacilityEffectedFifthAdvances', window );">Credit Facility Effected Fifth Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AllocationOfDebtOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of debt on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AllocationOfDebtOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AllocationOfWarrantOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of warrant on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AllocationOfWarrantOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible multi-draw credit agreement issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CreditFacilityEffectedFifthAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents credit facility fifth advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CreditFacilityEffectedFifthAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CreditFacilityEffectedFourthAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents fourth credit facility advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CreditFacilityEffectedFourthAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PayrollCostsExcludeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of payroll costs exclude compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PayrollCostsExcludeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount need to be issued against warrant purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfForgivenessAmountForNonPayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of forgiveness amount for non payroll costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfForgivenessAmountForNonPayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfReductionInAnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in annual salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfReductionInAnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_UnamortizedDebtDiscountPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of unamortized discount of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_UnamortizedDebtDiscountPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702196265304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Deficit and Capitalization (Detail Textuals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190644568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Restricted stock awards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2019 | shares</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released | shares</a></td>
<td class="num">(450,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, June 30, 2020 | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released | $ / shares</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, June 30, 2020 | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702119423336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of forfeiture of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of forfeiture of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of option vested and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price of vested and outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,709<span></span>
</td>
<td class="nump">$ 173,084<span></span>
</td>
<td class="nump">$ 92,851<span></span>
</td>
<td class="nump">$ 344,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average grant date fair value (Price per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,159,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,159,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares', window );">Percentage of share reserve of the number of issued and outstanding shares</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share reserve of the number of issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702195389368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 28,709<span></span>
</td>
<td class="nump">$ 173,084<span></span>
</td>
<td class="nump">$ 92,851<span></span>
</td>
<td class="nump">$ 344,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost related to non-vested stock options</a></td>
<td class="nump">$ 164,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190658200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2017</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember', window );">UM 5050 pro-drug agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember', window );">UM 8930 analogue agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember', window );">UM 5070 license agreement | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AggregateMilestonePaymentsIfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualFeesForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual fees for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualFeesForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PaymentForUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents payment for upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PaymentForUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents time to pay, after milestone is met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702196107544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters (Detail Textuals) - Independent contractor agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Dr. Avtar Dhillon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFee', window );">Monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFeePaidEachMonthInExchangeOfServices', window );">Monthly fee paid each month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices', window );">Monthly fee accruing from effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfAccruedConsultingFees', window );">Percentage of accrued consulting fees</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfBonusForAccruedConsultingFees', window );">Percentage of bonus for accrued consulting fees</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalFeesIncurredUnderAgreement', window );">Fees incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalExpenseIncurredUnderAgreement', window );">Expense incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AccruedExpenseUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total accrued expense under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AccruedExpenseUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fees accruing from the effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFeePaidEachMonthInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee paid in exchange of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFeePaidEachMonthInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfAccruedConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfAccruedConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfBonusForAccruedConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of bonus for accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfBonusForAccruedConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalExpenseIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total expense incurred under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalExpenseIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalFeesIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fees incurred under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalFeesIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_AvtarDhillonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_AvtarDhillonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139702190939752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Private placement stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock called by warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Private placement stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,113,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">22,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
<td class="nump">$ 0.045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common shares</a></td>
<td class="nump">18,486,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances', window );">Threshold exercise price of warrants to waive rights to anti dilution protection upon subsequent issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfCommonStockUnitsSold', window );">Number of common stock units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfPreFundedUnitsSold', window );">Number of pre-funded units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CommonUnitsSoldPricePerUnit', window );">Common units sold price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PreFundedUnitsSoldPricePerUnit', window );">Pre-funded units sold price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_GrossProceedsOfUnitsSold', window );">Gross proceeds of units sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,939,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Management Deferral Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid', window );">Amount of deferral agreements paid to certain senior members of management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Separation and release agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement', window );">Payment in consideration for restrictive covenants in Separation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CommonUnitsSoldPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per unit of common units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CommonUnitsSoldPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_GrossProceedsOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gross proceeds of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_GrossProceedsOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfCommonStockUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfCommonStockUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfPreFundedUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfPreFundedUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of payment in consideration for restrictive covenants in separation agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PreFundedUnitsSoldPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per unit of pre-funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PreFundedUnitsSoldPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold exercise price of warrants to waive rights to anti dilution protection upon subsequent issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution made to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_StockOptions2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_StockOptions2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_ManagementDeferralAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_ManagementDeferralAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*XVO=;=__#I&55Z@0R:G_N3; -D[;(.YA_R&"B;W^LHO>-97AV1.+\KF=\*
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MS ?>5X]EL.)5@?=J>PE-/9\M7ZH*X[YLV\0&'DLK@ZILP*2@%+)>^6MS#GL
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MFV?W(M-U^765AU3*=%4^+@57.ZP0J+\_IJG\\5)\ V;_G:JS?P%02P,$%
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M7&$SG%+]]_4B-![F\C\O;'#>;7#.&YS_/\GW9>KSJ?J_;+#_Y8\E?A988%V
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MU,A2$H8S:J2+8=30?=5)[X06.1L25S*WKH#9-6?)OZ&]HLV-.'[F E:@3G)
M)=(20TFT-+CQ K[4EQA_PF]S)$J4HGN;<?PE:480T"7U D1+L]/)!>DS"'$O
ML +MO8;VWEQ=1:OJ@E&L5]\P#Z,2CU(QG:U)>#C)TOJP&P(1W1MDY#6R)<%F
M7=:JK0]'9(K$# ?T .1_2RLA.GAYB$;2!@D#O3WU2IFJ']V& 'O"3:V<ZL5]
M@5'82H+R5.=X 76I)@BWW*+1. _1[\/7LA46$73U2L+DPA066P8)14,A;1"U
M&:?6&A9N*HXG1"$F#HA*9*^=V$+3YGP(N!"=%IF%%1=8D8MX&QB"!L@,.&H7
M#:<#![+@A2T(I211@;0 D)I@;\60E0EDB=,"-61U!+-<X@Y^!5>PIW3%&W;F
MH")Q$)A(IXP6KM@^\M^0)\ECEDM)?<18,(J'<P!L&^P9\V_ <4OLD-B;[0A(
MNO.D0^10H0T-R\]2T"+;X9JG8H,<G)LBB8'0J$2R[,//U<GBH>RG-RHRD2K!
M%!OA4RR!#QKPT X'31\I$%[N#-Q19#_^X/5&W4KRVN=AHX;5SL.^<_5"LJ:^
M>S1&\K3SOS-KUXB)A8+/[P&3,6>5U"PQ&?D"$; =_%E^T^*_Q/<D0B?7>J((
M+PQ$,-HA*B9S:$N"E"=+",PI:5<DZ$Q,)<)EGRWTP G4(IB$I&8S^;,#ZCUJ
M< 6D^]9%#$KDH(B99%BO+A,5\8P-I*U67G/EC]V=3\[<U;A3%/6#^WFL)IL7
M3OL\0)0ZI^07SQ'_]"9W&XZMG"^LL&Q%5/>=OF=86GU$#/EM*\'CD,UMD /J
M2@"\;W8-]P+IJ\E%%$5 VB_%.N$BO)BSD]W"'.(""?.-LOG W&9,Y]5L>C&C
MQ%GH<--0R#P2&2XT"=Y\SAE"E[C#TLO0;?+,G#Y(@LMOLN!*Z?N+R$<!>>Q"
MW".('="E:WTC8+&T2_J53**M.'-YR69',3Q($+\0B1'!5V=),1!>+7V)(D)G
MM\T":-7W\"#"J[^QJ) =MV7LO$@#?0>S3D]W2K2J,3%XM<%$;W&9,7GH(;W;
MEKQL92HNGOK<B+;;3213V3(]:$R41O/(BV4:P^QAP7:!=\%1](F:,)0T,J3U
MEC8TD5@E@W3E>MME0@N3S+VSF[33$$Q/_QA,41IOD3-AMP</-);./G["^TOZ
MM\0^SF\%JE_ HU?S^>7D"C8PA-J'AP>:0E0=M+)*;@G:/NL8[VYT]77O(O4S
MMS_[(I7TWCVD#KVD0P11@]8R47KI3#M;=:QU;NW!UI/U;5#7-I]0"\&:I<#,
M1V@.$LFH-=9R7_ ZVPF&UU\^/M+=OHV8E\BE@LA\L94B>/HX58\E5;#]\"B^
MMS,/>;RY[DA]-XR7/'.09/A%#4O?*G;=  I=KSN2>[VW-3\DAU0K5Q>7D[.S
M,_PY'Z-A6W$-CKR;S#K0E(F*["4\U_3(-UI"DJ2GHYO1OOGAY:S;"Q70,65$
M)G]YI\%[0TH'M^'A $ _*2;6-PXH2?@JQE:99@^:#$=@=+Q7E],Y<LFBZ/I'
M^W8,L80P8RZ#).*'(LCL4C 5OV;S,:).>"N*%LET]V]+#1E*U:65D!IOS^45
M^#"1"ZYG:5Q;<)OET KF?6%,SSV70<NV*/X0ID?"C2>XC^(_ -0)E"<QR>&A
MV!BXNP 9.^'/?*-OV',SAOLGW#:4A.IB]K?$3)SET&4P%>4Z?84U2/Y+RLG[
MH<Q\UE-X-F[H6G_42T.T,%SH4]."NF+%=MPB)]:IL$(I&(<*-)5-T7^O3T_V
M[TO5"%D*@^6SFI B&2NQ+T@*&A<0S9ADZQ:II.>>ULY0HM8":2Q$'_OL(XG@
ME*A\BY1RK@QU.R5ND0MR P2O+ES5LK#G(L#00G]QW=B8NM9J5SY*/A>HTY:J
MI]@J37[MR:VX31D'B+B3&]2IRR0Z6)5T"[F\)@-?I?);AP!C#;H@T^L;_Y(A
M!R+E^$S#58.R?S3Y18;CNKQ?I=&TC](AU?#!=PK"/NSK)VT+=D]NONN =[@/
M2&GCA'BAA)3\[],X3^6:,SPGO-AR*L'UI8BF'PE/QH6]+=HTK>)2E]8,.W9P
MQK;(8T7-MMQU;61\H)') +L413E;26#HPVT*>;?W__KTX7C^IHM[AC\^8&CY
MM5W'86.E$4*Y"8E35MS9(4.6+Z92(C#J-DN#M5I*0C!$+V^H94:V#JN)" E@
M*62X&+^L&(7:7^EIR@GO_4I7]M]B\KG)"NW3IP9MLP _7#2D8\5F1^$6E&>"
M)X.,(E5OR:2EG1W/(K9,I=RS,TT&PQ]VU)T#$%TJYG;]?:?M'"=&0<&T"&LI
MXQOU%)XWA#YQUZ%VE72 AJ>=I,F!-"1Y<A@1A-N4^T8!H@U+,WIP@MM/&O5E
M2U,UZ4KE W9+V'WKXSS;,PYQD2N!JA-I'R4@(;*[U(XD0A,@#K=I"52)V 3&
M29E8;,@N4F+6/_^]U>3Q=!N>88KEL45NI".YL#8%C9>.;74,B(I=7VZGDN^0
M&V5=:M$90V<A*3)W0H7)]%A#LAQ(</?<^)^B-V0H[5J:R?&,EU(=:#UK4MLQ
MP6#H Q(BD 4:M;H81=:VHO:SH1869:Y1'!-X8UVXK727Z("#K4S*CW%<W]:B
ML&@<T>"77;>NU/ZK:;K6XG )G:6P7Q$1N<TE!_B#7J+TU ;PEDHYS@.Y4HAY
M!Y VT!B5\6]*E0T0=/PM!K10D)Q9:-;GQS4/$)$ M$O-+70O702Q5IGM[)FB
MDJK[13%?Y6I-YO4[DT6\0-5V_%#B\\T<_U$"%]VS_PYI9XI&GTVV8HC==S);
MZJFX6H:^1L":IDM%<%1JQWG[7E=<M'P*$L)6PLR*J ,4CG5& Q_N=:("M'TS
ME=Y'> HH@+-N>$G%H6<YM@U] +(/OR3<A03IG_A+G2H6;5UU2Y9(_;+HVW1*
MW3D1J\Y3 DSA!REB0&F]Y6A9#<R?>9-..?R4)^+,.EG;\%N?H>B26/GKE(U!
M#*;I&9,D2D^NP!&-?.9R0ED&WB9&P:]',$T-DQZD21U[N^LR3AYHD#YBX(_P
MQC,,4N*=*18X3&5VX3^D@+@'8%C5I"G62K3WC+R'6QG?8!3<V@"\4B>U1E*Q
MEO@F\;?*>.3]5;IT$JX8M'G"UX_-QGB3OD5@>+.EH0\KI:>V3P@HCYPWSR?
M86V73?Q@C@<[!++KEKXSB,L'#M-5:H'PB)J#Q9(>Q^@M<(2+.3.T]+I$@GD-
M^EX*R]QT+;8NU41&99XL ^?NJ&,RG+RL>8XE+=@^U?8\$=@S)%FDH/[7AB3L
M'Y1(55+?*<VGZ!JR?5^J0]W0STBT3UVDZ;[O;T\&WSJS = 7W4',1SY[[NYV
M'XU?R[?2_>ORQ3DRJ)6%( NSQ-+9].KB2'GYBELN&E?SE],+US2NY)^P/2B"
M7L#SI7--NJ -ND_IW_\O4$L#!!0    ( !6*#5%?OBW0[14  +I!   8
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MQ4^S7EH_SR97+[/+JY=BFIU/)MG5^<O>;U>3\^QB?"$^40-#H[D=SR%HG-X
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MO9+-9]OMV@(RT';.5'CF[ZQ"+RF;$!C)67",0(^@AB>B^"'+(]NQU^BZAB6
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MY/H10Z :M9R\S)*/!^J'085Z:JL?V!Z.-0KA$HZYE>)BI!\J4;[S8!1 ]$4
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*U7;6_;-A#^*P<O&UI
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M<<\?[<W&JK6[N<^5I>\ MUS1AQ=J%J#W"Z5LLV$#[:?<V;]02P,$%     @
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MS*<#^'ZIM4MO2$'WCR N_PM02P,$%     @ %HH-49U7Z+)6!P  YQ,  !D
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MQ?E'AN[$Y-V^>+^R_WWNN?B1"YZ$=U\+W';#"G^&CF?-PI)!&_(OMT)*TT>
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MP.*Q%0F[4XK,FM;'>?';%[=PC<BFT5A 1"E!/K":&$7*A,IJFO_]_S,P/,Z
MS?P"W; P/TGF9Z=Q5CCAZ\>CPHO#&E-(9_'1:9K,CL^V)K0XOL?H?%6BC04E
M4'KRT]50.$S)?(U.*94FQ_ZJ:NS!30,8,9Z)6Z2R31RQW6:<9#4WUD'5@=>Q
M^TIBY>?0,LU1H#&C,ART%;V8/M_Z$[0M'^\ HMAI;SE--B!>UG%5%#Q($9'L
M.MLCN(Y3/-8OJJ+W!Z%M'M](Y)/7ZT?FC/=]()AL?7S!W0O^Q$2%BZ4:O\,,
MJ\-7K*OX\68C'C^!(0$M:'#74.+6='QZ/!(N?E:*-\$V_"DGLP%["5]6(#'7
M20"?E]:&_H8.&+[M7?X+4$L#!!0    ( !:*#5$,LL,_2@D  &,8   9
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MM*?CYW^<S::G;V!.Y9V'.%KOVS46'Y!_RKHF7*UA6PT7KQ11C?89%,&Z4@)
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M)I,ADCI.AUAE<1*&HPU)#6D> S.<C>Y2ETU$I8\S]$OE96:>5)WS-.#AML:
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MQ$B2>LBCOFH@<7\PQLFC$!@TXF1+]8##!U@C>!9FC3/Q??RS1MX%.(3W$R>
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M<?R,R?:Q/&'OI9);YUB2H^KA80B/W&V*4'7O7#-8(Y$S2A>87EY".5TR*<(
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M>S_R;;_=9[%S19L$20.$]LP@4>*& ]U-NV8<A20-H'C8DL>8IJ1:\.8R[;4
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MUAF:FK^O!"C& $4(4+Q49GI,=2_1UYF>AG5<U3Z:;;BA6*2M=-O2E%+#JQO
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M#!^"JKX?K!^,7+H[N5MIC"S<<,$9V&\7P/N9E*9YL K:6]KC_P!02P,$%
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MH78.]'^IE-T9+D#[6";_ %!+ P04    "  6B@U1B-.,!@P(   1)   &0
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M&$>#('ZV]"N7/-R/,$S='/F+8R1)!C!TB)LCKUTRX[A/2-QBSO[&G'VO.;]
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M=*3U/!@JS;G4M*0986L8NLA*"@%;SH_<9"&!G103L 4#,ZH%50TR ].C.\;
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MV)_.P?%S" I(H:;5G+KM;DK\NEFR)'LV)=^C/H_([@8FB7WZ6HHE?HJ]+*'
M03HAB&Y0$:(<]"FKPJF%7U32A<;;%_B6EXE_%W&CTT['UY0Z.7"T!_\Q55T4
M'_WEAQ^@S!.?2I:LB9^L]W+CJ!9P$.V%EI-#/R?/>"5TQ?_SV"^TE!OB%V>_
MT')OZ&_>V[C&Q&BA;^*ZMJ>UT,9>(FY/E'#K#I>?C"^R&?AA785.=_R G'Y
MO]V8C:S7))9^P^CE'6)I-_33[C<Z9)=J0P]SA99I0S_3WK)4DX1>ZF1-M-;N
MID]^WQUUT1>:E0]"/\E#YL8!=.'=(W1]/4+_07]@@QA:2@V3E_>2Y<[0SWT?
M*AUO>O;1JM:8NX[H<YE!4;KEN>N9R5DMLW%_L!_J3]3B)DN<H9\XK3X3,,I%
M9=)GCS9#1^?@TR:R=!KYZ?1GP<'^$\%3QJ92:^57I1;7:!2&X;!U8QQ9<HW\
M_>ROL*_4\Z\;!N?L?A$Q>F)42$_81)9MHSVW2KY#-L&E1@RZE]I4V/)Q]']X
MY+#US,'?".]M!\YJ <UV(.BWA(TEX6C/,X3OXR?(S3>S56X>XB5+TE'_Y;UD
MF3CR=Z0'>"EQW;D(\#,W];8>M1=,S,T[)_K.%>PO5H^*-U<W[[6<FJ?[SZZ?
MX;>CU=LI5LSJ99D;*N:9WM&P&8@,N@G$@5B]?[(Z47QI'NC?<:5X80X7C$Z9
MT /@_QGG:GVB)]B\!73R7U!+ P04    "  6B@U1G>P>B(\#   )#@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6S-5UMOVS88_2N$GE:@C4B)LN7
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M+:FX^2H/O] FH<3Q99)K_Q\<&EL8@*S21I8-V$90,E'_DL>F$"< R],/B!I
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M-EQ5OSOJCI%[?['>2&.OZ;Y9V+<:5<[ SF^E-$\=YZ!]_<W_!E!+ P04
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MR($OG#[PA"O.<O!APA3E20[01] '7^\GX,,?'X<#I<,73@:S*M35+A3J"!6
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M;!'8L:FQ^/)E:&)XQ;H-9?RL$*?,V& 4GRG%L5^R_H;Y]J&@40$SH#KD\/*
MW-A7?>H<6QJ[NG ACLV.#?\LB7\HB9,B]_O'4.4-8Z OAMM:8&/(^.'TE[0?
M*FF@6 UU&JE.,^S,(WX8_,S-1M"(('%-T-%@3)%,/5_5&Z>+:D2YTXX&GFJY
MI9D4C3>@\[76[G'CIYYVREW\ E!+ P04    "  6B@U1[ 1FD"T#  #6"@
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MTAJ8]ULA],/&3C3=!+OX#E!+ P04    "  6B@U1*1_<Y$ #  "]"@  &0
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M[]1ZH)O>V 2D*M]>;A399N6'N;U.4+L$N[Y0BIX"U[&Z"RKY"U!+ P04
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ME>*Q>5P""T!H ?Q\SKG:ON@-BJNNP;]02P,$%     @ %HH-45T=1$;L @
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M#D([X/F"<W58Z 3EWX7^'U!+ P04    "  6B@U1N'-X6?$#  !H$@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R]6%UOVS84_2N$L(<66"*1\E<*
MVT!B8UB&93.:IGT8]L!85S)1B=1(.HZ!_OB1M"*IL$T9JV? L"5*YWX>'5YK
MO!'RJUH!:/1:Y%Q-@I76Y8<P5,L5%%1=BQ*XN9(*65!M3F46JE("31RHR$,2
M18.PH(P'T[%;6\CI6*QUSC@L)%+KHJ!R>P>YV$P"'+PM?&392MN%<#HN:0:/
MH)_*A31G86TE805PQ01'$M))<(L_S,G0 MP=GQEL5.L8V52>A?AJ3^Z321#9
MB""'I;8FJ/EY@1GDN;5DXOBG,AK4/BVP??QF_1>7O$GFF2J8B?P+2_1J$HP"
ME$!*U[G^*#:_0I50W]I;BERY;[2I[HT"M%PK+8H*;"(H&-_]TM>J$"T [AT!
MD I 3@7$%2 ^%="K #U7F5TJK@YSJNET+,4&27NWL68/7#$=VJ3/N.W[HY;F
M*C,X/7UD&6<I6U*NT4QP+4TC%+I"3]RT0RJFMTBDZ($I93]ER="[.6C*<O0)
M7O6:YNJ]O?MQCM[]]'X<:A.2-1PN*_=W._?DB/O?*+]&./H9D0@/#\!G'?!U
M?HUB[."C _!Y%]QXCYUW$GT/#TT=ZV*2NIC$V8N/V&L5[<_OBW:;20#SN)C:
M_O6[0:%[#87ZV^,SKGW&SF?OB,];SDT7D'W$-7#*EX!2 %32+7W.X5!-=O8&
MSIZ5A9?IL!]%)O^7 V'TZC!ZWC">'E _ZD>HE.(JD>L,T2;C;QXV?4/W)N[<
MRH!-8R&-HDF]]12F7T?4OU@S!K7/@;<*"[JU=I'18[0N4RGL,8 ZQ.S!7AMP
M%!WMP[".8-C5A]%-'"'*:2ZR-?Q_?1C5$8TNUH>;VN?-V?JPL]1O]8%X^H"C
M1EBC4QY,Z];%D;.EV2Y;#3DH=]$>*[S1M&0>=S^?PV@_BC.S C=:B2\GEKA1
M2^R7RT\@"YNEKPMW'38PV@*5OG :U<1^V?Q#:-,09*K*1.)HHDV C%,[%!T,
MS6]O$*&$;I4OMD8_<=]/X,S4**,:S-R1@YE$N-M6=HUA:;.JS/2V8O "R<&(
M^_O[C8_2C=9BO]@^%;LMQ[#R:FZWG%N>(+/H]._6Z5^;2O^!YV;]H4X=^XK:
MR#,>7H[UC03CT0^S?M9A(^ZF5B//V*_/YZ'6K/)RZAY*&NTF?NV^,+6(;_9L
M))[@BU&+M$9>\N/4ZK#132W2"#SIF(?/0RVR/R7[-F+2*#[I&)0O2ZW85]1F
M*R"7FZ5)(_#$+_"G4<MOXP1J-=I-_+/UN:@UW*-6[Q"UPM:_>OL.YH'*C'&%
M<D@-,+H>FI[)W6N-W8D6I?NC_RRT%H4[7 %-0-H;S/54"/UV8M\=U"^7IO\"
M4$L#!!0    ( !:*#5'8"HG0X@,  % .   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;+5746_B.!#^*Q:ZDW:E6Q(G$&@%2&V!7597";6[MP^K>W"3
M"42;V)SME/;?W]A) Y3@LGNZ/I38F>^;SS.3L3W:"OE#K0$T>2IRKL:=M=:;
M2\]3\1H*IKIB QS?I$(63.-0KCRUD< 2"RIR+_#]R"M8QCN3D9U;RLE(E#K/
M."PE4651,/E\#;G8CCNT\S)QEZW6VDQXD]&&K> >]-?-4N+(:UB2K "N,L&)
MA'3<N:*7'VED -;BKPRV:N^9F*4\"/'##!;)N.,;19!#K T%PY]'N($\-TRH
MXY^:M-/X-,#]YQ?VN5T\+N:!*;@1^;<LT>MQ9]@A":2LS/6=V'Z">D%]PQ>+
M7-G_9%O;^AT2ETJ+H@:C@B+CU2][J@.Q!T">=D!0 X+7@-X)0%@#PG,]]&I
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M 3L2I>"PIIA#2=%7FV*CN7A0=?K2\O#VB-GC]2$VHHWMHGT*@0$;=7I6%<F
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MKF_2>A^L_X'X1,4ZAGXM82L .N,IY*VH7NI7)XKGY2OB!ZX43\O##:- 7C\
M]U<<BNKZ1+]U;OY:6?P+4$L#!!0    ( !:*#5$LY7*-1@(  %X+   -
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V,MNPC 0A>%707D
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M+GAM;%!+ 0(4 Q0    ( !6*#5'[6&KE[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !6*#5&97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ %8H-49"!D:B' P  APP  !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !6*#5'SS:="WP4
M !47   8              " @<L+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  5B@U1[ V>2NH"  !Y"0  &               @('@
M$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ %8H-477@
M(<6X!0  -!8  !@              ("! !4  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( !6*#5&368*$& <  *X:   8
M  " @>X:  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  5
MB@U1VBQ.Z&0"   Y!0  &               @($\(@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ %8H-46(FDC<,!P  7R4  !@
M         ("!UB0  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( !6*#5$ XJKXH1$  %8O   8              " @1@L  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  5B@U17[XMT.T5  "Z00
M&               @('O/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ %8H-4598LC7?#@  6BX  !D              ("!$E0  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  5B@U1)FL;@-D/
M  "8+0  &0              @($H8P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( !6*#5%177?G=P4  -8-   9              "
M@3AS  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ %HH-
M45"E#:QP"@  $"$  !D              ("!YG@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  6B@U1G5?HLE8'  #G$P  &0
M        @(&-@P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( !:*#5$,LL,_2@D  &,8   9              " @1J+  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ %HH-444AHF*Q%@  :T<
M !D              ("!FY0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  6B@U1K.]>C/0"   [!@  &0              @(&#JP
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !:*#5&/@YWK
M(@8  +$5   9              " @:ZN  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ %HH-44\"8G.R P  K @  !D
M ("!![4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  6
MB@U1#+4GP'@"   X!0  &0              @('PN   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !:*#5&(TXP&# @  !$D   9
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M970R-2YX;6Q02P$"% ,4    "  6B@U1+$GSKA8%  #%&   &0
M    @(&-TP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M !:*#5%U5N0_0P,  /$*   9              " @=K8  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ %HH-4>P$9I M P  U@H  !D
M             ("!5-P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  6B@U1"K0C:RH%  "7%@  &0              @(&XWP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !:*#5$CA&Z)3P,
M ,T*   9              " @1GE  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ %HH-42D?W.1  P  O0H  !D              ("!
MG^@  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  6B@U1
M&LX.NU<(   Y)P  &0              @($6[   >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( !:*#5%]SB9#< (  *P&   9
M      " @:3T  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ %HH-47-2"-?  @  ;P@  !D              ("!2_<  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  6B@U1=9\=B:T$  #V$@
M&0              @(%"^@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( !:*#5%='41&[ (  #H(   9              " @2;_  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ %HH-4;AS>%GQ
M P  :!(  !D              ("!20(! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  6B@U1V J)T.(#  !0#@  &0
M@(%Q!@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !:*
M#5'+_R>;Q 4  &89   9              " @8H* 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ %HH-42SE<HU& @  7@L   T
M         ( !A1 ! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  6B@U1EXJ[
M',     3 @  "P              @ 'V$@$ 7W)E;',O+G)E;'-02P$"% ,4
M    "  6B@U18#^/:X<#  "!&@  #P              @ '?$P$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ %HH-44"[PRV' 0  O!<  !H
M     ( !DQ<! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ %HH-4?]Y:I*? 0  '1@  !,              ( !4AD! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     "\ +P# #   (AL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>192</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Nature of Operations and Business Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</Role>
      <ShortName>Nature of Operations and Business Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Warrants and Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</Role>
      <ShortName>Warrants and Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Significant Contracts - University of Mississippi</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</Role>
      <ShortName>Significant Contracts - University of Mississippi</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Related Party Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMatters</Role>
      <ShortName>Related Party Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Warrants and Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</Role>
      <ShortName>Warrants and Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0022 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals</Role>
      <ShortName>Nature of Operations and Business Activities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Warrants and Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsandDerivativeLiabilitiesDetails</Role>
      <ShortName>Warrants and Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Warrants and Derivative Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Warrants and Derivative Liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Warrants and Derivative Liabilities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Warrants and Derivative Liabilities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0030 - Disclosure - Warrants and Derivative Liabilities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals</Role>
      <ShortName>Warrants and Derivative Liabilities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Debt (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1</Role>
      <ShortName>Debt (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Debt (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals</Role>
      <ShortName>Debt (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0034 - Disclosure - Stockholders' Deficit and Capitalization (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals</Role>
      <ShortName>Stockholders' Deficit and Capitalization (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0035 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Stock-Based Compensation (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals</Role>
      <ShortName>Significant Contracts - University of Mississippi (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Related Party Matters (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals</Role>
      <ShortName>Related Party Matters (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/RelatedPartyMatters</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="embi-20200630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SubsequentEvents</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>embi-20200630.xml</File>
    <File>embi-20200630.xsd</File>
    <File>embi-20200630_cal.xml</File>
    <File>embi-20200630_def.xml</File>
    <File>embi-20200630_lab.xml</File>
    <File>embi-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001640334-20-002095-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-20-002095-xbrl.zip
M4$L#!!0    ( !:*#5%T?ZYMN>D  .<@"P 1    96UB:2TR,#(P,#8S,"YX
M;6SLO6EWVT:R,/Q]?@5>/S//<<ZA%*Q<["3/D24YXWN]:"QY<N\G'9!L2IB
M  < M<RO?ZNJNX'&1H*;1$IP$D<B@>[JZMJZNI9?_M_#U-?N6!1[8?#K&^-8
M?Z.Q8!2.O>#FUS<_KCX>]=_\O]_^\LO_=W3TZ>O5^>^?_D<;/FKG_SGZGP_?
M/Q\=_?87[9>'8>1K,$H0__KF-DEF[W[^^?[^_A@_/@ZCFY]-7;=^]H(X<8,1
M>\.??#=F7OHT/1FST?%->/<S? %O&(,CW3BR#/DXFPZ]W.ALRB+7'P^]\-CW
M)@Q>@6FZEBY?\.+0-HW>(HCX$_(%WPO^7/ T?CUTXQ3^.$K2IR=N/*0GX4,"
M) _[/#ZZ<=U9^7'Q1<4K./>X@" !2O=G_F7Z: GP>XN>-0:#P<_T;?IH[%4]
M"(,:/__/E\^7HULV=8_2G?KM+W_1X$_[5_M7^U?[5_M7^U?[5_M7^U?[5_M7
M^U?[5_M7^]>BOW[!P_>[F([5W]E$H\/XN]N(37Y]@PZ-(^FT.'Z(QV_$U\GC
MC/WZ)O:F,Q^.X+_\G!_C-QQV% 8)>T@T;_SKF]-K&J1O&=?S&+T)E_-AS/X]
M9T%R?@=_7<%P)P]>7/WM%P"#1>*[4]^-XV^3/]PH<H/D6_3=N[E-Z%T$]IP[
M7#YZ@1N,O.!&/!;S(:2S(%U^[H=?8"HO>52>R7U=^@7>\,;XSL1CD4:+9SG/
MA706G7[Z[S>_Z;IN.$;7<8Q??LY>^TV,^$O,;J;P86'RBCDK/J !N+_E'7N8
M^=[($SC3QAZ,RIUFPH_SKA:!;WY##+Y;C,)??JZ<Z+>_K Y(#0V\^:WF@48
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M7BTEO=*J$/3\(1=A.&R*:GO*'4)/N0.@L9(CLU3>J>ULN=C;5U&BZ:D;7!X
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M8ALPW#4K0%X":]TE]JK KD00!&P506P1V$]Q/-^4# A.8W4X^=SK@K@Z*G<
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M([D-*P&TK76L<* 2&]+%* NK6V:+9UW'ZIP!ZS -:[!_^[$Z@]@#JQP- WH
M&,?>I\4(!U1U[QJ<CW*<S\HYSHU3.FT'IBK5E]X8%U*34ME,%F_D/E'=$YB$
MJAL]PZXPLHVN>G0JS+P25*OQ..4-V#VK:PW*00H#8)@M0;66+G-Z?;OD(+.L
MWJ"O;PU7*_,?PE\.,\  %O44N0BJKV$0YHVT+5!8!I\)?%&V (P!V#$*@+5
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M;:GE0);"M>$JUMT6OHH^2/VN7LYLI*6MNXA/P2AB("O.&/__IR#?T'-K.S&
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MP^&)J<9T$Q',&6<DA!5Y$M4MF'K!R)L!!X7Y>U*2=P'UG4'$/#(T&.GU&:!
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M=Y>:)<[L(S"(/!#P<]?/F<'S  -3&%X\XI%<H*,#W#CSPT=^)X@+5*9BT@4
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M+T!704,9@<X:V^A:"V2$<6PXKQ>;W/&R"C9[MMVOQZ9SZ+19@;NK4)BLETJ
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M((H^936?1,FGNIV&O;8PXM#LR9W6[2/3WG!%P EL4>2SN>8JLOI<6'^HH=X
M4D8GE5W2&X;1[:EZHVX-ZRUTZT> FA!WVW2ZO9Y97)Q=C'#?[NJV0HS+-LZP
M^PXP>W^CC:. =AF_J#C0,=4ROL3Z5%7!6"G+[6E85I-(8A <IJWGLA]DU*?3
MM?"/+>+]%Z&GC,2+B'VD:*_7@$+'LH$**U#8U2M16$9.AL K%DVS@\Z!(JWJ
M.&@[NC7H]=[\=N'\K\!'?JT9#BZIVM.7-+/Q5"EF=.&[@9++M_0@4KUEIFV;
MO;[^YK?#+U8E<+D"SK:&Z(P2-W)'U&R18^I.SWKS6UN,J[(8UYK[+O7A95:A
M8T$R;%/V&MHCTV2F<309#MB18;#!T< 964=LV.V:W<E@,C#!&LXE8G\Y^?[[
MIZ_84$F3_QG'NK.5QHIK][]*6T^9Q]KE?#J5#9N5<B89MC2)KM7:5I5STBM0
M@1?MJV>YBTSI#0??/9[9M(QQRMU&9*O9VU68S5Y^'B17C/A,J/S$2T2$,] %
MO.Y%IG-$1P&U0\R/P)V/J7;(*KUBLH)8LXCQ)DTHQ6215!3#0]JZM-9(93V!
MDVSJ)1/*;LL3+\;R%E16@-<C+S6"ZHA21:*-#587R=K8=$IU7$&$!]C-%FL^
M82<TWB](>2&K  1B?.)ZD?\H*E4A0$HO7 W+Z6%WQ%L-*RQX@2Q#NA%>:XKG
M1W.?R8X6-Z*>2EK*-+/2>+WE!VHK3YN Q^!R.>3STT*-95YB2E8.";%RE.CI
MDULQZ:TP3 *LZCN&O1$5L/)(FW'FK:_Y4+%&48 5.T_*ZCAN)F1%86V_KD18
M;G6_GYSDBU0O:SZZ%E?OO6"XXB7#YCXOTJ_4=9/,Q1L(\)(W#XL:"6"-#JSW
M*'<9IJ?:8"->K$90H9P,*&#(LHY=<C;)P[B?!2:&*<C(?90]]&;D"XT7,M0'
M;@-IE[>,)75=XJCT>:[C;GVQ$R&<JJN45 ^?-IRAOG^BZ(JWH(_921#,8>3O
M5%8092A6G0+3[NB_85Y?K><//(K?RT,)1Q-'R#Q8"&L>$!#*_YB[$9BYL&GE
M>?^AQ;=4\6F(&^C22R R_S4/"L6CY)0C=0^J<85-%$/1<P<,V7!SU*RB#0J]
M#5UM&(4NEO-#>37GTG!1 _:TO%]:=\^+_T2LXF("44['6]H)O52ZIK7VBM;>
M#U[+\!P P6IBE2;T'AIZ^X'4*UXF'8R&7,&S5:P/SNJHW;'($W$ZZD[97C%6
MZTH!%T_=/T&LR\T2;5_C^516<Z0R<-1F1J@#63HUZQ1#)8ACT5J<QX]*HR6S
M)G@=6%+\.'/=.TFI/=,J:\^*:I:A!-F![0WQ$=$.3QMG;7?X&V25D)8ZQI85
M<[(GN?[C%?3&'M:7ESHGC!74B9*&89SD:F0J]DZ&Y53LI"U&*K:\0HHMT@SJ
M)J95.,G+!786;_ NVGG?N?Z<[X<P!JLW0U6#:">@(D$; <9T"7C>/Y<<'+RX
M88Q':W@C3T[_FH]OLJI@\\3CC;Y1_%.!YB/>*#3G2A$[U*DJ^TR*G]LH.6AY
M!\-APFD>%<@8E<F$4=.AI<WJFXKVUR3+OY.21,3^2+N!UGA%]END]YY5HE?R
MLEJ2.:("@/\B(1OF>DE'Z0[,U1U0"_=B35+D3RH-3!WEX'Q,1\7T7"4;8?""
MO:+ ):Z11KZ)PGO@&%E<,^U>+2KV\D:)P>-"R50N\=I1SRD-VHQV\BL$A$14
MW!J7F)5955^N.3;B%&GMSTZJ$Y;50G03>&.$QZ%[6:F_M08WEB ?72_2_DD*
MYPNOXDT[UTJ0YJ@]7:BE27B@:O?0W$G(MR4T/&_[A\;?L?8Q^YA:#$_H=L3E
M'529="WQ#D*\'VEV?APQ?M F,2 :3E!!7X\7WH_<($:KR$WA>BSW 6,/7L+'
MSSNI2DW6\'X-C2AJ?9> I8I5X;DH2H^,*0S9A+P-)Y5XQS+B4=9J:<B2>W3&
MB3&PGK&'4Y%=&(@KOI0TR?8\)I+EIDC"1K>!]V^LT4^-S]%FYH^KN)[B]=04
MPPQ1JN*8<WX."H>PDW<N[PHXFXL-Q*9FQ2?G0>E9L$+526X]D.(@11_5WNKH
M[?%1* HK%]_KX(]9/R[>'#ZY#SFQB&JT.$ Z828G?1<[0\?J8RID'?RN'A'O
MGH]_$T+<B/G^#"O"!S<46")FX<7_CP 6O#E\IQ=KI=][X^3V'=[7IOR:#,/Q
M8_I+)$>Z97@O_LYP9@_9HV/Y+1^G^[?WU MRY/IB 4DX>[-@Z<\D6CXCW6A&
MXTW[.1F7EWP0*TWY69@SU;(4Q,98>NOI@)&:0'C420] :9L;E&?4:(8??]**
M[?^>AZ*-\XC%5<,!"!YV6J RWP(819QYJQQ7LCWY.8F:TFL%(ZE[N\7SSWKP
M'11Q<38R7P$;?2MIL[?< 0 V _8L)7&2)_^?5N**&-2B[T;5/-$I#R'?3=L5
MX$E(C)OGLN6#I[VRQ-+2,16]C#T*>#^'40CG$^J>PSN8*@\)2P,L";=EX\,A
M;DZ^UBM@XQ]E4S.C]G@^$]Y3H&K@C823?1!*NA9G]L>LE36]IC@]*9B.QV!)
M!ZMBQLI&+]5<F#DVI':=AF.&O8K0F8R^5'06NO&M-O'#>S!!D]MP'/KAC?0Y
M2R[/#/<-F?#GG"7X,]F9I3WE72-P3P_WYB'O(8X;NJ*]-/8:7<;R9A'.E&RF
M.K1K6\]SEU"U3S<EA@YM>8=[RKW4A8]N7^Y@CS$XCQ]0<#;LDNUCEVSJ!$52
M'>-"<+[<X1G]XP_DK,;7@$05.AW/TU9G\2U>7TYY_H.7HB9FU7C@=P'5BR)F
MH0E$N$T6L<*C;;B'''\7 BE5M=1VV?KIN$!<M82]8W))<9P_+<*/=SS,$3N2
MI YY?$ZD1FE1VD%$V8 XW2$A9R+N1DS?XGV0I9\ MIL[ 67WR:E+;91X;TU,
M9CG6SK(=E,#FJ3ABOLN[(HLMIK;(28D7\G!F-*)LA792%TU0(_[0OX%6#'?3
M$*,560/C'/YJ=/J]7F=@]3MYP+)N]'1L3STA@-7*B(D,U+]:_5Y'[^D\QBH?
M6W"*NP<JC.P8S$XY&D?NO3;BH+DI:$<<=VB,80.P#G5C!EBDD%X8%= D^ .=
M'X317-1*/H@;=)(?!C<, P=NW!L*#*"N9!PH0KB(ZIHQ9%(O)N7$-Z(*Y=3-
MRN6BBG[VR!G"^Z*BXJ-N4Z#>0CCT88-S)!WIEA+=I24:E/AE>2,VKB"$*@F"
MW;ZR *T9;D@@+FS%4/5ZM5;0IM$3^'@*F;PG([:-*)!"7)G)5I&YWD552CC5
M%,M857*G$*2/0J39S8.Y6D][G:==9=PL'>H />W/; 2E"2+2KD#NOGT<1AY/
M=$(I$!?NF,N\4QD.R5WQ)Y>G6M]P.B"EI7W #=>_L_$-LME)>B>6#X$4+^;]
MYVE8!P\'%MU"A]YD'HU$1JD$+10Q'3)B#@3'+7K:%<.%QW_PE4NQ-D4Q. $A
M<B23YE7+IM+^$2LGF1&F808C8'GL+LBM(_E;)I9&7C2:3ZEQ*L<?]V"_=7_B
MDDIV&QW=NK@)\#(0QDC$S](]J6Q3*/=%@3.#+G43C'SFXF4!;W@+@MM_3)6:
ML!J:STF8E/31T=X..=""<)39R>P!"$/JS3<,I;V\!&;AG<]-(S53Q(Z$)[[Z
M"HCLWWMJE3J;^:#"4$8TCLTETE4NE)7ATS@;^!APB8>]6%PJ/6KA".PY OSM
MZ"=L4LMC7'++2H\+,>A<WB<\O91:C)#T?DJQ/-WJ9W<2*;QC(9])SH:V_B%+
MUY&BNNC H(J2M20MBDJ[IQ^AP7B6'D%.LY>1++_1L?";D(HE4<O?+]Q63H1!
M6)5B5F%!B3!<9%(@U50JCQ?)X&/M!W&MN@;5Z,4.V=&8PK-8D,7H9_Z16+1V
M3''*XW:EE8I-MV$Z$&I9(%A92:08]X+RGO#KQ_E,7)_RJ#CLD)I>ME:;IB2.
M_$?>9A*3C7D$F)8B$),ATUO85.BEL# *1$3N5B F9_"Q]L<MRYTXLBV*LRVJ
MHB.^8B5BNKA-V%JUL$F=_&ARN[U8$K:X+Z\A3=#BZBZ3->!J%(&8ZW([8FP<
M9S?P*<*QM2:-*)5/WCSAW8RI:VZFRLJ[D0G+DK]"]!7ER9C^(S^1\RM?X0,$
M'>:"<L[B)FG'TGMI>93/9E5\0\N5B9IYD$MSV$26OPJK%9M83T*?3F4D0?KZ
MD8%2D*=+S;WXEEQ+BD.*B)P7,*V0@O1^7@J2X&'B<"W.A8KM0(2//%.T?7@\
M0X7!6#"*  WS !L4R[;NX1!P*KI-X^UM]2#*312&@F1%GC3*VB].HM7-D$H+
MZF ;\=@.2OO&0%3RAP\?Z4MRPP#Y@AE+<C8-V\/ER]!5JAB _^-NJA%60_,F
M'@^_R<7,J $V'G;EGK*\48P*J(.\A\VL9Q):C#H.6()Y6CG^SM:$_,Q94W@L
M,'P'+"8P;0&/">]E3B%^0>:6("+"8 FRP!'G#]@!6TXEW$]_!N%]D -)>XL$
MP!Z 9"BN1#IF!>[&,ANZ FT9TO/^HAPJ?WI/UC6]SG65P%5"E*U00;786SI!
M:0&5U(:I^@^9>+U$6L-,=%1:%V%8F."2?L7_+C1'U^&$#F_SZXJM806 1DL[
MAQA4<H5S32$V=!L(NH^PA@&HXGDBU:ELJ,Y5*CH'.1.*Y?YTK/V])!ZT*6-2
MH,3*"5$>V"98CP^=?5STI#%ICU6'!7&65:/C\NR6/RE)A2:2\ %:QH09DF;O
M'ZEQ8JJZXC0GTPK>\E2#-+8MEZI;X_I4DAA@%U":1PRD;(S*^.WG, ;6_T2C
MM@JPK #)]"M>.)(__XC\^7>@>-!/S'^3 GB4YEO4W3ZIUB2/H9.4%PM+.G.S
M*=P"A,!K6Z()=^?%9+=HO\OS=@=/$6[!VLH1)J6HT! D"0J=V#MX!)&7'GEM
MDJT9V"N\9\#]'7AJY(H00VZ#XYVH AKW?^1\+\2\J.X\6+S(_"DH^,J3=@%G
MP'AL,D<70X8WU((3E]?I4&1$&G5.L@K&\\2TBL0E.V7(*)5&8'A, 1D1H]."
M%GN)</??8WY-M@]5S@)@XS!A,AE5'JV.,DA1A]==X96L7YXUA/F+/+[3_1-O
M=F9C5YZ\"!^JW3M*FF ^3ZRMFWQC-WE:?^D3:CEYY14P)3$V+3#3.L_7/8;D
MG(N9H^=>(M]+D3\J()]\#20!N<4Q23>#Z^^1;+& \HP_@YDC/N;VHKS(II"U
M(VKL?#2%"(QJHTM8.MQG(H[V !SH:!16P),R<Z188 B9-V#<U!*GA0)<='%V
MC)G0)80(4V-SB*M Q51-?FG'X<H<&0774HU=F );-J3J3"=>VH(/6GWJ7VH]
M;6HP::W0W%AHD@OUDW0ZG8:QT%VRUNWAR<GG2^<Y2[VTRIE,<3DJ)Y@.7;NE
M7@SUI)0)T.$\&./Y44EY$<FPJ9=PQ#<L8H(7Y5D(S*#Y2$J6BJ"7U$\H1#(<
M^<':P>3=\$Z$K/C>)/_</(MY2)VU:5@ #];+VUS<5)+"0=Z[E=_%JR.*R% \
MWA0_!98L1G?0TQ1!Q44K03/A19D]:5G->$\[4D84W0('V#02)R\+L0H?MT>I
MVEM,%EP!I6@/^TJ*C1@)E05%(PD'=I!B+A9^;GRY$H<"X,=6:&V>O*SFG)XI
M.:?G(G:0OOCLC;AVN<)P48PC?3P\:?:,V/]>E]F;"1VAV<?<;PSJ'>\&N!2(
M)3.@U22*>I%A]P!<'_#R"]7#RP#0=#QQUYU&J*5ER[QH?,3#P=+[D734,+IQ
M ^\_,@^;2H[=8835#3_TP8F2RX5L$$#"'$]OO'9$>0!<!4@6-)3> VL3=5%Q
MS_<:F\[\\)&Q(RGYLRC67'T;+09+*I+QS$.PI2>>4CX-SIHQ6LWHCKP+_;LE
M)7C ,!KY(,THU8A"'<0OXVA^4Y.,_5Z5G&DQAC'#L;RL:ABWW+*K)KF>]ZD%
M/TNC%WR7DB4PAQLCS/U5<IS:B_G=9A@3"Z:,).F,"@"32D;WD2\%92(%I9<Y
MD6O9E"XQXUQ8/Q^(_$B,R718.+\EZ."2H8(=[KF%(\T-MY"6"0**U90KP L!
MZ0N*A3-(U>U8!!8=RCP[B'O/@*)]$CH\K(F7+,.%ITG'(XJT&@N\=!3_\LQ+
M7%[5I&9F<8 ,<C-63G>L?0U))N(]4(C,IM8/$WZ\ZKU(2]NJ &&L*F8TM_;$
MIO8$%48_^N#RHZA2K$;8$]KAV0W/=PJZ7%+Y!]DE"YH6+I8;=#\4 @UJ@NOO
MW6B<Y;03/WD421'>!,07;JK7\&3A#O$.5!KD9 %D3EWB/I "$^;Q@*-\C$<N
MWBU_MIG'PN+_X+NPW,O1;8@1=5]8E&2!)[DT)QJQ$.*M+#N_4AX\(R-VLI-7
M>G6KEO)J,_-Q'#L;9;M)D>6)#J,$P*)WX\?I,/05##P,>\MDV4M+E?QGB!E"
MY.<\TDAJB2HI=]D7.5F52I&T5BK=.J8"R]6 &2A!(Q)5[KQ@C.6*'D'><#_#
MHH)%O"H=YWP%!%[L6$@D46@U"Z%6<S.S8 ;N0^;O8Z919IL\1=;R#CGP( BK
M9;S%^#G/L<\1Z=4\2Z5!3<15L0>G:VY9<S>CH'U>ZRC./&TBOOR>2!,M 4"'
M>Y.:#M))@&Q&T\AHJEEVQJ\P$DAOXRT(F1XM [4,]-SXP>*-1WB!P!4-YZ H
M_3"?C"L/N7D.RY%^CM_(R!:,HZ3KXE<_CB_!"HXH5$JMW$E)(KR2K%)X5;!/
MJJI2ZQU.SWAL)N.WU4@M0ST_?LX\O#L*@#(Y+XW%[]JCQWRU;'*)4RI-N5LO
M)F^HK$@\2M* M)E+MW!!F,Z1A6N&Z EC=*+B7J,=5K>H= ;MOM+%"W0>B9"$
M<YDD=P&'!-YO3Z.>V:WO:,U\!WZ3H'T\N?Q ^0Y?PV/-[.J=#-6@83B.>>B-
M/Z)&*WB?SC.9O)$H5>[/4?%AJ/);GW:+J4/(A"4<Z5C[0.]5/<?#G"FI2LEP
M\GB"[ER4U2&V)A;/9I,%RM/J<I3%E8UQ&_IC/!\.'W/VZY%4P^5(H (,:D:$
M<I?DR1MYB8&U5W4#J\+@3%$N/J1@SZR><.Y5O!RZ<WT>P%,+F)IGE_FWDM2X
MH*%D5 '>^HL2#"(M%^&3&TZY([*J?8@/4N?#'%2=-/844R5H<*4NL[#X.UD@
M5-TX:6L_23!Q/O5M0;ICH4(G;[M2ASF^;YF[KY3S4B8"%>_W/$A6%/](&ZGP
M+<VBHQ7&0,K0WDK*^&D!:>3W,9;M@Y!01#QR=B.48)(YC]'->B<!@KTCFMN[
M:UY65-$1U3]6"+4&ODONI"2W9=&-B;\+YZ7JUKPZ_Y^KHY//GW[_^LYGD^3]
MQV]?KTC\:0F)-RPS':%X>Z.1P_#7-TU<G'\___3[WZ]6L%[7<%_>>@DC=RQ[
M%X3WD;O0%%MA_%&(> I^?=--D?3AV_>S\^]''[Y=77W[\LX O4(!?JI>&2'1
M1,(+//C;&_1^P^?H-TZ2<-K43.3#O"DKYBLJH/N%MTFJTL)-+Z%K9SC/]U[:
MR1QOTPYP/RT<_VEW_'52U*7WT-+3]O>[\C3_(N2AN4_4BT6V5M_RBY.SLT]?
M?U<@?W_X4F7/]L48M/NRC_O2\LM^[LM>\\LR;?9^Z([^O*$&.$> X#!Z]W]&
M(P8G:S6R0:)L37?II1H^TH2">"3&WW9/JD\UD8(8"NI;3(YVQ^AW.[U^]_D!
M?WD3K;859L<VC$[?;K?BV;>BY8J]V0JSTS?LCJ,[SP7X&EIM0G^VJ-5^4 ('
M)?CG7;G[M*][2D#9!:6]!["_O(E69&=]T-&=9V/FESQ1RQ;[--&*;&'U.KU!
M_X!TW-9/;J=-KQ;W:9?WE)R<CF$Z':MK/S_@+V^B5L[NTT0M8^S-1*MMA6%T
M>J;9,4WS@+3>UD]VLG37/NWCGA(,$(NEVYV>HS\_Y"]OHA69M]_IVW9'UY^-
M>5_R1"U?[,]$J[HW.I9C=0Q[']R53:/@F_R\W4CY17'6+S!0_CO#*UWM)*LV
M>P%?P<\CUO:S6A7)GP+M9'Z#Y>NSWGD4*2_*QYU<_J!OCO0N[Y-2/(%QS#;M
MH'(Y'X)IYXU$VY*?1.6MRBY7ZDRG:5LM+]#.8=>30JK,M_L@;5"03M(WG"-;
M_^F=2BL8=5S3"(TFS\WD+IOL6*$N[0JCR1%AU!V0YY#>S#W>V2,,<JZ78D>M
M?+>-6(M'X4QMD2J:X.1 8Q6@8:E]41>5:E5-L9Z=K'2>@27+2YU?7&8@XAS4
M;4HB4$2/XY)D->FL[!XO61S,J017OL@Q3#=)8-O3)I/8O02HR!+UL[!F^S1]
M5A2O3FZQ,:(8,1T',Y]X"ZYQEF,XPX#_1%16KX6!\2CW:E#T8^T/QKL2)[@T
M;*D0I^D#HK1R.%'I'[<PG-,VB'*C([7<:)8U'Z>%1]OR57LCY5("R#JN%N4<
M)0;!MT>&J66B3=2(O7(?6*QR^]LKDC$]$# RL_Q1TD]!WJA#<);Z$&(C"#$W
M9:'P2N"8>HY%Y&2'D$N1LBXJT7^BBI/$?ECIES,W4K%+:1S8/5 4U!W/10E*
MF6@R\]D#E7&X]:C_/'"ARTOASV,LP1Y@>>12OU&%E EN?$\M#(\ETK'7DNC?
ME\JK7#DOGC4L)9FHWRGJ/RO=N7F7U%SZ%<=;@G@3,B\O/'B]0)>*WA\EX1&A
MD#)0<#XFA!WFB6";4>12^E)FGN!KV$=5PV2-K%<*R4DNFN7&*J"H9>YE^P;:
M@'B.N?VQ>%14+II$@,E;K#!/J^AHS/>PI4I:ND=T9Q3=3\.T5%Y>N,AF2;RT
MV811#3,$)BV&%*2;@*J%EXHGH:_.P$N<IJH#OIKX;)3$2D55JJT8N'0IKO8!
M@;E\]YZ*1T>\^+U8.Q>_F5[ )R.^@"Q)2#Q<V#V")FWN2##@S&E[+YFP-?2Q
MOZ+L7LDW*9;=5+"T2DXI3;P8:Q?BYF*U,S E@@5ZH%.IDZ@@FQ>(CE0%#92J
MGWPIIYGO\L0Q>I!S-8H5D>&; 3D655W^RP7418\:=6 V#:4A@\<K_,N!F)0.
M"(@'P'N30E, -T(2F[I_4G9='MR)>Q=&,EU0R37FT"O$+C9)S*74'L:,8I#8
MU/#+&WN\\*2T"'A^I2BQ,0W'O,!&Q))BT=T2<^'(>?:H&I1YO(1D84@LS[M@
M,D[[,)@H0)G-6@EW185@=6NQV1F9"8665L).H+PXCF_Z@A[GY%G19:,VW3O'
MV-3CB2^CV!J>-\S ;+GH#GM0 [6,0\;K%?(T<=P)ESKC^#D8:0,D7<C\QQ34
MIFI>GF1_^7D>']VX[NS=958]*%-]%R"]1@#S%:C\#R#4_OSM+YKVBWP%TV/C
M;Y/"XX_\[_05LGGAE^]L\NN;TVMD6-W0C22DG[J6_D;SQK^^^?@PC'S^K:-W
M#4>'[YR^\^:W0S_K$I9PIRYX<B1)TP,YX#Z?K<<KDH!UPZD<GG)OE%X&N6Y+
M:1I371N!CZDQI#04R))09Q$VK95R1!0H1@7&Q5!:E[.2XT^RJ9=,*$T61;EI
MO$98JM$LTB-HW'*-)II;X.&&2G^)JJD"1$H&G@#4($H"["./1R@T,TA7JB^D
MU=1)8+L>*A>R"X5*S[K08U<Z^ U6S-6G%*(;X;6B02;937-?6#@1NQ'IVZD!
M>YF5E,$GSA^X)4/U%,#HIA9TV4Z,WE^>GV:_8O]"<20'^PA47T<+0=\K]E6V
M8GQN$H8)]D^E[JI@7U(!R!S21&9SK6U=M<;&S9>%UOX1>&G3BT*K6CP6Y):W
MDV/IW@N&J]N:CJ$I<R64Z4LM][P'[&.(&9HLGTR)2B9M-R=W&:;'&GUT3+M+
MZX3)R7B&?EHW23U]2"=%@8EA"M$02I3]%7;I0H;Z()JK7%)S%7XB+ D'*N-'
MCB8UG[^ZD* 03I446S.\+%/.:VF(L@&+2H^?\./#=_+>H P%BW^J&?K1?\.\
M:=-#XNGS4_S^"Y5X-G7IQ;FBAF4+8<T# D+Y'V!V)Q@053'O/Y0VOW"LDQV(
M_C4/E!9$I$7$E$N=0$10O,$RB10\N6^*FE6T0:YP/#;U&$:ABX7P45[-N304
M%%L)QQ#+:J!W0/HI>5=[+\#%<*E&PGY]\[&9+9@S'W_$[-OD7)34C-<V$XT>
M_'WX9N(/7O0[Q<>!6(C[@524(-S:<),<+S0W6[B,0+. 7&PH(L@7)UPOL6*"
M\@[9?[*T'JPXJF9EF(631I3(N57:7O.&NB1YZXZ'5*9(FB&B<3MR%#F/:M[A
MLTBOQ*IK3Z5"!92R8%&0-GY0"_L57?;'V@DOJBD5)V_\R'O'2V6%EP0IZH13
M$MV<:@%;Q5#*L)S**R%S*[>\0OPM4BGJ)J:=B=S9+ IGV&&WJEV2M"*K-T/5
MGVA@H 9"XP+&=*.TPR7W:<3A/!HA#B[1\9@GIW_-QS=9M: YE@#^CS ]XB5U
MU3MI)]_4B.[4]C_E_DAY]U?L=M_\_J.L$_("GF0_#.^]PYJ5\4DP_A$(3"(@
MV_(:F+;3[QZ^.B <T=[DL'1X6F$O*L@5+EBS8P/='F;%OUREOEJ4[L!<W0'U
M5F0X3XC%\3Z ^UD[Q<;;\HZ$ 3V'TT?A^(8UTL@W47@/3"=D5U9$C1=;S7K*
M+A)N(*FPP1O(*3B'4"O:CGI&JFVIDO4!ZN17" B)*,83ERA.YEC"4GFYYLB*
M4YQ@E7/8:S=KS%!]-)&M-0'K"6_8A-6R)GS>-:1.8]&2,T(_NE[T3Q3L7[*N
MW]MU8UJ.U7L! @D1I1&F- 55K4!:I0/30KLAW\4^U[:>-SU#<_18^ZAT58U%
MW?.Q+'?.I)>,=R\@*_0^.PJ/&/<9D%3A8*"38N9Z=$=$S24G=%&3]7U]B^.J
MKBB\@^;CY_UMJ4U&;BWL:1MQLX[Z)29@.X?S6):13MLM21BR"?DE,97B ZM)
M:7@):TCNT:\HQL!+=KH4)DN5SS[-2%-</_Z3W_;@]]A&"=NB8Q<5?BLF'E=Q
M/<5 JJG[ "+]/TQMQQ0.\;+&Y9$_LWDBFUH%I2?G0>E9L(O526X]4 H@E!_5
M"L+HN/)1Q@J[&]_KX(]9S6S>@#*Y#XL5)+,),['KN[P?CO*8"ED'OZM'1-M)
M!L?I'DB#E\](-YK1>-,.MSYWRL_".JJ6I2 VQO+B@8X\J46%AZ_T2)96X97M
MF<2!+ T$^?<\1/N&Q%U<-1R P#NJ4.-%#HPBSE;I?[A!4?L\(ZE[N\5K@/7@
M.RCBXFQDO@(V^E;29F^Y2P)LAD 3XB1/_C^MQ!4QJ$7?C:IYHE,>0K[+/6?"
M=^)F(4$9ERT?''[GBQ%+2\=4]#+%J06\[C(<=ZAM*2]PK3PD+ VP)-R6C0^'
MN#GY6J^ C7^43<V,VK$#+_?G E4#;R2<[(-0TK5P 3P*DU&^IKAAL;&H*,Z>
M]ATL]V&LYL+,3Y)K?HBN2"^6O15';GRK3?SP7HDBE5YPR>69X;[#+AA/V/EB
M]VZOO,\Z;N@<5Q(:.MDE:1;V*T8YF?)[RE,X4<!1\$3VXA8>IFHO<TH,'=KR
M#O?=>VIW;.'RQ^CI1WY P=DN+BXT/W355M0RDC9W>$:/_0-YFO$U(%&%3L?S
M-' ROL6;V"GZMOF+?%$QJ\:#Z)E0N2AB%II 1 YEP3<\<(C[[/%W(9!25?L5
M8TVLGXZ;QN?OF%Q2'.=/BY3L$N#68Q_Q](I AG"G;:6XY,@V($YW2&D:130@
MWL*MS/P$LAMT&M8Y!=L=S\/A_ ;#!$SS6#O+=E "FZ=B"G6%#<+ )MIB:FV5
ME'@A#V=&(\I6:"=U@1$UX@_]&R-9HH4S6I$U,&3CKT:GW^MU!E:_DP>,W[;)
MX3)/"&"U,O@C _6O5K_7T7LZ#Q?+ATFH&5+3N8]]%B+W7AMQT-P4M*,T3!@=
M*H\=:@%!'2&XD%X8X- DC@6='X317 !.1QT4=9(?!C<,8R!NW!N*<4ANO4@
MI=VE7AR,\04F]6+>K8,VH@KE'31472ZJZ&>/G"%H5<[0VTRF)*JW$ Y]6+D6
M22?M9\$;C$@T^&&:5I2U "T30I4$P=R$+-9LAAL2B"OD0@/@\GBU@C8-!,''
M4\CDS=TH2]\3EW@B@80SMGR^2@FGFF(9JTKN%(+T48@TNWE<6OFZL+$K/N?
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M5]OAN=*;:O\_B<#IU,LR7E.AE\*2I8TJ$)/G^UC[XY;ECE?9%L79%E71D<@
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M."7FX*==8DXS#=WLP)RJ$V+K \3<=&7O]C%G$T5Q=%W7+%T_,IXCN^6Y G/
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MC7M14+*PB\1N2/+Z!:QML0W&;@!P%-ERK#6@Z 7%!6OUF+6:E3>"P02#;1V
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M%?XQ(*PC(0S<V;@PJ3WPK4'N^SSPR]*6BYL/DFXK9P1"JMJ?^QBDJ/KS('U
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M0N1L@,8Y.K>"L, G4Z8[D=59)L2(&/9BF,"$W]N\::J*9IJ$3*/KS %GS3H
MMGP:_$'OW? RRH 1YB8#5@/;TF?!-G1,DTV!;9F68O>41]K:9S4$.-H, M ;
M5YUI!.B&YNP?_B7!4 F9!8,X1)D!X\PQ#&7W<,Q1F8>7=5LQ;7V:Z2W5 DMD
M&S/(4@&'FGX =&U=V!%N<T;'Z1K\H,\(^YENVR@#/>63=>4=<6 9'3APB-.!
M QT^W3\&E@7$-F< T0F>!\P 8A #0LV5N)@Y\]5C7ZB;Y@FCQ^=HDK,A8W^5
M<]!NJ?<0!?_):=H]=PSK.98?&[8G/5'.)J-WID]6FDVV2HVA&$A65'2=UC"
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M[@!3")SZM(4'?/1J=(&+WS-\-'!0WN^\SA/OP4UI;1>"[.'W#_]R@^B)E<'
MIC_$?_SQ84$+' B&544SE'W;"5O1U\=1!R0 A&HJMF5N!,D-NW"+Q>749_$%
M^"[L;_-43=]\@<V/31U-M?2I>['?)_!FA@?TH+7&X>E<A!T[6E<]QG0TTS*-
M16@UG9VC=27;OI;[L$S^4U6,]EG+#"J:,=JV45%8N)Z@PC"5Z1N'4Z@8GK"M
MFR!4%5N=OGJX=[[H#3)4W6D=$FR#,ZH>T9VUG1=952*ZXD7%[IN9Q#3 E#@S
MMP;%E;^MWZ8@=@_N_.'DL>(+(V"8LS3X/\KH,_^1D3L.PN=?;AG]O@+]OB']
M9/:[G *3UG7O]26_F^"'A'KW(94N(Y_Z+T^A:,TY:_UR",*]= =@N&S8AYNG
M^^+"C]1CRES2B+PFS_44,K2%1P82&K;C@HB9:2D>'1=4M5\B-1R3;:KTO5W_
M%GI7B+(0Y6E1EGB,(B1:2'1%_0\/F%F3@NBX!  5%5*"R;9T7+ )XRQ$N8LO
MOE$/DV#!*/!8*O2XN![$N+9JZS)^3V'+8HDW55U74PF!/D:!+E-KQ\7LF"<\
M,I!$6#0,J(XHPW&H7C9X^+,/PA5GP1(K$3C#&@&)%PE(596 =(8M="8(HN37
ME W+V5/,F*8YP]X;PGLS%;]N1.->='":.WUW=R1Y_0+6-N\-M6, '$6V'&L-
M*'I!<<%:/6:M9JLKP6""P;8.P)N=**\# /)VJ.(AN%:H1<%@@L%V&Z2MW:=V
MGT%95:$+(=@3+ZZ<$W:I1Q9V;76A7DF2:IFRHNK]$Z)C7JA7'-!O77K,"_6*
M#4 /6(HM&.!D&4#H <$&\%W-4&5+4_O' 7UHX[]CW/.+2]+[%_UK;8#^];R#
M^X-OH%?B1S1=-BQG#?'K.H,\.E4IF&@/IEQPDN"D@I- &6E"&0D6VH"%WJBF
M;)C:[IE(G&H)]ES#X2*J;!C&('1<'P;@[=IU"9N5>[=QYH9=55Y;KM\[D$AH
M(!)^G-^%M&^*K4V&UZOA>B7 >Z4,VF ;"I%U9<7N!DMH"NT$O"'!VKUF[=D(
M4?"WX._CX>\W#CAU^]?<!X?[[>8@"X$2 M4A4,TH7DB4D"@A41N"K9N&K-K6
M$+VO$SB*_8.FJ2Q%<>3E28*WSB9Q@K?KL:_$HGS$L!(0(BFX[6L7(F<]C&BN
MXJXA;__X%A($Z=E"@B#"HIYD2<JQ7>)I!Q\?"J_VS@W=R*,O>;7BE$W$P3N+
M@XDBF\K^,TO#M#;"_)_V0H(@/5M($$18XV.RQD>1E?ZY-7CF9S;]9L$*AZQU
M:WRWL]]:!;?40$$;&?,)T^V<BV% 8AC0)CIBT3 @XFPU8A3#@$2;W%,<!F0?
M&4BB5>XPH#JB5KE"[PI1%J*\)5'N*8QBLI%03U,L<<23C8X+HD>A=86&.D4-
M)08V#16V:F"3D&<AST<_KTE,I.X]1")R[;G./8&;,JV13=)Z(YNJ.4U]KRSL
M6<G"X!OYJV!D=&.=YE"](+G@K1[SED%,63%$2VO!6]L'X TJ+J)M>VZ"N [8
M:UP-GFTWO(73"[H+!NLQ@Z'-U:P>#ML\@=:)RXUIJF8S#3G4VNI"O1(@8LBJ
M062=B)CH=)E F&G!!AADZ+)M6[*CKM.!O6>>S6##C.-E+Z%E!!N@QZ'(FJG)
MNMW#(9 G<'RR<.93->BI[\ZZ:(*RU#05L.9&V5!\)3D3\U0$$PVUDX[@I)YR
MTAM=EQ63[)Z)1+PAV',-]B3 GYJUA]$\@C\%?ZY.0M5Q0'VN$S4==S<[,3FJ
M+S)Y\&XR6V^BTU-5T(::&+)CV+)FFIN#?X+NNN@0U>L.4:VRNF%UB!*L+5A[
M$=AO#)D81":JOG?N/CCL8LZ-$*K="%4KC!<B-021$N%%CP6*@(6R;-E1MR]2
M_<Q$#.U(5\R..N6TX)OU[[2)M/4P@CK1^;N7"PF"]&PA01!A4K=B4M>_5G1,
M)O7D#O'$E*H^,&B;)B>:Q2*&;&D0=!,QJ*J7"PE7HV<+"8+T;"%!$&&0C\D@
M*[)IJK*A#[(28<E953_[P2/^_(^?\_3LWG4GO]QX#]3/0WHUJKOD-9KD7638
MY)"U!;S%%]T" =^'L??W;_\E2?\H7]+Y5<D#6L#CW^CHUU<?OF/_1Z)JY'N>
MXG=N,C=CO=P^8._:J]%-!B^]^!&DW^GX+KA]BF\?XCQU(_\2^832J.A&P+K"
M85,XWA.N:@GW+W[7*?W"9KB\ K_>"\9NF+)Y4X'_ZZM//^Z2$':A*HI-%*(H
MIF$20_E>_]E0X \$O#)-M5])>13PK?]Y\_'5;XYB.5:-M4Z UT )K&IJ2K]1
M8JH.<12'3*-$V3XZ"@[Q:? 'O7?#RR@+LN<* P6X53N*U>"R]%E2&Y:F.]-P
MJ9:IJ/K.:+T?X(!HFJ)IZC1PFJ%:FKHSRBW#R/R"XON".U>#T]%FB&@KCJ/,
MR"O1=,-R#BJP6X43Z*EKQ)H10D)4PS!V1<\EMZL2,DL6%8#0IK=K*$17=J X
M.%G6WBY@US!4Q9C>KFX:JKT#M4_L7EE"6S%M?5J#6*JIV98RHT& KKJA[8+C
M>F4*Y^#$PI]GI- @IF;MCD^V;C(0.'/&SNLJK&;," $Q5(/H9'<DWQ=XFF8Y
MNC(#GJ*9FF[OP."O(.7KV@J$U#)F":EJJCXCN3H\N@OENX+D;AE.30=3,^O
M@4-@[HR>RV[7-F>W:UB*:<[*EV/8FFGNBC ;;!AV[-BS&R;$LAUUVUX'__G[
M1?K]:O1=(=^_QH\,Z;>*\IW_[_9JSM^?)Q"_7B!/W3/>8_PVSQ8LPW4(OJI9
M1 -O>8:]%)TH.W&A&V+4#1**T,9@Z;KNV!VN&3$5PUX&+-S%+U5:X&I4&E<^
M/*W+-P,>R^*!1+O@NSK.K*,->G,QW%M!S9Z"0V)H!OCAAX%Q_[$3,0R]P[O?
M"[CKQR3P?[:CS5BWG>P:=$^QZV&XX:9NF]:,@U.JL#W@9V\NN68[S@R@_>&!
M;3NNND-F7?2]@+N)FZ3HQJQZ694;I\>X-3/RZ6W,!X4-W;JJ%F94]'D47@H'
M6T?9OE*RH.1M9RYW'P;V V0RB6YJLU';F0J/:X?$Q0;I0Z(ZQBQ7[Q^DH=EQ
MB+# W3ZH1!S,M&O$M@VK7[ ?(H>CVD2?";?.B*YKEG%(9&SB$*CPYYDSJ8U@
MNK@'X;L'NES^H(D7I/0Z"3SP)J[R+,U <H$CIX1T(8"-S&1!Y(*>5\DWU %S
MV;X4_3(I\+PL Q#% &%W9O(..B!144JV7QW,5J:E<K,NTI1FZ47D-Y(77ZB;
MYO#EJPAPGR<)O L>^!I'2?GK>S<-4OP^H\@M]1ZBX#\YD*-5^K =H[HT8CMR
M.+IN@6]E::]^PZ*.HJ:#E:#@1B6/AN'$]1%9C!I%5<E=G/@T8:4G\,DO2K,:
M)Z2C[!T6S[#2&BECI3,1?9(2+)TIJU<4I:[Y:E69U.7C#Q39AY6/-ZK$9RI<
MQFYR'T2[FS:[UOM7F#9;UBV]>Z1)!A(<%GCDU4L+AE[V=$1F.7-66K/RO:=@
MH<2L"='2MS]VQ8V"VW<X$-9CRE72R/%Q/'$&R?&=EY$:UF2I>_S%UZ;8M)]7
MDSX&CX%/(U]Z#FCH;T2DE8I+-U)&^UUH&8W#ZHCW02_E?*U.ZQ7*NB%9@,@=
MPO+3)H ()A-,METF6T/WSUY$'9+N_RL.(<1D(SE&KI?%B5#_?9=,6SU73T\R
M!9/ME<DLYWR=]O0#9[*3<_V_!>G?9Z.$4BG *)&FF92X&15&H._RJ9R3C681
M#U,^!9/ME<G(N7F"GL;)Q0"7/R;4RZ@O@0482V^>J9ND>YS.)Z1SS2DMY^;.
M1VD/B#:GR03:^>[GJ8L4^HMD^#/R:1(^!]&]Y,7C<8POP0/Z"18-#$R5]LEJ
MOUZ;MWLEI>"MF_V34L%DQ\9D_38%J_6#V4L%U5!KMKI+'[L*M. GS=(<4: E
M2E;652SLNU41QT4JQ2.N6HZE5*6L.3LNJ$3)F9#?>?)[9+5FS3*ZXX),5-$-
M)04@JNB&%BZ=8H&38#+!9.($3531G;QD$D4_=TY/- 67[;N,3E10'+_O+\KH
M!BJ?FQ[,#5,^!9/MNXQ.! '''P2(,KI!2B>8 %UHSI-G K.'3'!R?K0HH]L-
M7H^GPDF4T0DFVSF3B3*Z3<KH/M*[['.49DG.RM?BB-$6'N<_IO >UDN-=,PU
M4 AQENH&URZ Z^C_J':7P[%Q0-94B]SO$YI\OWEP$_KJ-SRQ:?:>7Q*6+6&@
M70+X$"?9+003^#[LP\^@+[!3OQ0_Y?"_T#'R=^J&V<.-%]#(H^GGR%L&:ZR]
M(#$4S;"U15C3U\8::[=7M"3^P*P^JW7\X(8A]=\_ER1>C*L-N:5[0@%V7U0U
M;::A<K.;ZLL;GV&-CT'JA3$*WO)5H<7^[G1/5:FJG8WN''I&"'7.',/3SNB=
M::KFR!DYJLI+/3N<.JGZ]UPS)MEZ/MZ[1;I4XLI4FE?-HI]+B "N41<4M"RJ
MRED6BCDZM2=X80UMS["CK<3;2$I5'\DSZ1L-74PD7+M)]GR*V+E]H!)(%+SN
MF>_T!]9!O4L9]TA/0?8@%3I-XDI-*K4:"A)8K(P5N67PFE$<AO$35C$O0&2C
M+KK[QU5"I#FHY077O+*:*9SIVFO\/>45U\U:[-O+_W=[=O''YW]^Y:77GZZ^
MWG:67K^2F _RZZMEBJ]_O_S\S]]O7RR^WFBZ\:Z&&K]8O/G?"OM'JHLX9RKY
M7I[WNZV"P(T49FTP-]*9^]_X=1VQ+[/G_3+0P1ET^(RYW"V ?O'DTF7^_=KV
M4G7\.ZGZ%<(EA&O9/:]4@M^OK2]58]\3 >L\$F@X<TL="92\OY-#@%5=_3AS
M0TSP1UXP@9\>,9Y&Y]VKTP80J$/06 4"^KND") F+P1(FV?J-E*!"Q::IW^V
MAM>.;&S7'J<SK"]KR*WM$'-&RVVR%Q03K+$_UE!ED'+9Z*J=[RW9!'^<*G^L
M89-G*YWZ9)/_C-QQ#*;W_\#$HNF5_"#U8/O9($WM#A9R?AKT]H]IH0-JH3=$
MU@Q;-NV.3IR]4^H=E8B"07;/(*:JRIK>45LV+ 8YNK!SQL0%:9J[D4<A[DRS
M5!@Z8>B66VAQVY #;N"0>D\'P]AQ[VW9S%EOU:#@KW[PER$K=D<EZ.#YZ^@B
M2?:R^C3;31)6W%TE>3.6_9U.]4IG4D>&=_USY*,S.L(X"^6Y'9$T#2+K)GE1
MPK:@6@4+'2<+:;8E*];+)0K]8*&CBV3G'J!&<71VW(>H6UWH@/(4_>SV+.HX
MN'8[^ 8.R ZZH<C*LF=;P@B?*)>TC7!3L1^O)1Y2L,OMLC<3\KK^H\MN*N1X
MV9G=41BSRR ^7@;Q^&40M[P,(D)?$?KN367N66>]7DM1]5X5$YDH(J@6S-E+
MYAQLL+[,K?=%/Z]Z][[['N#6J'(525=>%F/!O"%+>/5=9JY <>M18H7O$)P'
M41;S#Z9NB2Z\!2E+;CN#+KVYH53Z&F=4LMZ>2[#ZQ20)0DEU<'%5>6'Q"UC1
MAS^LN E@"N]!<O'+J>1&OH2=$6%3:2=$LN2S#4_AY5SZ%">2&V*.@Y[1'P%X
M;^!/X>OPZF/I3LF+-YK0<?R(O;G@(>_!C>ZQ52.[=9W$H>3B]B3ZB$^"B^;3
MD0LN60-IVENV('Q $[[[_^2 5VQ6 PA^'A=?K+H_YE$&V&WBU(/_'U*$W06G
M<!*@<YBX0<I]PDP*J0O?>VU@Y(?_GDMX"9;A#M\.BW)2M)%0^I)/L*SD>JQ(
M#Z <(<9PI7'L!Z/ 8\T;:D167QN[/GQME!5^Z"QY\24<I7)CL0#><4=;QS8
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MT9CWWH0O,'/I)LQ<XI_H:,3%0L(^G-CFDDKY9 3Z/"M!:^HC*< ^F0JKQ&&
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M$F%H5"YV-H1$RZVS/&%+E@/H2?'_%*6!?,4068_P[0Z\6L^C= ]/Z?G$MB
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MQ]>:;HV 0<>,KUU8KXWZPKMCY?-<I6W;\H?T $%GBG,'_*]Y):'PF .E"X:
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M5Y1%O5#9KFY22&;**PKC4$ZI6A3QZS##.Q2/#D].0=PW3]P_.&K*P'9J;,9
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MK@)1Q%,^6\@BFZ*PZ6%60/ _(.J;IV60@0CRAFIZTKYE[:0-9R32BFOF8J%
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M()57+O)]JN?[U&6^S_1\G[G,=U99+BWWTG\B7"6#$NSU0^ ^@59YNKSN)-A
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M]WW-%F"K=NO7_S[B L2C(05?/2S)N>D7?IS_JXROV1&6R/BX',FU4,O(3V%
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M71K+2V N%!/E(!M;A'+1\'R,Y?5&I9:U''!935(),L')KB\J@RKAM4( .5^
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MI%B)R1)* "^:J85YA!_J9&:[LN$*%D,J)%N50Z\*<]MX!IC;5$@QXR;2!D/
MW;QF9O9[V;="F$7GCR_E[2LF6X/5#18#YD:6$<W8RT)\QV"X%*!&+#X098>3
MZ74+.:2ON352#XDR;!FP<2S ; 8FK=!<Q PPDX#A>58&UP#+M&I8##<-0#?
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M!&A,JR:/$N@*T.!632;E,!B@<:R:?(J -4 #5/7-_P9 -4 C5PW)0@5: S2
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M>(X9'IFV\M<;4 [S 8 \D%W.*#Y2ZIVXQ=8/&!S(IK:>[-Z6!7=&K?F";/V
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M8"(%, :RD%*.#PQF0J?48@ZU/8"I@6Q?^9C3/TO<!E>GF]4>@)UDN3C>[B2
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M*:.\I!; 6$_;MCUC#U'! V7G$6RYRR#&%9H9&KR"74;KA_2"%<'2/IO:@@H
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M(=ES,0^MAL"N'Y^)<>'@G,OM@%D_/I',A+.(.^V!>3_>!];7>X"O:,ZAE.V
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MO 1%UB<G#%)[8-Z3?Z!@QL6TZKL!%$\>@X(GIVL#2T\ Y,D_J.NJ]G$3=)T
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M([V&W?;\*BF"Y EON/EHGKY^#/Z19NRECN54JP<5 .K%BS.PV##H=$/6DQ(
M]N+E_0+?QAQH-PELJ]<BJ?_-@C-J\LK,'0&.%R\*N<J1+0J,77S!9U9EE"_Y
M.HQW+19$QKX RHOW\@M-L-0:+(LG\Q6H%=IU//FRITFS] 1 7CR9)O4>3^N%
MS^%*$+=(N0>.XBE=I!GE[1Z"+Y@'#%A/LWF4!-DKN_3'@TL\YT]CX.^IBF\P
M"&/$KX(@O?A8G%46S[%R2\:DZ0$ O/A9'7:N\4MX06@V)(9> ,2+CZ5AR6HF
MC/UFQWXRTTHSP'*[VVD)#'OQ3SIL?*+V*2 W!K:]>!LU)V(]YH' 3KRW>P
M+]Y#-RG-5=+)C6V&8NX+H+SX$$K&Y"32?4')?0&4%Q]BD[%/:4&WS?2^!34
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M0__.2PQZX2SW1.U"$D3@R:?1\OO6Q4M'!J!Z\H.T/'Y,$]CPMDJ8;V65;.0
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M+UY0PZ7;AL%64G(K>@#>BZ?4,*M.\R_5YP.V-VKIL.3_[@)YXS= 2%Z\*QL
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MJ#;598/(TE>QH?6GK?U#YZVYLDT)P[_%+M]T?_W-=QX4MW_ O*^' 0Z.0/^
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M6I6BGSTN;TK-XE=X L<%^PY/)DV3<2)+;;-H("%IIA0*">9,BWYE -D7Z@H
M[*EL4VF8"8DE].3?X4FIX4L>S<I HM),N.'UR=_<R^C1P>%[Z16%V' [5E3
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MB ^I:"2_N'/3V^(%GY2)L5Z(L<ZK^,8FND<]_$7:Q'C*WYZ"SK]1;LX3HQ;
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M<[R*958,,*^CH@K-/DM9?!1-,(.2)@Z[;L_OE^4>/E<  P[E!K2#(QP;A\M
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MTFP*9I/53JAJ*%PE)R'+X0@*\ZK-1EKU(M]6_= =(%57(OKZU7P++F6*KPK
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M/L=7<9.LR6QL))H*=!;OENT\XJSCTEGKZJ<K-GK)6\JRCWMZ7MF6A1IMY&P
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M#6!2^)Y$Q&'NG,_?+LDK\4,Y)ZNJ2):UD+,X;]4&QG&JI-</V07I"VVRO4*
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M8!3:7G1PPHA+A6^I*[(I*ZF.#<'QRD;@!.H/"CBA^H,"2[#O#@UB(FX3(%S
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MC!5P6'PJJXM<0J>/,C=MCHR8?<-#1LV^X6$C9X9*'VNO:86-BEN!P4:\K<
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M=BRY#WW_.F1O#O.>SO0IE#9=('"J(6 B< (-(Z]^NB2*Q.T^H4N(QR> ^A1
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M]-41L>"+,)![11_Y.]/5]?%!1?"JHAVH_C.Y5BN9>QK])7<O'A]4Q$HJVJ'
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ML1\D&%C?#Q)(=LE"384%E3'0O?$D)(^ZR@S)F/6"6-F6PD-S@%K; %SK6R,
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MB G0%X5DD1"-<.&N?L;\HY#0:*XF,>+4.8=EC"36-P:VED5D^VLSP)6?962
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M,'"<KR9)=+Y>&R8+>AV; Q<5S2#MVC^:_;(-8.1;B75A0&,.?%0T V=:KVC
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MY\8;3^ZBS(!,Z2PSX"KQ3T?P-%X[Q7%)7$:<2,Q0C-/WRG: O+&"!Y!35O#
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M7.R:H$]1JY!_9FNBI;@D;K,4((Y'^-6F\4/1/EAPRQ%FL28#N-_>(;,/)?U
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MRSCE^8\/B,(7>"G]U_\'4$L! A0#%     @ %HH-471_KFVYZ0  YR + !$
M             ( !     &5M8FDM,C R,# V,S N>&UL4$L! A0#%     @
M%HH-417R_)\S%P  &!0! !$              ( !Z.D  &5M8FDM,C R,# V
M,S N>'-D4$L! A0#%     @ %HH-498!,7XW"   5V4  !4
M ( !2@$! &5M8FDM,C R,# V,S!?8V%L+GAM;%!+ 0(4 Q0    ( !:*#5',
M,W(ST2X  ,Q/ P 5              "  ;0) 0!E;6)I+3(P,C P-C,P7V1E
M9BYX;6Q02P$"% ,4    "  6B@U1F "U$C?(  #." L %0
M@ &X. $ 96UB:2TR,#(P,#8S,%]L86(N>&UL4$L! A0#%     @ %HH-43]F
M]2ET0@  %-\$ !4              ( !(@$" &5M8FDM,C R,# V,S!?<')E
:+GAM;%!+!08     !@ & (H!  #)0P(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
